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ABSTRACT 
 
Smokers  with  asthma  display  reduced  responses  to  both  inhaled  and  oral 
corticosteroids with associated increased symptoms, accelerated decline in lung 
function  and  increased  use  of  health  care  services.  Little  work  has  been 
undertaken to address the possible causes of this reduced response and to find 
effective replacement therapies. Therefore this thesis was carried out with the 
aim of identifying potential mechanisms and new therapies for this group. 
The  oral  bronchodilator  theophylline  has  been  suggested  as  a  treatment  for 
corticosteroid insensitivity due to its ability to increase HDAC activity in-vitro. I 
undertook an exploratory proof of concept clinical trial based on the hypothesis 
that low dose theophylline would restore corticosteroid sensitivity in smokers 
with asthma through theophylline induced recovery of HDAC activity. Low dose 
oral theophylline added to inhaled corticosteroid increased pre bronchodilator 
lung  function  and  reduced  symptoms  of  asthma  whilst  low  dose  theophylline 
given  alone  reduced  symptoms  but  had  no  effect  on  pre bronchodilator  lung 
function.  This  research  provides  a  foundation  for  future  studies  designed  to 
examine the efficacy of theophylline in smokers with asthma. 
Agonists  of  the  nuclear  hormone  receptor  peroxisome  proliferator  activated 
receptor γ  (PPARγ)  have  been  demonstrated  to  be  effective  at  reducing 
inflammation  in  both  in-vitro  and  animal  models  of  asthma.  Therefore  to 
examine the hypothesis that PPARγ stimulation would reduce the inflammation 
present in smokers with asthma I undertook an exploratory, proof of concept 
clinical trial using the PPARγ agonist rosiglitazone. Treatment with rosiglitazone 
was  associated  with  a  trend  to  improvement  in  FEV1  and  improvement  in  a 
marker of small airway lung function and as such may provide an alternative 
treatment for small airways obstruction in conditions such as asthma and chronic 
obstructive  airways  disease.  This  trial  will  enable  powering  of  future 
confirmatory studies. 
Altered cytokine profiles, specifically the combination of increased interleukin 
(IL) 2 and 4, are observed in asthmatic subjects with corticosteroid insensitivity. 
Based  on  this  work  I  examined  the  hypothesis  that  the  altered  response  to 3 
corticosteroids in smokers with asthma was associated with an altered cytokine 
milieu including raised levels of IL 2 and 4. Smokers with asthma, characterised 
as corticosteroid resistant by oral corticosteroid trial, demonstrated significantly 
raised sputum supernatant IL 6 levels and raised levels of a number of other 
sputum cytokines compared to non smokers with asthma. This altered phenotype 
suggests cigarette smoking in asthma may be associated with a deviation to Th1 
mediated  inflammation  and  could  provide  an  explanation  for  the  reduced 
corticosteroid response of smokers with asthma. The cell type/s responsible for 
both this shift in immunological phenotype and production of increased levels of 
sputum cytokines is unclear and will require further study. 
Previous in-vitro and in-vivo research has identified altered histone acetylation 
patterns  in  subjects  with  relative  corticosteroid  resistance.  Therefore  I 
examined the hypothesis that smokers with asthma displayed reduced responses 
to corticosteroids as a result of a cigarette smoke induced reduction in histone 
de acetylase  (HDAC)  activity.  Smokers  with  asthma  provided  sputum 
macrophages and blood for peripheral blood borne monocytes to examine total 
HDAC activity. Sputum and blood macrophage total HDAC activity was equivalent 
in smokers and non smokers with asthma. Therefore reduced blood total HDAC 
activity does not appear to explain the altered corticosteroid response in this 
group. However the number of sputum macrophages obtained may have been 
too low to allow conclusive examination of this endpoint. Another consideration 
is that contamination of the sample due to the technique used may be altering 
the  signal  obtained.  Further  work  either  through  modification  of  sputum 
induction techniques to increase macrophage number or bronchoscopic sampling 
is required to conclusively address the role of alveolar macrophage HDAC activity 
in the reduced corticosteroid response displayed by smokers with asthma. 
Exhaled nitric oxide has been exploited as a useful exploratory and confirmatory 
endpoint in asthma. However exhaled nitric oxide, measured using standard flow 
rates and methodology, is unhelpful in smokers with asthma as cigarette smoking 
is  associated  with  a  marked  reduction  in  exhaled  nitric  oxide  levels  in  the 
majority of subjects. Recent research has demonstrated that measurement of 
exhaled nitric oxide at multiple flow rates followed by mathematical modelling 
reveals increased levels of alveolar nitric oxide that were unaltered by current 
smoking. Therefore to examine the hypothesis that smokers with asthma display 4 
altered  levels  of  alveolar  nitric  oxide  and  flow  independent  parameters 
compared  to  non smokers  with  asthma  I  carried  out  a  cross sectional  study. 
Alveolar nitric oxide, determined by linear modelling, was significantly reduced 
in  smokers  with  asthma  compared  to  non  smokers  with  asthma.  The 
concentrations  observed  were  within  the  range  for  normal  subjects  and 
therefore this method does not overcome the problems inherent in measuring 
exhaled  nitric  oxide  at  standard  flows.  The  use  of  non linear  modelling  did 
demonstrate parity between smokers and non smokers with asthma for alveolar 
nitric oxide. Nitric oxide flux was lower in smokers with asthma when derived by 
both  linear  and  non linear  modelling  and  displayed  sensitivity  to  oral 
corticosteroids. Therefore nitric oxide flux is worthy of further investigation as 
an exploratory endpoint in smokers with asthma. 
In  conclusion  treatment  of  smokers  with  asthma  with  low  dose  theophylline 
alone, the combination of low dose theophylline and inhaled corticosteroid and 
the PPARγ agonist rosiglitazone was associated with clinical improvements and 
further clinical trials to assess the role for these treatments in the management 
of smokers with asthma are justified. Smokers with asthma display an altered 
sputum cytokine profile with raised levels of the proinflammatory cytokine IL 6, 
equivalent blood total HDAC activity and reduced alveolar nitric oxide compared 
to  non smokers  with  asthma.  Sputum  HDAC  activity  requires  further 
development before it can be confidently employed as a method of assessing 
total pulmonary HDAC activity. 5 
TABLE OF CONTENTS 
1  INTRODUCTION  28 
1.1  Asthma  28 
1.2  Smokers with asthma  28 
1.2.1  Prevalence of active smoking in asthma  28 
1.2.2  Clinical evidence for reduced corticosteroid sensitivity in smokers with asthma  29 
1.3  Corticosteroids Role in the treatment of asthma and mechanisms of action  32 
1.3.1  Corticosteroids-Discovery and therapeutic role  32 
1.3.2  Corticosteroid resistance  32 
1.3.3  Corticosteroids-Mechanisms of action  33 
1.3.3.1  Cellular localisation and chaperones  34 
1.3.3.2  Transactivation  34 
1.3.3.3  Transrepression  34 
1.3.3.4  Epigenetic effects  35 
1.3.3.5  Post translational modifications of glucocorticoid receptor  36 
1.3.3.6  Non-genomic effects of glucocorticoids  36 
1.3.3.7  Heterodimer formation  36 
1.4  Potential mechanisms of reduced corticosteroid sensitivity in smokers with 
asthma  37 
1.4.1  Clinical studies-Sputum differential and supernatant  37 
1.4.2  Clinical studies-Exhaled markers of inflammation  39 
1.4.3  Clinical studies-Bronchoscopic samples  39 
1.5  Alteration of the glucocorticosteroid pathway  41 
1.5.1  Glucocorticoid receptor  41 
1.5.1.1  Cytokine induced corticosteroid resistance  41 
1.5.1.2  Alternative glucocorticoid receptor isoforms  42 
1.5.1.3  Altered glucocorticoid receptor kinetics  42 
1.6  Acquired defects in HDAC activity and potential implications for 
corticosteroid responses  43 
1.6.1  HDAC activity and expression in asthma  44 6 
1.6.2  HDAC in COPD  44 
1.6.3  Oxidative stress, smoking and HDAC  45 
1.6.4  Corticosteroids and HDAC  46 
1.7  Theophylline, HDAC and corticosteroids  47 
 1.7.1    Theophylline increases HDAC activity & potentiates corticosteroid mediated suppression 
of   inflammation  49 
1.7.2  Mechanisms by which theophylline may increase HDAC activity  50 
1.7.3  Possible role for theophylline in the treatment of smokers with asthma  51 
1.8  PPARγ and inflammation  52 
1.8.1  Is there a role for PPARγ agonists in smokers with asthma?  52 
1.8.2  PPARs-Discovery & structure  52 
1.8.3  PPAR family  53 
1.8.4  PPARγ-Endogenous ligands  53 
1.8.5  PPARγ-Synthetic Ligands  54 
1.8.6  Anti inflammatory effects of PPARγ and thiazolidinediones  54 
1.8.7  PPARγ modes of action  55 
1.8.7.1  Transactivation  56 
1.8.7.2  Transrepression  56 
1.8.7.3  Non genomic effects  57 
1.8.7.4  Modulation and utilisation of the glucocorticoid receptor by PPARγ  57 
1.8.7.5  PPARγ & HDAC  58 
1.8.8  PPARγ & asthma  59 
1.8.9  PPARγ and smokers with asthma  59 
1.9  Non invasive assessment of inflammation  60 
1.9.1  Rationale for use of non-invasive methods  60 
1.9.2  Induced sputum  60 
1.9.3  Induced sputum methodology  61 
1.9.3.1  Induction method  61 
1.9.3.2  Sputum processing  62 
1.9.4  Induced sputum-Clinical trials  62 
1.9.4.1  Induced sputum-Eosinophilia  62 7 
1.9.4.2  Induced sputum-Neutrophilia and paucicellular sputum  63 
1.9.4.3  Induced sputum-Definition of eosinophilia and neutrophilia  63 
1.9.4.4  Induced sputum-Reproducibility  63 
1.9.5  Sputum supernatant cytokines  64 
1.9.5.1  Effect of sputum processing on supernatant cytokines  64 
1.9.6  Exhaled markers of inflammation-Nitric oxide  65 
1.9.7  Nitric oxide in asthma  65 
1.9.7.1  Employment in asthma control algorithms  66 
1.9.7.2  Reference ranges  66 
1.9.7.3  Effects of cigarette smoking  67 
1.9.7.4  Extended flow nitric oxide analysis  67 
1.9.8  Exhaled breath condensate  68 
1.9.8.1  Exhaled breath condensate-methodological considerations  69 
1.9.8.2  Exhaled breath condensate pH  69 
1.9.8.3  Mechanisms responsible for EBC acidification  69 
1.10   Hypotheses and aims  70 
1.10.1  Theophylline & Rosiglitazone  70 
1.10.2  Corticosteroid sensitivity study  71 
2  METHODS  72 
2.1  Regulatory approval  72 
2.2  Recruitment methods  72 
2.3  Study design  73 
2.3.1  Efficacy of theophylline and rosiglitazone in smokers with asthma  73 
2.3.2  Determinants of corticosteroid insensitivity in smokers with asthma  75 
2.4  Demonstration of eligibility for recruitment to trials  77 
2.4.1  Reversibility testing  77 
2.4.2  Peak flow lability  78 
2.4.3  Bronchial provocation testing  78 
2.4.4  Urine cotinine  80 
2.4.5  Exhaled Carbon Monoxide measurement  81 
2.5  Clinical endpoints  82 8 
2.5.1  Spirometry  82 
2.5.2  Peak expiratory flow  83 
2.5.3  Asthma Control Questionnaire  83 
2.5.4  Exhaled Nitric Oxide  84 
2.5.5  Exhaled breath condensate pH  87 
2.5.6  Sputum induction  88 
2.6  Processing of biological samples  89 
2.6.1  Sputum processing  89 
2.6.2  Sputum differential counting  90 
2.6.3  Measurement of HDAC activity in sputum macrophages  90 
2.6.4  Measurement of sputum supernatant and plasma cytokines  91 
2.6.5  Blood tests  93 
2.6.5.1  Peripheral blood monocyte selection  93 
2.6.5.2  PBMC HDAC activity  94 
2.6.5.3  Biochemical assays  94 
2.6.5.4  Differential blood counts  94 
2.6.5.5  Serum IgE and IgE antibodies against common allergens  95 
2.7  Data handling and statistical analysis  95 
2.7.1  Data handling  95 
2.7.2  Statistical analysis  96 
2.7.2.1  Approach and performance of analysis  96 
2.7.2.2  Power calculations  97 
2.7.2.3  Multiple comparison issues  97 
3  REVERSAL OF CORTICOSTEROID INSENSITIVITY IN SMOKERS WITH ASTHMA
  99 
3.1  Introduction  99 
3.2  Methods  100 
3.2.1  Subjects  100 
3.2.2  Study design  100 
3.2.3  Measurements  101 9 
3.2.4  Statistical analysis  101 
3.3  Results  102 
3.3.1  Lung function  105 
3.3.1.1  Theophylline and inhaled beclometasone  105 
3.3.1.2  Theophylline  108 
3.3.1.3  ACQ score  108 
3.3.2  Sputum samples  108 
3.3.2.1  Induced sputum cytology  108 
3.3.2.2  Inflammatory biomarkers in sputum  109 
3.3.2.3  HDAC activity  109 
3.3.3  Serum theophylline levels  109 
3.3.4  Compliance  110 
3.3.5  Adverse events  110 
3.4  Discussion  111 
3.5  Conclusions  114 
4  EFFICACY OF A PPARγ AGONIST IN A GROUP OF SMOKERS WITH ASTHMA
  116 
4.1  Introduction  116 
4.2  Methods  117 
4.2.1  Subjects  117 
4.2.2  Study design  117 
4.2.3  Measurements  118 
4.2.4  Statistical analysis  118 
4.3  Results  119 
4.3.1  Lung function  122 
4.3.2  ACQ score  123 
4.3.3  Sputum samples  125 
4.3.3.1  Induced sputum cytology  125 
4.3.3.2  Sputum supernatant  125 
4.3.4  Compliance  125 10 
4.3.5  Adverse events  125 
4.4  Discussion  127 
4.5  Conclusion  130 
5  IMPACT OF SMOKING ON CYTOKINE PROFILES IN ASTHMA  131 
5.1  Introduction  131 
5.2  Methods  132 
5.2.1  Subjects  132 
5.2.2  Study design  133 
5.2.3  Measurements  133 
5.2.4  Statistical analysis  134 
5.3  Results  135 
5.3.1  Baseline demographics  135 
5.3.2  Lung function response to oral corticosteroid trial  135 
5.3.3  Change in sputum cell profile in response to oral corticosteroid trial  138 
5.3.4  Change in asthma control questionnaire score  139 
5.3.5  Sputum supernatant cytokines  139 
5.3.5.1  Baseline sputum cytokine correlations  144 
5.3.6  Baseline plasma cytokines  146 
5.3.6.1  Baseline plasma cytokine correlations  150 
5.3.7  Correlation between sputum cytokines  152 
5.3.8  Correlation between plasma and sputum cytokines  152 
5.3.9  Cytokine response to oral corticosteroid trial  153 
5.3.9.1  Sputum cytokine responses  153 
5.3.9.2  Plasma cytokine responses to oral corticosteroids  156 
5.3.10  IL-6 high sensitivity ELISA  159 
5.3.10.1  ELISA results  159 
5.3.10.2  Comparison of Luminex and ELISA results  160 
5.4  Discussion  161 
5.5  Conclusion  168 11 
6  RELEVANCE OF HDAC ACTIVITY TO CORTICOSTEROID RESPONSE IN 
SMOKERS WITH ASTHMA  169 
6.1  Introduction  169 
6.2  Methods  170 
6.2.1  Subjects  170 
6.2.2  Study design  170 
6.2.3  Measurements  170 
6.2.4  Statistical analysis  171 
6.3  Results  171 
6.3.1  Baseline comparisons  171 
6.3.1.1  Clinical characteristics  171 
6.3.1.2  Lung function measurements  172 
6.3.1.3  Baseline sputum characteristics  172 
6.3.2  Corticosteroid response  172 
6.3.3  Change in clinical characteristics and sputum profile  172 
6.3.4  Baseline HDAC activity  172 
6.3.4.1  Baseline sputum macrophage HDAC activity  172 
6.3.4.2  Baseline blood monocyte HDAC activity  173 
6.3.4.3  Relationship of sputum HDAC activity to lung function response to dexamethasone  174 
6.3.4.4  Relationship of blood HDAC activity to lung function response to dexamethasone  175 
6.3.4.5  Correlation between sputum HDAC and blood HDAC activity  176 
6.3.5  Change in HDAC activity in response to dexamethasone  177 
6.3.5.1  Change in sputum HDAC activity  177 
6.3.5.2  Change in blood HDAC activity  177 
6.4  Discussion  179 
6.5  Conclusions  181 
7  NON INVASIVE ASSESSMENT OF INFLAMMATION IN SMOKERS WITH ASTHMA
  182 
7.1  Introduction  182 
7.1.1  Extended flow nitric oxide analysis  182 12 
7.1.2  Exhaled breath condensate pH  184 
7.2  Methods  184 
7.2.1  Subjects  184 
7.2.2  Study design  184 
7.2.3  Measurements  185 
7.2.4  Statistical analysis  189 
7.3  Results  190 
7.3.1  Baseline comparisons  190 
7.3.2  Exhaled nitric oxide-FENO50  190 
7.3.3  Exhaled breath condensate pH  191 
7.3.4  Extended flow nitric oxide  192 
7.3.4.1  Alveolar Nitric Oxide and Airway Wall Flux  192 
7.3.4.2  Airway wall Nitric Oxide concentration and Nitric Oxide diffusion  195 
7.3.4.3  Comparison of linear and non-linear models  197 
7.3.4.4  Impact of corticosteroids on extended flow measurements at one month  198 
7.4  Discussion  201 
8  CONCLUSIONS AND FUTURE DIRECTIONS  206 
8.1  Summary of findings  206 
8.2  Limitations of presented research  207 
8.3  Conclusions & future directions  209 
9  REFERENCES  210 
 
 13 
LIST OF TABLES 
 
TABLE 2.1 WITHDRAWAL PERIODS FOR BRONCHODILATORS PRIOR TO REVERSIBILITY TESTING...................77 
TABLE 2.2 ADVISED DURATIONS OF WITHDRAWAL FROM MEDICATIONS AND FOODS. ................................79 
TABLE 3.1 BASELINE DEMOGRAPHICS............................................................................................................104 
TABLE 3.2 BASELINE SPUTUM COUNTS AND HDAC ACTIVITY........................................................................105 
TABLE 3.3 CHANGE IN LUNG FUNCTION AND BIOMARKERS FOLLOWING TREATMENT (RELATIVE TO 
RESPONSE TO TREATMENT WITH INHALED BECLOMETASONE ALONE). .............................................107 
TABLE 4.1 BASELINE DEMOGRAPHICS............................................................................................................121 
TABLE 4.2 BASELINE SPUTUM COUNTS..........................................................................................................122 
TABLE 4.3 CHANGE IN LUNG FUNCTION AND ACQ FOLLOWING TREATMENT (RELATIVE TO RESPONSE TO 
INHALED BECLOMETASONE ALONE).....................................................................................................123 
TABLE 4.4 CHANGE IN SPUTUM COUNTS AND SUPERNATANT CYTOKINES FOLLOWING TREATMENT 
(RELATIVE TO TREATMENT WITH INHALED BECLOMETASONE ALONE)...............................................126 
TABLE 5.1 BASELINE DEMOGRAPHICS............................................................................................................136 
TABLE 5.2 PRE STEROID LUNG FUNCTION......................................................................................................136 
TABLE 5.3 BASELINE SPUTUM PROFILES........................................................................................................137 
TABLE 5.4 WITHIN GROUP LUNG FUNCTION RESPONSE TO ORAL STEROID. ................................................137 
TABLE 5.4 SPUTUM CYTOKINE RESULTS-BASELINE COMPARISONS...............................................................141 
TABLE 5.6 BASELINE PLASMA CYTOKINES......................................................................................................148 
TABLE 5.7 POST STEROID TRIAL SPUTUM CYTOKINES. ..................................................................................155 
TABLE 5.8 POST STEROID TRIAL PLASMA CYTOKINES....................................................................................157 
TABLE 5.9 PRE AND POST SPUTUM IL-6 LEVELS MEASURED BY HIGH SENSITIVITY ELISA. ............................159 
TABLE 6.1 COMPARISON OF HDAC ACTIVITY ACROSS GROUPS FOR SPUTUM AND BLOOD. ........................173 
TABLE 7.1 RANGES FOR NORMAL ADULTS, NON-SMOKING SUBJECTS WITH ASTHMA NOT TREATED AND 
TREATED WITH INHALED CORTICOSTEROID.........................................................................................189 
TABLE 7.2 EXHALED NITRIC OXIDE MEASURED AT STANDARD FLOW RATE OF 50ML/SEC. ..........................191 
TABLE 7.3 EBC PH AT BASELINE, POST CORTICOSTEROID TRIAL AND ONE MONTH AFTER ORAL 
CORTICOSTEROID TRIAL........................................................................................................................192 
TABLE 7.5 LINEAR REGRESSION ANALYSIS RESULTS FOR 100, 200, 300 ML/SEC...........................................192 
TABLE 7.6 NON LINEAR REGRESSION ANALYSIS.............................................................................................194 14 
TABLE 7.7 AIRWAY WALL CONCENTRATION AND DIFFUSION OF NITRIC OXIDE PRODUCED BY LINEAR 
REGRESSION USING 30 AND 50ML/SEC FLOW RATES..........................................................................196 
TABLE 7.8 AIRWAY WALL CONCENTRATION AND DIFFUSION OF NITRIC OXIDE PRODUCED BY NON-LINEAR 
REGRESSION. ........................................................................................................................................197 
TABLE 7.9 VARIATION IN ALVEOLAR NITRIC OXIDE AND AIRWAY NITRIC OXIDE FOR LINEAR MODELLING 
USING 100, 200 & 300ML/SEC FLOW RATES........................................................................................199 
TABLE 7.10 VARIATION IN ALVEOLAR NITRIC OXIDE, AIRWAY NITRIC OXIDE FLUX, CONCENTRATION AND 
DIFFUSION FOR NON-LINEAR MODELLING...........................................................................................200 15 
LIST OF FIGURES 
 
FIGURE 1.1 MEAN (95% CI) CHANGE IN MORNING PEF (L/MIN) IN SMOKERS COMPARED TO NON-SMOKERS 
WITH ASTHMA........................................................................................................................................30 
FIGURE 2.1 METHACHOLINE CALCULATION METHOD. TABLE ADAPTED FROM (247) ....................................80 
FIGURE 2.2 SCHEMATIC OF 2-COMPARTMENT MODEL FOR NITRIC OXIDE PULMONARY EXCHANGE............86 
FIGURE 2.3 LINEARITY OF IL-6 DETECTION AND EFFECT OF TWO CONCENTRATIONS OF DTT ON 
ANTIGENICITY.........................................................................................................................................92 
FIGURE 2.4 RESULT OF SPIKING EXPERIMENT FOR 30 CYTOKINES..................................................................92 
FIGURE 3.1 RANDOMISATION SCHEDULE......................................................................................................101 
FIGURE 3.2 CONSORT DIAGRAM SHOWING FLOW OF PARTICIPANTS THROUGH THE TRIAL........................103 
FIGURE 3.3 CHANGE IN PEF (L/MIN) BY 28 DAYS OF TREATMENT.................................................................106 
FIGURE 3.4 CHANGE IN FEV1 (ML) BY 28 DAYS OF TREATMENT....................................................................106 
FIGURE 3.5 CHANGE IN ACQ SCORE BY 28 DAYS OF TREATMENT.................................................................108 
FIGURE 3.6 CHANGE IN HDAC ACTIVITY FROM RANDOMISATION TO 28 DAYS OF TREATMENT..................110 
FIGURE 4.1 RANDOMISATION SCHEDULE......................................................................................................118 
FIGURE 4.2 CONSORT DIAGRAM....................................................................................................................120 
FIGURE 4.3 MEAN GROUP FEV1 CHANGES FROM RANDOMISATION TO 14 AND 28 DAYS OF TREATMENT.124 
FIGURE 4.4 MEAN GROUP FEF25-75 CHANGES FROM RANDOMISATION TO 14 AND 28 DAYS OF TREATMENT
..............................................................................................................................................................124 
FIGURE 5.1 WITHIN GROUP CHANGE IN FEV1 IN RESPONSE TO ORAL STEROID TRIAL..................................138 
FIGURE 5.2 BASELINE SPUTUM SUPERNATANT IFNΓ.....................................................................................140 
FIGURE 5.3 BASELINE SPUTUM SUPERNATANT IL-2. .....................................................................................142 
FIGURE 5.4 BASELINE SPUTUM SUPERNATANT IL-4. .....................................................................................142 
FIGURE 5.5 BASELINE SPUTUM SUPERNATANT IL-6. .....................................................................................143 
FIGURE 5.6 BASELINE SPUTUM SUPERNATANT IL-7. .....................................................................................143 
FIGURE 5.7 SCATTER PLOT OF SMOKERS WITH ASTHMA PRE-STEROID SPUTUM LOG IL-6 AGAINST PRE-
BRONCHODILATOR PRE-CORTICOSTEROID TRIAL FEV1........................................................................145 
FIGURE 5.8 BASELINE PLASMA IL-1RA LEVELS IN NON-SMOKERS WITH ASTHMA AND SMOKERS WITH 
ASTHMA................................................................................................................................................147 16 
FIGURE 5.9 BASELINE PLASMA IL-10 LEVELS IN NON-SMOKERS WITH ASTHMA AND SMOKERS WITH 
ASTHMA................................................................................................................................................149 
FIGURE 5.10 BASELINE PLASMA IL-13 LEVELS IN NON-SMOKERS WITH ASTHMA AND SMOKERS WITH 
ASTHMA................................................................................................................................................149 
FIGURE 5.11 BASELINE PLASMA GM-CSF LEVELS IN NON-SMOKERS WITH ASTHMA AND SMOKERS WITH 
ASTHMA................................................................................................................................................150 
FIGURE 5.12 COMPARISON OF PRE STEROID AND POST STEROID SPUTUM IL-6 IN SMOKERS WITH ASTHMA
..............................................................................................................................................................154 
FIGURE 5.13 INDIVIDUAL PLOT OF IL-6 LEVELS OBTAINED BY HIGH SENSITIVITY ELISA IN NON-SMOKERS 
WITH ASTHMA AND SMOKERS WITH ASTHMA....................................................................................160 
FIGURE 5.14 CORRELATION BETWEEN LOG LUMINEX IL-6 AND LOG ELISA IL-6 RESULTS FOR SMOKERS WITH 
ASTHMA................................................................................................................................................161 
FIGURE 6.1 BASELINE SPUTUM HDAC ACTIVITY IN NON-SMOKERS, EX-SMOKERS AND SMOKERS WITH 
ASTHMA................................................................................................................................................173 
FIGURE 6.2 BASELINE BLOOD HDAC ACTIVITY IN NON-SMOKERS, EX-SMOKERS AND SMOKERS WITH 
ASTHMA................................................................................................................................................174 
FIGURE 6.3 RELATIONSHIP BETWEEN FEV1 RESPONSE TO DEXAMETHASONE AND BASELINE SPUTUM 
MACROPHAGE HDAC ACTIVITY.............................................................................................................175 
FIGURE 6.4 RELATIONSHIP BETWEEN FEV1 RESPONSE TO DEXAMETHASONE AND BASELINE BLOOD 
MONOCYTE HDAC ACTIVITY. ................................................................................................................176 
FIGURE 6.5 SCATTERPLOT OF BASELINE BLOOD AND SPUTUM HDAC ACTIVITY (WITH REGRESSION)..........177 
FIGURE 6.6. RELATIONSHIP BETWEEN CHANGE IN BLOOD HDAC ACTIVITY AND CHANGE IN FEV1 IN EX-
SMOKERS WITH ASTHMA.....................................................................................................................178 
FIGURE 7.1 PLOT OF ELIMINATION RATE OF EXHALED NITRIC OXIDE AGAINST EXHALATION FLOW RATE. .186 
LINE REPRESENTS LINEAR REGRESSION THROUGH THE DATA POINTS. THE SLOPE OF THE LINE REFLECTS THE 
ALVEOLAR NITRIC OXIDE CONCENTRATION AND THE Y-INTERCEPT THE AIRWAY WALL FLUX............186 
FIGURE 7.2 PLOT OF EXHALED NITRIC OXIDE CONCENTRATION AGAINST EXHALATION FLOW RATE. LINE 
REPRESENTS NON-LINEAR REGRESSION THROUGH THE DATA POINTS...............................................187 
FIGURE 7.3 BASELINE EXHALED NITRIC OXIDE (FENO50) LEVELS......................................................................191 
FIGURE 7.4 BASELINE ALVEOLAR NITRIC OXIDE (CALV)-NON-LINEAR MODELLING.........................................194 17 
FIGURE 7.5 BASELINE NITRIC OXIDE FLUX (JAW)-NON-LINEAR MODELLING...................................................195 
FIGURE 7.6 BLAND-ALTMAN PLOT OF ALVEOLAR NITRIC OXIDE (CALV) DIFFERENCE (LINEAR-NON-LINEAR) 
AGAINST ALVEOLAR NITRIC OXIDE (CALV) AVERAGE FOR LINEAR AND NON-LINEAR MODELS...........198 18 
DECLARATION 
 
I  am  the  sole  author  of  this  thesis  and  have  personally  consulted  all  the 
references listed.  I was solely responsible for the day to day running of both 
projects and I recruited, screened, obtained informed consent and performed 
randomisation  of  all  the  patients  and  the  majority  of  follow  up  visits.  The 
remainder of follow up visits were performed by Maureen Brannigan & Joyce 
Thompson  with  occasional  help  from  Rekha  Chaudhuri  and  Jane  Lafferty  (All 
employees of Asthma Research Unit, University of Glasgow). 
I generated the majority of approach letters and performed the majority of GP 
practice  searches  with  occasional  help  from  Joyce  Thompson,  Maureen 
Brannigan, June McGill & Janice Reid (both West Node, SPCRN). 
Hiran  Cooray  (GSK  Discovery  Medicine  Section),  Colin  Rodden  and  Anne  Watt 
(Gartnavel General Pharmacy) provided medication packs for the theophylline 
and rosiglitazone study. Colin Rodden and Anne Watt provided dexamethasone 
packs for the corticosteroid sensitivity study. 
Iona  Donnelly,  Lisa  Jolly  and  Poh  Lin  Winn  (GBRC,  University  of  Glasgow) 
prepared the sputum, supernatant and blood samples and performed sputum cell 
counts,  supernatant  and  plasma  Luminex  and  the  sputum  RANTES  ELISA.  I 
performed the sputum IL 6 ELISA with help from Lisa Jolly and Grace Murphy 
(GBRC, University of Glasgow). The sputum IL 8 and MPO ELISAs were performed 
by GSK Discovery Medicine Section. 
Kazuhiro  Ito  and  Kenichi  Akashi  (NHLI  Imperial  College)  performed  the  HDAC 
activity assay. 
I performed the data entry and the majority of the analysis for the theophylline 
and  rosiglitazone  study.  Lisa  Sweeney  (GSK  Discovery  Medicine  Section) 
performed the lung function analysis. I also performed the data entry for the 
trial  examining  corticosteroid  responses.  Dr  Chris  Weir  (Robertson  Centre  for 
Biostatistics, University of Glasgow) performed the majority of the analysis in 
the  trial  examining  corticosteroid  responses  in  subjects  with  asthma  with 
supplementary analyses performed by myself where required. This thesis has not 
been previously been submitted for a higher degree. 19 
ACKNOWLEDGEMENTS 
 
I would like to express my thanks to Professor Neil C Thomson for the guidance, 
patience and support that he has provided in his capacity as supervisor. It is 
unlikely that the work presented here would be of as high a quality without his 
involvement.  
I  would  also  like  to  thank  Iona  Donnelly  &  Lisa  Jolly  for  their  tireless  work, 
enthusiasm and dedication in the laboratory. Thanks to Rekha Chaudhuri and 
Charles McSharry for advice and support, Maureen Brannigan for arriving in my 
hour of need, Joyce Thompson and Jane Lafferty for helping out when Maureen 
couldn’t,  Kazuhiro  Ito  and  his  team  for  the  HDAC  assays,  Chris  Weir  for  his 
excellent advice and statistical work, Colin Rodden and Anne Watt for their work 
in preparation and handling of drug prescriptions for the studies and Poh Lin 
Winn for her efforts in the lab. 
I would like to thank Hiran Cooray and Philippe Bareille of GSK Discovery for 
their  professionalism  and  enthusiasm  for  the  theophylline  and  rosiglitazone 
project. 
Thanks  to  Chest,  Heart  and  Stroke  (Scotland)  and  the  Chief  Scientists  Office 
(Scotland) for recognising the potential strength of the work presented in this 
thesis and for providing research training fellowships as a result. 
Finally I would like to thank Annabel who started off as girlfriend, progressed to 
fiancée and then became my wife during this period of research. Thank you for 
your patience, support and understanding. 
 
 
 
 
 
 
 
This thesis is dedicated to the memory of Dr Stuart Wood who died suddenly, 
shortly  after  the  commencement  of  recruitment  to  the  study  examining 
theophylline  and  rosiglitazone,  a  project  which  had  benefitted  from  his 
considerable enthusiasm and energy. 20 
ABBREVIATIONS 
 
ACQ    asthma control questionnaire 
ADP    adenosine diphosphate 
AFU    arbitrary fluorescence units 
AQLQ    asthma quality of life questionnaire 
AP1    activator protein 1 
ATP    adenosine trisphosphate 
BAL    bronchoalveolar lavage 
BMI    body mass index 
Calv     alveolar nitric oxide concentration 
Caw     airway wall concentration of nitric oxide 
CCL    chemokine with C C N terminal motif 
CD    cluster of differentiation 
cGMP    cyclic guanosine monophosphate 
COPD    chronic obstructive pulmonary disease 
CXC    chemokine with C X C N terminal motif 
Daw     airway wall nitric oxide diffusion 
DNA    deoxyribonucleic acid 
DTT    dithiothreitol 
EBC    exhaled breath condensate 
ELISA    enzyme linked immunosorbent assay 
eNOS    endothelial nitric oxide synthase 
FEV1    forced expiratory volume in the first second 
FENO    exhaled nitric oxide concentration 
FENO50    exhaled nitric oxide concentration at flow rate of 50ml/sec 
FEF25 75  forced mid expiratory flow rate 
FEF75    forced expiratory flow at 75% of FVC 
FVC    forced vital capacity 
GM CSF  granulocyte/monocyte colony stimulating factor 
GR    glucocorticoid receptor 
GRα    glucocorticoid receptor alpha 
GRβ    glucocorticoid receptor beta 
HAT    histone acetyltransferase 
HDAC    histone de acetylase 21 
H2O2    hydrogen peroxide 
ICC    intraclass correlation 
ICS    inhaled corticosteroid 
IFN α    interferon α 
IFN γ    interferon γ 
IgE    immunoglobulin E 
IκB    inhibitor of κB 
IL    interleukin 
IL 1RA   IL1 receptor antagonist 
IL 2R    IL 2 receptor 
IP 10    Interferon inducible Protein of 10 kDa (aka CXCL10) 
iNOS    inducible nitric oxide synthase 
IQR    interquartile range 
IU    international units 
Jaw    airway wall nitric oxide flux 
J’aw    maximal airway wall nitric oxide flux 
JNK    c Jun N terminal kinase 
kDa    kilodalton 
kg/m
2   kilograms/metres squared 
LABA    long acting β2 receptor agonist 
L/min   litres per minute 
Log    logarithm 
LPS    lipopolysaccharide 
MAPK    mitogen associated protein kinase 
MCP 1   Monocyte Chemotactic Protein 1 
MEK    MAPK kinase 
MIG    Monokine Induced by IFN γ (aka CXC9) 
MIP 1α  Monocyte Inflammatory Protein 1α (aka CCL3) 
MIP 1β  Monocyte Inflammatory Protein 1β (aka CCL4) 
mRNA   messenger ribonucleic acid 
NCoR    nuclear receptor co repressor 
NFAT    nuclear factor of activated T cells 
NFκB    nuclear factor kappa light chain enhancer of activated B cells 
nNOS    neuronal nitric oxide synthase 
NO    nitric oxide concentration 22 
NSAID   non steroidal anti inflammatory drug 
PC20  provocative  concentration  of  methacholine  causing  a  20%  fall  in 
FEV1 
PDE    phosphodiesterase 
PEF    peak expiratory flow 
PBMC    peripheral blood borne monocyte 
PI3K    phosphatidylinositol 3 kinase 
pl/s    picolitres per second 
pl/s/ppb  picolitres per parts per billion per second 
ppb    parts per billion 
PPAR    peroxisome proliferator activated receptor 
PPRE    peroxisome proliferator response element 
PTEN    phosphatase and tensin homolog deleted on chromosome ten 
p38    p38 MAPK 
RANTES  regulated upon activation, normal T cell expressed and secreted 
(aka CCL5) 
RNA    ribonucleic acid 
RU486   mifepristone 
RXR    retinoid X receptor 
SAE    serious adverse event 
SD    standard deviation 
SEM    standard error of the mean 
siRNA   small interfering RNA 
SNP    single nucleotide polymorphism 
STAT    signal transducers and activator of transcription 
SUMO   small ubiquitin like modifier 
TGFβ    Transforming Growth Factor β 
Th1    Type 1 helper T cell 
Th2    Type 2 helper T cell 
Th17    IL 17 positive T helper cells 
TNFα    Tumour Necrosis Factor α 
Treg    Regulatory T lymphocyte 
TSA    trichostatin A 
VE     exhalation flow rate 
VNO    elimination rate of exhaled nitric oxide 23 
4HNE    4 hydroxynonenal 
15d PGJ2  15 deoxy ∆
12,14 prostaglandin J2 
95% CI   95% confidence interval 24 
PUBLICATIONS ARISING FROM THESIS 
 
1.  Effect of theophylline plus beclometasone on lung function in smokers with 
asthma a pilot study 
Spears  M,  Donnelly  I,  Jolly  I,  Brannigan  M,  Ito  K,  McSharry  C,  Lafferty  J, 
Chaudhuri R,  Braganza G, Adcock IM, Barnes PJ, Wood S & Thomson NC. 
European Respiratory Journal. 2009; 33 (5): 1010 7 
 
2.  Bronchodilator  effect  of  the  PPARγ  agonist  rosiglitazone  in  smokers  with 
asthma 
Spears  M,  Donnelly  I,  Jolly  I,  Brannigan  M,  Ito  K,  McSharry  C,  Lafferty  J, 
Chaudhuri R,  Braganza G, Bareille P, Sweeney L, Adcock IM, Barnes PJ, Wood 
S & Thomson NC. 
Clinical Pharmacology & Therapeutics. 2009; 86 (1): 49 53 
 
3.  Role of symptoms and lung function in determining asthma control in smokers 
with asthma 
Chaudhuri R, McSharry C, McCoard A, Livingston E, Hothersall E, Spears M, 
Lafferty J & Thomson NC. 
Allergy. 2008; 63 (1):132 5 
4.  Peroxisome  proliferator activated  receptor γ  agonists  as  potential  anti 
inflammatory agents in asthma and chronic obstructive pulmonary disease 
Spears M, McSharry CP & Thomson NC. 
Clinical & Experimental Allergy. 2006; 36 (12): 1494 504 
 
5.  Corticosteroid  Insensitivity  in  Smokers  with  Asthma:  Clinical  Evidence, 
Mechanisms and Management.  
Thomson NC, Shepherd M, Spears M & Chaudhuri R.  
Treatments in Respiratory Medicine. 2006; 5: 467 481. 
 
6.  The influence of smoking on the treatment response in patients with asthma. 
Thomson NC & Spears M. 
Current Opinion in Allergy & Clinical Immunology. 2005; 5(1): 57 63. 25 
ABSTRACTS ARISING FROM THESIS 
 
1.  Exhaled Breath Condensate pH response to oral corticosteroid in smokers, ex 
smokers and non smokers with asthma 
Spears  M,  Weir  C,  Thompson  J,  Brannigan  M,  Lafferty  J,  Chaudhuri  R, 
Braganza G, Cameron E & Thomson NC. 
Poster. European Respiratory Society Meeting, Vienna, Oct 2009 
 
2.  Comparison of extended flow nitric oxide parameters in smokers and non 
smokers with asthma before and after an oral corticosteroid trial 
Spears  M,  Weir  C,  Thompson  J,  Brannigan  M,  Lafferty  J,  Chaudhuri  R, 
Braganza G, Cameron E & Thomson NC. 
Poster. European Respiratory Society Meeting, Vienna, Oct 2009 
 
3.  Smokers  with  asthma  display  an  altered  sputum  cytokine  profile  that  is 
insensitive to short course oral corticosteroid therapy  
Spears M, Donnelly I, Jolly L, Winn PL, Weir C, McSharry C, Chaudhuri R, 
Thompson J, Brannigan M, Lafferty J & Thomson NC.  
Poster discussion. American Thoracic Society Meeting, San Diego, May 2009 
 
4.  Efficacy of two new approaches to treatment of smokers with asthma. Spears 
M, Donnelly I, Jolly L, Brannigan M, Ito K, McSharry C, Lafferty J, Chaudhuri 
R,  Braganza  G,  Bareille  P,  Sweeney  L,  Adcock  IA,  Barnes  PJ,  Wood  S  & 
Thomson NC  
Poster. RCSPG Triennial conference, Glasgow, November 2008 
 
5.  Efficacy of low dose theophylline and inhaled corticosteroids in smokers with 
asthma  
Spears M, Donnelly I, Jolly L, Brannigan M, Ito K,  McSharry C, Lafferty J, 
Chaudhuri R, Braganza G, Bareille P, Sweeney L, Adcock IA, Barnes PJ, Wood 
S & Thomson NC.  
Poster. European Respiratory Society Meeting, Berlin, October 2008 
 
 
 26 
6.  Efficacy of the PPARγ agonist rosiglitazone in smokers with asthma.  
Spears M, Donnelly I, Jolly L, Brannigan M, McSharry C, Chaudhuri R, Bareille 
P, Sweeney L, Lafferty J, Wood S & Thomson NC.  
Poster. American Thoracic Society Meeting, Toronto, May 2008 27 
ORAL PRESENTATIONS OF WORK FROM THESIS 
 
1.  Overcoming relative corticosteroid insensitivity and enhancing the treatment 
response of smokers with asthma.  
November 2008. Celsus meeting, University of Glasgow.  
 
2.  PPARγ agonists in asthma a proof of concept clinical trial.  
August  2008.  Divisional  Away  Day,  Division  of  Immunology  Infection  & 
Inflammation, University of Glasgow.  
 
3.  Reversing corticosteroid sensitivity in Smokers with Asthma.  
August  2008.  Divisional  Away  Day,  Division  of  Immunology  Infection  & 
Inflammation, University of Glasgow. 
 
4.  Efficacy  of  low  dose  theophylline  and  inhaled  beclometasone  and 
rosiglitazone  alone  compared  to  inhaled  beclometasone  in  Smokers  with 
Asthma.  
May 2008. Scottish Society of Experimental Medicine Meeting, Dundee 
Awarded Sir James Black Prize for best oral presentation 
 
5.  Therapeutic impact of Rosiglitazone and low dose Theophylline in Smokers 
with Asthma. April 2008. Scottish Thoracic Society Meeting, Perth 
 
6.  Rosiglitazone  in  Smokers  with  Asthma;  a  possible  new  class  of  anti 
inflammatory treatment? January 2008, SSPC meeting, Carnoustie 
 
7.  PPARγ  agonists  as  potential  anti inflammatory  agents  for  Smokers  with 
asthma. August 2006. Divisional Away Day, Division of Immunology Infection 
& Inflammation, University of Glasgow. 
 
8.  Corticosteroid insensitivity in Smokers with Asthma. August 2005. Divisional 
Away  Day,  Division of  Immunology  Infection  &  Inflammation,  University  of 
Glasgow.  28 
1  Introduction 
1.1 Asthma 
Asthma  is  a  common  condition,  characterised  by  variable  symptoms  of 
breathlessness, cough and/or wheeze combined with variable airflow obstruction 
and  inflammation  (1,  2).  A  recent  report  estimated  that  300  million  people 
worldwide  are  currently  affected  by  asthma  (3).  The  prevalence  of  asthma 
varies between countries and the UK has one of the highest rates with 5 million 
people currently receiving treatment (4). Scotland is disproportionately affected 
as it has the world’s highest prevalence in children (35%) and a high proportion 
of affected adults (18%) (3). 
Whilst the majority of patients with asthma can achieve a degree of control with 
either  inhaled  corticosteroids,  a  combination  of  inhaled  steroids  and  other 
inhaled or oral therapies there is still a large sub group who fail to achieve this. 
Smokers with asthma are normally excluded from clinical trials due to a desire 
to  exclude  subjects  with  chronic  obstructive  pulmonary  disease  but  recent 
research  demonstrates  that  smokers  with  asthma  have  a  poor  response  to 
inhaled corticosteroids (5 10) and worse symptoms from asthma as demonstrated 
by asthma questionnaire (11, 12). Therefore it can be reasonably argued, given 
the  prevalence  of  smoking  in  asthma,  that  smokers  with  asthma  are  a  large 
neglected  and  important  group  that  require  further  study  and  new  therapies 
(13). It is against this background that this thesis was undertaken with the aim of 
understanding and exploring possible mechanisms for improving asthma control 
in smokers with asthma. 
1.2  Smokers with asthma 
1.2.1 Prevalence of active smoking in asthma 
Despite many years of public health programmes highlighting the negative health 
effects of smoking this habit is still surprisingly common in asthmatics. Current 
estimates suggest twenty to thirty five percent of adult asthmatics in Northern Chapter 1    29 
Europe are current smokers and at least half the adult population with asthma 
are current or ex cigarette smokers (11, 14, 15). The prevalence of smoking is 
higher  in  asthmatics  that  visit  emergency  departments  with  asthma 
exacerbations  (16,  17)  or  who  have  died  from  asthma  (18,  19)  than  general 
population estimates of current smoking in asthma and the death rate six years 
after admission to hospital with a near fatal asthma attack is higher amongst 
smokers compared to non smokers (20). Even when mild forms of asthma are 
included in analyses smokers with asthma have worse symptoms compared to 
matched non smoking asthmatics (11, 12) and smokers with asthma display an 
accelerated  decline  in  lung  function (15,  21).  This  phenomenon  is  associated 
with  evidence  of  an  altered  response  to  both  inhaled  (5 10)  and  oral 
corticosteroids (22 24) in smokers with asthma. 
1.2.2 Clinical  evidence  for  reduced  corticosteroid  sensitivity  in 
smokers with asthma 
The first prospective randomised controlled trial to demonstrate corticosteroid 
insensitivity  in  smokers  with  asthma  compared  the  effect  of  three  weeks 
treatment with inhaled fluticasone propionate (1000 mcg daily) to placebo in a 
cross over  study  of  17  smokers  and  21  non smokers  with  corticosteroid naïve 
asthma (7). Non smokers demonstrated a significant increase in FEV1, PEF, PC20 
and a decrease in proportion of sputum eosinophils. This contrasted with the 
smokers with asthma who did not demonstrate improvements for any of these 
endpoints. 
However a potential criticism of this study was its short duration and therefore 
another clinical trial addressed this issue (8). Inhaled beclometasone at doses of 
either 400 mcg or 2000 mcg daily were allocated for 12 weeks to smokers and 
non smokers in a double blind randomised controlled fashion. At the conclusion 
of  the  trial  the  non smoking  subjects  treated  with  400  mcg  significantly 
improved  their  morning  PEF  compared  to  smokers  (figure  1.1).  This  was 
associated with a reduction in asthma exacerbations and was in contrast to the 
smokers with asthma who did not demonstrate any significant improvements. 
However  when  treated  with  2000  mcg  inhaled  beclometasone  there  was  no 
significant  difference  between  smokers  and  non smokers  with  asthma.  This Chapter 1    30 
result would appear to indicate that higher doses of corticosteroids can produce 
an equivalent level of lung function response to that produced in non smokers 
with asthma using standard low doses. However an interaction analysis suggested 
that  the  higher  dose  was  not  performing  significantly  better  than  the  lower 
dose. Therefore further trials using high dose inhaled corticosteroids in smokers 
with asthma are required to clarify this point. 
 
Figure  1.1  Mean  (95%  CI)  change  in  morning  PEF  (L/min)  in  smokers  compared  to  non-
smokers with asthma.  
Mean  change  above  the  line  demonstrates  greater  improvement  in  non-smokers  with 
asthma.  *; p<0.05. Adapted from (20). 
 
A  further  study  carried  out  by  a  separate  group  examined  the  corticosteroid 
response of smokers with asthma with lower pack year histories (9). The multi 
centre randomised cross over trial undertaken by the Asthma Clinical Research 
Network in the USA examined the treatment response of a group of smokers with 
asthma  (compared  to  non smokers  with  asthma)  to  eight  weeks  of  400mcg 
inhaled CFC free beclometasone (‘QVAR
TM’) or montelukast. The mean pack year 
history  in  the  smokers  was  7  years.  Treatment  with  inhaled  beclometasone 
improved FEV1, PEF and PC20 in the non smokers but not in the smokers.  
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A post hoc analysis of a large management trial designed to achieve total control 
of  asthma  through  the  use  of  inhaled  fluticasone  and  the  combination  of 
fluticasone and salmeterol for one year confirmed and strengthened this finding 
of reduced response to inhaled corticosteroids in subjects with low pack year 
histories (10, 25). Logistic regression analysis demonstrated that smokers with 
asthma with less than ten pack years had an odds ratio for poorly controlled 
asthma of 2.8 (95% CI 2.0 3.7) despite treatment with inhaled fluticasone (23). 
At the conclusion of the trial only 40% of smokers had achieved well controlled 
asthma on inhaled fluticasone alone compared to 63% of non smokers (10). 
The lung function response in smokers with asthma to a short term course of oral 
corticosteroids  has  also  been  examined.  An  early  study  found  that  current 
smoking predicted an impaired FEV1 response to oral corticosteroids in patients 
with  unstable  asthma  (22).  In  a  subsequent  randomised,  placebo controlled 
crossover trial, 14 smokers, 10 ex smokers and 26 never smokers with asthma 
took oral prednisolone 40 mg daily or placebo for two weeks (23). This study 
demonstrated  that  pre bronchodilator  FEV1,  morning  PEF  and  asthma  control 
score improved in the never smokers. However no change was observed in the 
smokers  with  asthma.  A  larger  study  examining  corticosteroid  response  in 
smokers  and  non  smokers  with  asthma  found  no  difference  in  FEV1  response 
when smokers and non smokers with asthma responses were compared. However 
non smokers with asthma demonstrated a larger PEF response than smokers with 
asthma (24). 
An  important  diagnostic issue  for  the  studies  discussed above  is  whether  the 
smokers  recruited  have  asthma  rather  than  chronic  obstructive  pulmonary 
disease (COPD) given the widespread recognition that subjects with COPD have a 
reduced  response  to  corticosteroids  (26).  There  can  of  course  be  overlap 
between the two conditions with some subjects displaying clinical features of 
both asthma and COPD. However the smokers recruited to the discussed studies 
had  features  that  were  more  in  keeping  with  asthma  rather  than  a  COPD 
phenotype. For example, the average onset of asthmatic symptoms were either 
early twenties (7, 9, 23) or mid thirties (8, 25). Patients were also required to 
demonstrate  either  airway  hyperreactivity  (7,  9)  or  reversible  airflow 
obstruction following inhaled salbutamol of >12% (9) or >15% FEV1 (23, 25) as a Chapter 1    32 
requirement for entry to the trial helping to reduce the number of participants 
with COPD. 
1.3 Corticosteroids-Role in the treatment of asthma and 
mechanisms of action 
1.3.1 Corticosteroids-Discovery and therapeutic role 
Following the discovery of the chemical structure and effects of corticosteroids 
synthetic analogues were rapidly developed for clinical use. As a result of their 
ability to control previously refractory inflammation, corticosteroid preparations 
became  crucial  to  the  management  of  patients  suffering  from  debilitating 
inflammatory  diseases  including  asthma.  However  the  side  effects  associated 
with the prolonged use of oral preparations led to a rapid reduction in their 
prescription. Inhaled versions were subsequently developed for the treatment of 
asthma  to  reduce  systemic  exposure  and  alternative  disease  modifying 
medications have superseded corticosteroids in the management of rheumatoid 
arthritis and inflammatory bowel disease.  
Since their introduction inhaled corticosteroids have become established as the 
cornerstone  of  asthma  management  due  to  their  consistent  ability  to  reduce 
symptoms, asthma exacerbations, improve lung function, suppress non invasive 
markers  of  airway  inflammation,  eosinophil  numbers,  inflammatory  cell 
activation and inflammatory gene transcription in the majority of patients (2, 
27). 
1.3.2 Corticosteroid resistance  
However  there  are  a  significant  minority  of  patients  with  asthma  (and  other 
inflammatory conditions) who fail to demonstrate the expected improvements in 
response  to  corticosteroids.  Corticosteroids  have  been  estimated  to  fail  to 
control symptoms in 5 10% of non smoking asthmatics and this group is thought 
to be responsible for 50% of the total costs of asthma due to their increased 
symptoms and frequent admissions to medical wards and intensive care units 
(28, 29). However if also we include data from a recent asthma management Chapter 1    33 
trial,  total  control  of  asthma  by  inhaled  corticosteroids  alone  can  only  be 
achieved in 40% of non smoking subjects with asthma (25). 
Smokers  with  asthma  are  traditionally  excluded  from  studies  examining  the 
efficacy of new treatments because of concerns about recruitment of subjects 
with chronic obstructive pulmonary disease. As a result little was known about 
their  treatment  response  to  corticosteroids  until  recently.  However  it is  now 
clear  that  smokers  with  asthma  display  reduced  therapeutic  responses  to 
corticosteroids. 
1.3.3 Corticosteroids-Mechanisms of action 
The activities of glucocorticoids can be divided into genomic and non genomic 
effects based on the interactions with and through the glucocorticoid receptor 
with  genomic  being  mediated  via  the  glucocorticoid  receptor  (GR)  and  non 
genomic via both the GR and the cell membrane (30, 31). 
The  GR  consists  of  three  domains  with  differing  functions.  These  are  an  N 
terminal  domain,  which  carries  out  transactivation  functions,  a  DNA  binding 
domain and a ligand binding domain. This receptor structure is common to the 
nuclear hormone receptor family which also contains the receptors for vitamin 
D, thyroxine, peroxisome proliferator activated receptor  γ (PPARγ) and retinoic 
acid. However the GR has some unique features. It has a unique dimerisation 
domain, two charge clamps instead of one (unlike the other nuclear hormone 
receptors) and a distinct agonist binding pocket (32). 
The gene for the GR is localised on chromosome 5 and consists of nine exons. 
Due to alternative splicing from these exons the GR has several isoforms (32, 
33). The ubiquitously expressed and best studied form is glucocorticoid receptor 
alpha (GR α). The GR α is a 95 kDa protein composed of 777 amino acids. There 
is  also  heterogeneity  within  the  GR α  as  a  number  of  variants  are  produced 
through  differences  in  ribosomal  translation.  These  variants  have  different 
ligand affinities and post ligand binding behaviour providing a mechanism for 
differing  tissue  corticosteroid  sensitivities  and  between  subject  variation  in 
corticosteroid response (33).   Chapter 1    34 
1.3.3.1  Cellular localisation and chaperones 
Unbound,  the  GR  resides  in  the  cytoplasm,  associated  with  a  number  of 
chaperone  proteins  including  heat  shock  proteins  40,  56,  70,  90,  the 
immunophilins  p23  and  Src  and  members  of  the  mitogen  associated  protein 
kinase  (MAPK)  family  (30,  32).  Upon  steroid  binding  the  GR  dissociates  from 
these  proteins,  allowing  formation  of  a  homodimer  and  active  nuclear 
translocation by importins due to exposure of its nuclear localisation sequence. 
1.3.3.2  Transactivation 
Glucocorticoid  receptor  homodimers  interact  with  DNA  response  elements 
upstream  of  genes  and  recruit  transcriptional  co activator  proteins,  which 
enhance transcription. This process is part of what is commonly referred to as 
transactivation.  The  DNA  response  elements  contain  palindromic  repeats  that 
facilitate  glucocorticoid  receptor  binding  and  once  bound  the  glucocorticoid 
receptor can increase and decrease gene expression (27, 30 32, 34). Through 
transactivation glucocorticoids can increase the production of a number of genes 
such  as  the  NFκB  chaperone  protein  IκB,  dual  specificity  mitogen  associated 
protein  kinase  phosphatase 1,  glucocorticoid  inducible  leucine  zipper, 
lipocortin/annexin 1, the cytokine IL 10, and surfactant protein D (32) and can 
also down regulate genes via negative gene regulation elements. Transactivation 
can  also  involve  displacing  transcription  factors  from  response  elements  for 
inflammatory genes on DNA and occupying the vacated area (30, 32). 
1.3.3.3  Transrepression 
The glucocorticoid GR complex can suppress inflammatory gene expression as a 
monomer through transrepression. This mechanism is postulated to be the main 
method by  which corticosteroids  suppress inflammatory  gene  expression  (32). 
Transrepression can be performed through: 
•  Direct  inhibition.  Direct  physical  interaction  between  the  GR  and 
inflammatory transcription factors such as NFκB and AP1. Chapter 1    35 
•  Chaperone proteins. GR can stimulate increased production of chaperone 
proteins  for  inflammatory  transcription  factors  such  as  the  NFκB 
chaperone IκB. 
•  Co-factor competition. Competition for transcription co factors required 
by  both  the  GR  and  inflammatory  transcription  factors  can  reduce 
inflammatory gene expression. 
•  Epigenetic mechanisms. The GR can alter the behaviour of inflammatory 
transcription elements through actively recruiting multiprotein complexes 
capable of adding or removing covalent compounds such as acetyl and 
phosphate  groups.  This  activity  alters  their  affinity  for  their  response 
elements and hence their behaviour (27, 30 32, 34). 
1.3.3.4  Epigenetic effects 
The field of epigenetics examines the effect of post translational modifications 
of chromatin and associated proteins on the control of gene expression. This 
group  of  processes  appear  to  be  an  important  transrepressive  mechanism 
exploited by corticosteroids. 
The  transcription  machinery  protein,  RNA  polymerase  II,  is  unable  to  access 
promoter regions of DNA within chromatin’s tertiary structures in chromatin’s 
resting state due to DNA being tightly complexed with histone proteins. Histones 
consist of globular bodies with peripheral mobile tails and an overall positive 
charge which facilitates chromatin compaction. The addition of small molecules 
to histone tails such as acetyl or methyl groups and other modifications such as 
phosphorylation, ADP–ribosylation and SUMOylation have been demonstrated to 
affect  transcription.  Acetylation  of  histones  has  been  recognised  to  be 
associated  with  increased  gene  expression  for  many  years  (35)  and  research 
using an in-vitro model has led to the estimate that approximately half of the 
immunosuppressant activity of corticosteroids is mediated through the removal 
of acetyl groups from histone tails (36). Chapter 1    36 
1.3.3.5  Post translational modifications of glucocorticoid receptor 
The GR is also subject to epigenetic modifications with resultant alteration in its 
behaviour.  For  example  GR  phosphorylation  status  affects  its  corticosteroid 
affinity,  nuclear  sub  localisation  and  transactivation  potential.  Acetylation  of 
the GR is also an important control mechanism as it affects its ability to interact 
with  NFκB  (32,  37).  This  raises  the  importance  of  post  translational 
modifications of the GR by the mitogen associated protein kinase family and 
nuclear co activator complexes to the response to corticosteroids. 
1.3.3.6  Non-genomic effects of glucocorticoids 
The non genomic mechanisms by which glucocorticoids act are much more rapid 
than  the  genomic  mechanisms  but  can  still  be  inhibited  by  glucocorticoid 
receptor antagonists. These include effects produced by high concentrations of 
glucocorticoids  where  glucocorticoids  are  incorporated  into  both  cell  and 
mitochondrial membranes altering their properties. This results in a reduction in 
calcium and sodium ion transmembrane flux and mitochondria membrane ATP 
leakage (30). 
Other non genomic effects may be mediated through GRs imbedded in the cell 
membrane and through rapid changes in cytoplasmic concentrations of unbound 
GR  chaperone  proteins  (30,  32).  High  concentrations  of  glucocorticoids  also 
appear to be able to alter mRNA stability resulting in increased degradation of 
inflammatory gene mRNA and reduced inflammatory protein complex production 
(32). 
1.3.3.7  Heterodimer formation 
So far I have only considered homodimerisation and undimerised glucocorticoid 
receptors.  However  nuclear  hormone  receptors  are  capable  of  forming 
heterodimers with other transcription factors and the glucocorticoid receptor is 
no exception. 
Recent  work  has  identified  functional  interactions  between  the  GR  and  the 
signal transducers and activator of transcription (STAT) and Ets families (32) and Chapter 1    37 
with  another  nuclear  hormone  receptor,  peroxisome  proliferator  activated 
receptor γ (PPARγ)(38). For example GRα association with STAT5, a member of 
the  STAT  family,  results  in  increased  expression  of  β  casein  (32)  and  co 
stimulation of cells with dexamethasone and a PPARγ agonist results in enhanced 
suppression  of  inflammation  (38).  The  GRα  can  also  form  heterodimers  with 
other members of the GR family such as GRβ leading to altered behaviour (32). 
1.4 Potential  mechanisms  of  reduced  corticosteroid 
sensitivity in smokers with asthma  
Many defects in the complex action of corticosteroids have been described in a 
variety of clinical settings, but few have been directly attributed to cigarette 
smoking  (32,  39,  40).  However  previous  research  examining  corticosteroid 
resistance in non smokers with severe asthma & subjects with COPD coupled to 
in-vitro  research  examining  the  corticosteroid  pathway  and  research  utilising 
induced sputum in smokers with asthma can provide insights and evidence of 
possible causes. 
1.4.1 Clinical studies-Sputum differential and supernatant 
Smokers  with  asthma  have  been  demonstrated  to  have  altered  sputum 
differentials and supernatant cytokine profiles compared to non smokers with 
asthma. One study comparing smokers and non smokers with asthma found that 
smokers with asthma displayed increased sputum cellularity, sputum neutrophils 
and  reduced  eosinophils  (41).  Smokers  with  asthma  were  also  found  to  have 
increased  sputum  interleukin  8  (IL 8)  levels.  Sputum  IL 8  was  also  found  to 
positively correlate with sputum neutrophilia and pack years and to negatively 
correlate  with  lung  function  (FEV1  pre  bronchodilator).  Another  study 
demonstrated  that  sputum  IL 18  expression  and  transcription  is  reduced  in 
smokers with asthma and normal smokers compared to non smokers with asthma 
and normal non smokers (42). The smokers with asthma recruited to this study 
also  had  increased  sputum  neutrophils  and  reduced  sputum  eosinophils 
compared  to  non  smoking  asthmatics.  The  reduction  in  IL 18  was  thought  to 
reflect an alteration of the inflammatory profile in smokers with asthma as IL 18 
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asthma  may  therefore  have  a  different  Th1/Th2  profile  to  non  smokers  with 
asthma. 
However  smokers  with  asthma  do  not  consistently  display  higher  sputum 
neutrophils  compared  to  non smokers  with  asthma.  A  recent  study  found 
equivalent levels of sputum neutrophils in smokers and non smokers with asthma 
and  in  the  same  study  sputum  eosinophils  were  similarly  suppressed  in  both 
groups (24). However this lack of a difference in sputum neutrophils may have 
been  due  to  the  two  groups  having  more  severe  asthma  and  therefore  more 
neutrophilia in the non smoking asthma group compared to the previous studies. 
The  finding  of  equivalent  levels  of  sputum  eosinophils  in  this  study  can  be 
explained by the increased use of inhaled corticosteroids in asthma compared to 
the preceding studies and hence suppression of sputum eosinophilia in the non 
smokers with asthma. 
The presence of sputum neutrophilia in some smokers with asthma is of interest 
given the association of airway neutrophilia with non smoking severe asthma. 
This  group  demonstrate  relative  corticosteroid  resistance  and  worse  asthma 
control  (43 45).  However  not  all  smokers  with  asthma  display  sputum 
neutrophilia and therefore the presence of neutrophilia in a subgroup of smokers 
with asthma cannot explain all of the corticosteroid insensitivity displayed by 
this group.  
Should smokers with asthma therefore be regarded to be part of what has been 
termed non eosinophilic asthma? Non eosinophilic asthma has been suggested to 
be comprised of two subgroups; a neutrophilic subgroup based on a cut off of 
sputum neutrophils >61% combined with poor asthma control and a paucicellular 
group with a normal sputum profile and good control (46). Smokers with asthma 
do not easily fit either of these subgroups given that neutrophilia is not present 
in all in this group and their level of asthma control cannot be described as 
good. This suggests that the alteration in airway cell proportions observed in 
smokers  with  asthma  should  be  viewed  as  indicative  of  an  alternative 
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1.4.2 Clinical studies-Exhaled markers of inflammation 
Exhaled  nitric  oxide  (NO)  has  generated  considerable  interest  due  to  its 
potential as a non invasive marker of airway inflammation. Previous research 
suggests that exhaled NO may have a role in the monitoring of asthma due to 
correlation between exhaled NO levels and airway eosinophilia (47, 48). Exhaled 
NO levels have been assessed in smokers with asthma with comparison to non 
smokers with asthma (24, 49). A consistent finding is that smokers with asthma 
have an exhaled NO concentration level that is lower than non smokers with 
asthma  and  equivalent  to  (or  lower  than)  that  observed  in  normal  subjects. 
Exhaled NO concentrations also demonstrate a strong reciprocal correlation with 
pack year histories (50). The mechanism that produces this reduction in exhaled 
NO is not fully understood but may be due to increased consumption of NO (51, 
52),  competition  for  substrate  from  other  inflammatory  pathways  (53)  or 
reduction in production by inducible NO synthase (52, 54, 55). The consistent 
reduction of exhaled NO in smokers with asthma again suggests that a different 
form of inflammation is present in this group. 
Exhaled breath condensate (EBC) is currently being examined as a potential non 
invasive measurement of airway lining fluid (56). Studies utilising this method 
have principally focused on non smokers with asthma. A potentially important 
observation is that subjects with unstable asthma have reduced EBC pH which 
normalises with clinical improvement (57). One study has examined EBC pH in 
smokers and non smokers with asthma and demonstrated a reduced EBC pH in 
smokers with asthma (58). 
1.4.3 Clinical studies-Bronchoscopic samples 
The airway wall has recently returned as a focus of attention in asthma due to 
the hypothesis that epithelial damage may be driving the inflammatory response 
(59) and the recognition that differing patterns of inflammation and structural 
responses are present in bronchial biopsies from different asthma sub types (60). 
A recent study compared bronchial biopsies from smokers with mild asthma with 
low pack year histories (mean (SEM) 16.7 (+/  2.2)) against never smokers with 
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subepithelial neutrophils, subepithelial neutrophil elastase, intraepithelial IL 8 
and interferon γ mRNA expression in the smokers relative to non smokers (61). 
The authors concluded that their group of smokers with asthma displayed early 
evidence  of  a  corticosteroid  resistant  phenotype  similar  to  COPD  and  severe 
asthma. 
Another  bronchial  biopsy  study  from  the  same  group  examined  nitric  oxide 
production in a group of smokers with asthma with low pack year histories (mean 
(SEM), 16.7 (+/  2.2))(53). The amino acid L arginine is the substrate for both 
the  nitric  oxide  synthases  and  arginase 1  and  hence  is  a  point  for  substrate 
competition between the nitric oxide and ornithine pathways. In this small study 
a clear difference was evident in the expression of arginase 1 and ornithine de 
carboxylase, with increased levels of both in smokers with asthma. Smokers and 
non smokers with asthma were found to have equal levels of the inducible nitric 
oxide  enzyme  iNOS.  This  finding  supports  the  previous  finding  of  reduced 
exhaled nitric oxide concentrations in smokers with asthma and suggests that 
smoking could be associated with a deviation from production of nitric oxide to 
proline and polyamines and hence increased airway remodelling.  
A recent study which examined bronchial biopsies in smokers and non smokers 
with  asthma  considered  the  possibility  that  altered  dendritic  cell  numbers 
and/or  behaviour  could  contribute  to  the  altered  phenotype  displayed  by 
smokers with asthma (62). Smokers with asthma displayed lower levels of CD83 
positive (a marker of mature dendritic cells) and CD20 positive cells (a marker 
for B lymphocytes) and preservation of Langerhans’ cell numbers. The authors 
concluded that the altered dendritic cell and B cell phenotypes were the result 
of a different maturation state or the result of migration of both cells out the 
respiratory  tract  and  that  this  alteration  could  be  partly  responsible  for  the 
altered response to corticosteroids in smokers with asthma. 
A  recently  published  study  has  examined  the  effect  of  smoking  on  alveolar 
macrophage  inflammatory  responses  in  asthma  (63).  Smokers  with  asthma 
displayed  greater  concentrations  of  macrophages  in  BAL  fluid  and  BAL 
macrophages from smokers with asthma displayed a reduced cytokine response 
to LPS. This manifested as smaller increases in IL 6, 8 and TNFα in response to 
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alveolar  macrophage  corticosteroid  response.  No  baseline  comparisons  in 
bronchoalveolar  cytokine  levels  were  reported  from  this  cohort.  The  authors 
suggested that this muted response to LPS may be indicative of an increased 
susceptibility to bacterial infection in smokers with asthma. 
1.5 Alteration of the glucocorticosteroid pathway 
Could the altered response to corticosteroids displayed by smokers with asthma 
be a result of alteration in the glucocorticoid pathway or in processes affected 
by this pathway? Previous research examining the corticosteroid pathways  in-
vitro and corticosteroid responsiveness in non smokers with severe asthma and 
subjects with COPD may provide insights for the investigation and treatment of 
smokers with asthma. 
1.5.1 Glucocorticoid receptor 
1.5.1.1  Cytokine induced corticosteroid resistance 
Previous  research  examining  corticosteroid  resistance  in  non smokers  with 
asthma has identified associated alterations in pulmonary cytokine environments 
(64,  65).  Could  altered  levels  of  pulmonary  cytokines  induce  corticosteroid 
resistance  or  are  they  reflective  of  the  reduced  effect  of  corticosteroids?  A 
partial answer has been provided through the use of the combination of IL 2 and 
4  to  induce  corticosteroid  resistance  in-vitro.  Kam  and  colleagues  (66) 
demonstrated  a  reversible  reduction  in  glucocorticoid  receptor  affinity  in 
peripheral blood T lymphocytes in subjects with corticosteroid resistant asthma. 
T lymphocytes from the recruited subjects had reduced glucocorticoid receptor 
affinity which recovered after a few days in culture. However on addition of a 
combination of IL 2 & 4 this binding defect was restored. This finding has been 
replicated a number of times (67 69) and is reversible following the addition of 
IFNγ (66, 69).  
The mechanisms by which the combination of IL 2 and 4 could induce altered 
glucocorticoid  receptor  behaviour  have  been  examined  in  a  series  of 
experiments (68, 69). One group used peripheral blood mononuclear cells (PBMC) 
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demonstrate that the defect in ligand binding to the glucocorticoid receptor was 
due  to  activation  of  the  p38  MAPK  pathway  and  phosphorylation  of  the 
glucocorticoid  receptor  (68).  This  work  has  subsequently  been confirmed  and 
appears  to  be  reversed  by  concomitant  administration  of  IFNγ  (69).  Another 
study  examined  LPS  stimulated  cytokine  responses  in  alveolar  macrophages 
obtained by bronchoalveolar lavage from non smoking subjects with severe and 
mild asthma and normal volunteers (70). Alveolar macrophages from subjects 
with  severe  asthma  demonstrated  a  reduced  anti inflammatory  response  to 
dexamethasone with associated increased p38 MAPK activation. GRα is a target 
for phosphorylation by both JNK and p38 MAP kinase, and activation of these 
pathways leads to a reduced corticosteroid response (68 71). Therefore cigarette 
smoke  induced  alteration  in  the  pulmonary  cytokine  environment  may  be 
capable  of  altering  corticosteroid  responses  through  activation  of  MAPK 
pathways. 
1.5.1.2  Alternative glucocorticoid receptor isoforms 
The corticosteroid receptor exists in several forms, with the best studied being 
the  alpha  (GRα)  and  beta  (GRβ).  The  GRα  is  responsible  for  the  therapeutic 
effects of corticosteroids. In contrast GRβ can interfere with GRα function in a 
dominant negative fashion. This has led to their being termed decoy receptors 
and research has demonstrated a potential role in steroid resistant asthma for 
GRβ with a reduced ratio of α: β and increased β receptor levels being linked to 
corticosteroid resistance (72 76). 
A small sub study has provided evidence for cigarette smoke exposure producing 
a reduction in both GRα and β expression in normal smokers and subjects with 
COPD  (77).  Research  examining  the  α:β  receptor  ratio  in  peripheral  blood 
mononuclear cells from smokers with asthma has also demonstrated a reduced 
α:β ratio suggesting that an increase in the β form and/or a decrease in the α 
form may have a role in corticosteroid resistance in smokers with asthma (78). 
1.5.1.3  Altered glucocorticoid receptor kinetics 
Glucocorticoid  receptor  density  and  ligand  binding  characteristics  have  been 
examined  in  peripheral  blood  mononuclear  cells  (PBMCs)  from  non  smoking Chapter 1    43 
subjects  with  severe  asthma  (79,  80).  In  a  small  study  of  subjects  with 
corticosteroid sensitive and resistant asthma PBMC GR binding affinity and GR 
number was found to be equivalent (79). This finding has been corroborated in a 
slightly  larger  study  comparing  subjects  with  mild  and  severe  asthma  (80).  
However evidence does exist for differences in GR binding in severe asthma. 
PBMC nuclear extracts from subjects with severe asthma demonstrated reduced 
GR binding affinity in one trial (68) and in another study reduced binding affinity 
in  peripheral  blood  T  lymphocytes  was  present  in  some  subjects  with  severe 
asthma with evidence for reduced GR concentrations in a small subgroup (67).  
Therefore it is feasible that smokers with asthma may display altered GR binding 
behaviour, receptor number, an increase in the β or reduction in the α subtype 
or  post  translational  modifications  compared  to  non smokers  with  asthma. 
Future work should examine the GR in smokers with asthma in light of this work. 
1.6 Acquired  defects  in  HDAC  activity  and  potential 
implications for corticosteroid responses 
Corticosteroids exert their effects on gene expression via many mechanisms and 
pathways.  One  important  mechanism  is  the  control  of  epigenetic  changes. 
Epigenetics involves the addition of small molecules such as acetyl or methyl 
groups  and  other  modifications  such  as  phosphorylation,  ADP–ribosylation  and 
SUMOylation (SUMOylation = reversible conjugation of a small ubiquitin related 
modifier protein to another protein) to histone tails and other proteins and the 
effect that this has on transcription. I shall now briefly examine how control of 
protein  acetylation  by  corticosteroids  through  manipulation  of  HDACs  and 
histone  acetyltransferases  (HAT)  could  affect  chromatin  structure  and  gene 
expression and how alteration of these mechanisms could be responsible for the 
altered response to corticosteroids in smokers with asthma. 
Several enzymes have been identified to have HDAC activity. 18 HDAC isoforms 
are currently recognised and are divided into three groupings, class I & II and the 
sirtuins.  HDACs  form  part  of  several  important  intracellular  multiprotein 
complexes  that  are  involved  in  transcription  control  and  are  expressed 
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alveolar macrophages (81). A proposed mechanism for the reduced response to 
corticosteroids  in  COPD  and  steroid  resistant  asthma  is  that  oxidative  stress, 
either from active smoking or other sources, reduces HDAC activity impairing the 
ability of corticosteroids to reduce inflammation (27, 82). No published work is 
available from studies in smoking asthmatic patients examining HDAC activity, 
but inferences can be drawn from in-vitro studies and from several studies in 
non smokers with asthma, subjects with COPD and normal smokers.  
1.6.1 HDAC activity and expression in asthma  
Bronchial biopsies from atopic non smokers with mild asthma (treated with β 
agonists  alone)  and  mild  to  moderate  non smoking  asthmatics  (treated  with 
inhaled  corticosteroids)  were  compared  to  a  group  of  normal  non smoking 
volunteers in one study (83). The intensity of staining for the isoforms HDAC1 & 
2 was reduced in asthmatics compared to normal subjects. However subjects 
with asthma treated with inhaled corticosteroids demonstrated a restoration of 
total HDAC activity and HDAC2 expression and reduction in HAT activity towards 
normal  levels.  In  a  subsequent  study,  which  examined  acetylation  status  in 
airway  macrophages,  HDAC1  expression  was  found  to  be  reduced  in  mild 
asthmatics with no alteration in HDAC2 or 3 expression (84). Another study from 
the  same  group  examined  PBMC  cytokine  responses  in  subjects  with  severe 
asthma, mild asthma and normal subjects and identified a reduction in HDAC 
activity in subjects with severe asthma which was associated with a reduced 
anti inflammatory effect of dexamethasone in-vitro (85). 
1.6.2 HDAC in COPD  
Two trials have examined acetylation balance in COPD (86, 87). The first study 
(86) examined both HDAC and HAT activity and HDAC isoform expression levels in 
peripheral lung tissue from subjects with COPD of various degrees of severity. 
When  compared  with  normal  subjects  total  HDAC  activity  was  reduced  in 
subjects with severe COPD. This reduction was found to positively correlate with 
FEV1 and was associated with a reduction in expression of HDACs 2, 5 and 8. No 
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results  were  obtained  using  bronchial  biopsies  and  macrophages  obtained  by 
bronchoalveolar lavage. 
Another study examined subjects with milder COPD using tissue obtained from 
lung  resections  (87).  Smoking  played  a  critical  role  in  acetylation  status. 
Smokers with and without COPD were found to have a doubling in acetylated 
histone 4 levels compared to normal non smokers suggesting a reduction in HDAC 
activity.  In  contrast  ex smokers  with  COPD  demonstrated  a  return  to  normal 
non smokers’ histone acetylation levels. This reduction was not global however 
as the ex smokers with COPD were found to have a quadrupling of acetylated 
histone 3 levels compared to normal non smokers. In contrast to the first study 
(86), HDAC2 nuclear expression was equivalent. However this may reflect the 
milder phenotypes recruited. 
1.6.3 Oxidative stress, smoking and HDAC 
How  cigarette  smoke  alters  HDAC  activity  and  gene  expression  is  not  fully 
understood  but  recent  research  has  identified  a  role  for  increased  oxidative 
stress due to cigarette smoking.  Cigarette smoke contains at least 10
15 free 
radicals per inhalation in a mixture of short lived species such as superoxide and 
longer living compounds such as tar semiquinone (88). Each substance is capable 
of altering airway cell composition and intracellular signalling (89) and oxidative 
stress appears to play a crucial role in the development of COPD (90, 91).  
Experimentally induced oxidative stress is able to reduce HDAC activity to the 
levels seen in COPD and asthma. For example, hydrogen peroxide (H2O2) added 
to cell lines reduces HDAC expression and dexamethasone mediated suppression 
of cytokines to a level seen in smokers (92). Cigarette smoke condensate and 
H2O2 can both increase histone 4 acetylation and HAT activity and reduce HDAC2 
expression  and  HDAC  activity  (93).  Exposure  of  rats  to  cigarette  smoke  also 
reduces  HDAC2  activity  with  associated  increased  histone  acetylation  and 
corticosteroid resistant inflammatory gene expression (94). 
The reduction in HDAC activity following oxidative stress may be due to post 
translational  covalent  modification  of  HDAC  enzymes.  HDAC2  exposed  to 
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tyrosine motifs compared to controls (93, 94). Similar findings have been found 
when H2O2 was used as the oxidative stimulus (95). The relevance of cigarette 
smoke induced IL 8 production and its relationship to HDAC activity in COPD has 
been also examined in-vitro (96). IL 8 production was found to be increased on 
exposure  to  cigarette  smoke  with  associated  reductions  in  HDAC1,  2  and  3 
expression and HDAC activity. Cigarette smoke also altered HDAC1, 2 and 3 as 
they  demonstrated  increased  immunoreactivity  for  4HNE  and  nitrotyrosine 
antibodies. The mechanism by which this modification reduces HDAC activity is 
thought to be via the addition of 4HNE to histidines within the HDAC active site 
and/or destruction of HDACs via the ubiquitin proteasome pathway. 
A recent publication examined the effect of cigarette smoke extract on HDAC2 
in cell lines and a mouse model, and provided evidence for a role for HDAC 
phosphorylation  and  subsequent  destruction  via  the  ubiquitin proteasome 
pathway in oxidative stress induced reduction in HDAC activity (97). Exposure of 
cells to cigarette smoke extract resulted in a decrease in expression of HDAC1 
and 2 by four hours. Cigarette smoke extract was also demonstrated to cause 
rapid and transient phosphorylation of HDAC2 which peaked within half an hour 
of exposure and was reversed by two hours. The reduction in phosphorylation 
was followed by ubiquitination and evidence of destruction of HDAC2 via the 
ubiquitination proteasome pathway. 
1.6.4 Corticosteroids and HDAC 
What  are  the  cellular  pathways  that  link  glucocorticoids,  the  glucocorticoid 
receptor,  HATs  and  HDACs?  One  group  has  examined  the  effect  of 
dexamethasone  on  a  model  of  inflammation  and  the  relevance  of  these 
mechanisms  (98).  IL 1β  induced  GM CSF  expression  and  response  to  the 
application  of  dexamethasone  was  assessed  in  an  epithelial  cell  line. 
Dexamethasone  reduced  IL 1β  mediated  acetylation  of  the  tail  of  histone  4 
lysine  residues  8  and  12  and  GM CSF  expression.  This  effect  on  GM CSF 
production required dexamethasone binding to the glucocorticoid receptor and 
increased  HDAC  activity.  Half  of  the  reduction  in  GM CSF  was  due  to  a 
dexamethasone induced increase in HDAC activity as demonstrated through the 
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binding of the HDAC2 isoform to the NF κB subunit p65 following dexamethasone 
suggesting  increased  recruitment  of  HDAC2  to  NF κB  was  responsible  for  the 
inhibitory  effect  of  dexamethasone  at  low  doses.  Therefore  at  low  doses  of 
corticosteroids the glucocorticoid receptor is able to carry out transrepression of 
gene  expression  through  stimulating  the  interaction  of  HDAC2  with  the  p65 
subunit of NF κB.  
Subsequent work, utilising the same model, which compared the effect of the 
dissociated  steroid  RU486  (mifepristone)  and  dexamethasone  confirmed  this 
observation  (36).  HDAC2  activity  is  crucial  for  this  corticosteroid  mediated 
inhibition of inflammation as demonstrated by graded reduction of HDAC2 with 
siRNA (36, 37). HDAC2 knockdown did not affect either GR nuclear translocation, 
GR GRE binding, glucocorticoid induced gene expression or the ability of high 
dose  dexamethasone  to  inhibit  GM CSF  production.  However  following  HDAC2 
knockdown the GR is not recruited to the NF κB DNA complex and therefore is 
unable to inhibit NF κB activity. 
The  glucocorticoid  receptor  is  also  subject  to  acetylation  with  effects  on  its 
transrepressive activity (37). When interacting with and inhibiting the NF κB 
DNA complex the glucocorticoid receptor is normally not acetylated. However 
following  acetylation  of  the  receptor  a  strongly  correlated  reduction  in 
dexamethasone mediated inhibition of NF κB is observed. Airway macrophages 
obtained by bronchoalveolar lavage from patients with COPD were also found to 
have increased levels of glucocorticoid receptor acetylation and reduced HDAC2 
expression. HDAC2 expression levels were then restored through vector induced 
HDAC2 over expression resulting in reduced GR acetylation and restoration of 
suppression of GM CSF expression. 
1.7 Theophylline, HDAC and corticosteroids 
Based on the existing clinical research it is clear that inhaled corticosteroids, 
the best therapy for asthma, are less effective than would be desired in smokers 
with asthma. This is certainly true for their short term ability to improve lung 
function,  reduce  symptoms  and  exacerbations.  The  most  obvious  clinical 
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cessation. Smoking cessation is useful in this group as it has been demonstrated 
to produce large improvements in lung function (49). Unfortunately successful 
quitters take many years to achieve complete cessation (99). Clearly demanding 
smoking cessation alone for smokers with asthma is therefore an unacceptable 
approach for management of this group.  
An alternative approach would be to investigate the effect of high dose inhaled 
corticosteroids  in  smokers  with  asthma  based  on  previous  research  (8,  10). 
However this is unlikely to be a successful approach given the increased side 
effects  and  reduced  compliance  that  would  occur  as  a  result.  Therefore  the 
search should begin for alternative effective treatments for this group. Again we 
can extrapolate from previous research examining alternative treatments in non 
smoking  subjects  with  severe  asthma,  subjects  with  COPD  and  from  in-vitro 
research and animal models of asthma. 
The oral bronchodilator theophylline has been utilised in asthma and COPD for 
many years and is currently advocated as an add on therapy in those subjects 
not controlled on inhaled steroids +/  LABA (1). Theophylline appears to have a 
number of mechanisms of action (100). It produces its bronchodilator effects 
through blockade of phosphodiesterase (PDE) activity, specifically PDE isoforms 
3,  4  &  5,  resulting  in  an  increase  in  intracellular  cAMP  and  smooth  muscle 
relaxation.  However  significant  PDE  inhibition  is  unlikely  to  be  achieved 
clinically  due  to  the  large  doses  that  would  be  required  and  it  has  been 
suggested that at recommended doses theophylline is producing only about 5 
10%  of  its  maximum  possible  PDE  inhibition  (100).  Theophylline  has  also 
demonstrated activity as an adenosine receptor antagonist and can block A1 and 
A2 receptors producing relaxation of airway smooth muscle and stabilising mast 
cells as a result. However the relative contribution of this activity to control of 
bronchospasm and inflammation is currently unclear. Another therapeutic effect 
that  has  been  demonstrated  for  theophylline  is  an  ability  to  increase  HDAC 
activity  at  low  serum  concentrations  (around  3 7mg/dl,  normal  range  10 
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1.7.1 Theophylline increases HDAC activity & potentiates 
corticosteroid mediated suppression of inflammation 
In a double blind crossover trial incorporating bronchial biopsies, 14 mild stable 
asthmatics treated with β agonist alone were treated with low dose theophylline 
for  one  month  (101,  102).  Treatment  with  theophylline  was  associated  with 
increased HDAC activity in bronchial biopsies. This increase in HDAC activity was 
due to increased HDAC1 expression as HDAC2 was unaltered. Theophylline serum 
levels were low with a mean concentration of 6.1 mg/dl. 
Subsequent  to  this  trial  a  model  of  inflammation  based  on  stimulating  BAL 
macrophages with LPS was utilised to examine interactions between low dose 
theophylline and corticosteroids (102). After exposure to LPS, BAL macrophages 
displayed  reduced  HDAC  activity  and  increased  IL 8  production  which  was 
insensitive  to  10
 10M  dexamethasone.  Dexamethasone  at  10
 6M  did  succeed  in 
restoring  HDAC  activity  to  normal  levels  and  this  was  associated  with  a  60% 
reduction in the level of IL 8 production. Theophylline alone at a dose of 10
 5 M 
was able to restore HDAC activity to normal without reducing IL 8. At higher 
concentrations  the  ability  of  theophylline  to  boost  HDAC  activity  was  lost. 
Theophylline (10
 5 M) was then combined with low dose corticosteroid (10
 10M) 
resulting in increased HDAC activity and reduced IL 8. To further examine the 
ability of low dose theophylline to increase HDAC activity the HDAC inhibitor 
Trichostatin A (TSA) was then applied. TSA reversed the suppression produced by 
the combination of 10
 5 M theophylline and 10
 10M corticosteroid and reduced the 
suppressive ability of 10
 6M dexamethasone by 50%. Theophylline was found to 
increase the HDAC activity of HDAC1 and 3 but did not alter HDAC2. 
A  similar  study  has  also  been  carried  out using  BAL  macrophages  from  COPD 
patients,  normal  smokers  and  normal  non smokers  (103).    HDAC  activity  was 
significantly  reduced  in  BAL  macrophages  from  subjects  with  COPD  and  this 
correlated with the HDAC2 expression level. Low dose theophylline increased 
HDAC activity without altering IL 8 levels and low dose dexamethasone again 
reduced  IL 8  when  combined  with  theophylline.  The  IL 8  response  to 
dexamethasone  in  normal  smokers  and  subjects  with  COPD  was  reduced 
compared  to  normal  non smokers  and  was  associated  with  increased  NF κB Chapter 1    50 
nuclear  translocation.  The  addition  of  theophylline  to  LPS stimulated  BAL 
macrophages  from  subjects  with  COPD  potentiated  the  suppression  of  IL 8 
produced  by  dexamethasone.  Immunoprecipitated  HDAC1  and  2  from  normal 
smokers’ BAL macrophages and a cell line were exposed to theophylline and in 
contrast to previous findings (102), both HDAC1 and 2 demonstrated increased 
HDAC activity on exposure to theophylline. 
Low dose oral theophylline has also been examined in the recovery phase of 
COPD exacerbations (104). Subjects randomised to theophylline in addition to 
normal  care  (which  included  oral  corticosteroids)  demonstrated  increased 
sputum  macrophage  HDAC  activity  and  greater  suppression  of  IL 8  and  TNFα 
compared to subjects receiving standard care alone. 
1.7.2 Mechanisms by which theophylline may increase HDAC 
activity 
Several  potential  mechanisms  by  which  theophylline  could  increase  HDAC 
activity have been addressed in one study (102). Theophylline is known to cause 
bronchodilatation  through  non specific  inhibition  of  phosphodiesterases  (PDE). 
The ability of theophylline to inhibit PDEs and the effect of this on HDAC activity 
was  examined  using  non specific  and  selective  PDE  inhibitors.  The  authors 
demonstrated that PDE inhibition was not contributing to theophylline’s ability 
to  increase  HDAC  activity.  Previous  research  has  also  demonstrated  that 
phosphorylation of HDAC isoforms can increase their HDAC activity (105 108). 
Therefore the effect of phosphatases on the ability of theophylline to increase 
HDAC  activity  were  also  examined  using  alkaline  phosphatase,  a  p38  MAPK 
inhibitor  (SB203580)  and  a  MEK  inhibitor  (PD098059).  Pre treatment  with 
alkaline  phosphatase  was  found  to  reduce  theophylline’s  ability  to  increase 
HDAC activity by about 40%, providing evidence for a role for phosphorylation in 
increasing HDAC activity. The p38 inhibitor SB203580 also reduced HDAC activity 
suggesting that theophylline utilises p38 activation to increase HDAC activity. 
However inhibiting p38 did not completely abolish theophylline’s HDAC effect so 
another  phosphorylation  pathway  or  other  mechanisms  may  be  involved.  No 
effect  on  HDAC  activity  was  seen  with  MEK  inhibition.  The  final  potential 
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allosteric  interactions  with  HDAC  enzymes  to  increase  their  activity. 
Theophylline’s improvement in HDAC activity ranged from a 40% increase at pH 8 
to  75%  at  pH  7.8  suggesting  that  theophylline  may  also  employ  allosteric 
interactions in addition to HDAC phosphorylation to increase HDAC activity.  
Oxidative stress may also play a role in the ability of theophylline to restore 
corticosteroid sensitivity. Work using cell lines has demonstrated that oxidative 
stress reveals intracellular targets for theophylline with associated restoration of 
corticosteroid sensitivity and reduction in histone acetylation at inflammatory 
genes  (109).  In  the  context  of  oxidative  stress  theophylline  was  also  able  to 
induce  genes  that  counteract  the  effects  of  this  stress  and  to  suppress  the 
expression of genes related to oxidative stress induced pathways. 
Recent  work  has  also  identified  that  theophylline  can  act  as  a 
phosphatidylinositol 3 kinase (PI3K) inhibitor and it has been suggested that this 
ability may be responsible in part for theophylline’s ability to increase HDAC 
activity (110 112). Investigation of the PI3Kδ isoform has been carried out in an 
animal model of cigarette smoking pulmonary inflammation (77). Work using this 
model  demonstrated  that  PI3Kδ  is  involved  in  the  development  of  reduced 
corticosteroid  sensitivity  following  exposure  to  cigarette  smoke.  This  was 
associated  with  a  reduction  in  total  HDAC  activity  and  increased  tyrosine 
nitration of HDAC2. 
1.7.3 Possible role for theophylline in the treatment of smokers 
with asthma 
The available research suggests that HDAC activity may be low in patients with 
COPD and asthma and that this can be corrected through the use of low dose 
theophylline. However this is likely to only have clinical benefits when subjects 
are  treated  with  inhaled  corticosteroids  in  combination  with  theophylline  as 
increased  HDAC  activity  alone  does  not  appear  to  be  sufficient  to  suppress 
inflammation. Smokers with asthma display a blunted response to inhaled and 
oral  corticosteroids  but  the  mechanism  by  which  this  occurs  is  unknown. 
Previous research has suggested that smokers with asthma may partially respond 
to high dose inhaled corticosteroids (8, 10). This response mirrors the results Chapter 1    52 
discussed in the preceding section. It is tempting to speculate that the reduced 
response to inhaled and oral corticosteroids displayed by smokers with asthma is 
a result of cigarette smoke mediated inhibition of HDAC activity and that this 
could be restored by low dose theophylline. The studies discussed above suggest 
that the addition of low dose theophylline in-vitro can produce the same effect 
as increasing dexamethasone dose by 100 1,000 times. This effect is unlikely to 
be  as  marked  in-vivo  due  to  local  mechanisms  which  exert  control  over 
corticosteroid concentrations. However examination of low dose theophylline in 
combination  with  low  dose  inhaled  corticosteroids  appears  to  be  merited  in 
smokers with asthma based on the available evidence. 
1.8 PPARγ and inflammation 
1.8.1 Is there a role for PPARγ agonists in smokers with asthma? 
Given the failure of corticosteroids to produce their expected effects in smokers 
with asthma alternative therapies are required for this group. Could a new class 
of  therapeutic  agents  directed  at  an  alternative  anti inflammatory  pathway 
reduce the cigarette smoking induced inflammation that is present in smokers 
with asthma? A large body of literature detailing the anti inflammatory effects 
of peroxisome proliferator activated receptor (PPARs) agonists in animal and in-
vitro models of asthma has developed over the past decade and has led to an 
interest in the possible role for PPARγ stimulation in the treatment of asthma 
and other inflammatory conditions (113, 114).   
1.8.2 PPARs-Discovery & structure 
PPARs,  like  the  glucocorticoid  receptor  and  the  receptors  for  thyroxine  and 
vitamin D, belong to the nuclear hormone receptor superfamily and are ligand 
inducible  transcription  factors.  PPARs  were  first  described  following  the 
observation  that  certain  compounds  (for  example;  fibrates,  phthalate  esters, 
non steroidal anti inflammatory drugs) could increase the number and activity of 
liver peroxisomes after chronic high dose administration to rodents (115, 116). 
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functions  including  β oxidation  of  fatty  acids  and  have  a  role  in  cholesterol 
metabolism. 
PPAR possesses four structural domains. The A/B region is a ligand independent 
transcriptional  activation  domain  (also  known  as  activation function  1/AF 1). 
The C domain encodes the DNA binding domain that contains two zinc finger 
motifs. The D domain codes for a hinge which is thought to allow movement of 
the ligand binding domain relative to the DNA binding domain. The E domain is 
responsible  for  ligand  binding,  dimerisation,  nuclear  translocation  and 
association  with  activators  and  repressors  of  transcription  through  its 
transactivation domain (activation function 2/AF 2).  
1.8.3 PPAR family  
PPARs exist in three isoforms; PPARα, PPARβ/δ and PPARγ. The PPARs differ in 
gene and chromosome origin, display varied effects and have different tissue 
distributions. However the known PPAR isoforms do display strong structural and 
sequence homology. PPARα is expressed in heart, liver, kidney, adipose tissue 
and  skeletal  muscle,  PPARβ/δ  is  widely  expressed  in  tissues  such  as  bowel, 
heart,  muscle,  lung  and  adipose  tissue  and  PPARγ  is  found  at  highest 
concentrations in adipose tissue (115, 116). PPARγ is also expressed in the lung 
epithelium, submucosa and airway smooth muscle and expression appears to be 
upregulated in response to inflammation (117).  
1.8.4 PPARγ-Endogenous ligands 
Previous  research  has  led  to  proposals  for  the  reaction  products  of 
polyunsaturated fatty acids and eicosanoids to be recognised as the endogenous 
PPARγ ligands. Polyunsaturated fatty acids are metabolised to produce agonists 
such  as  α linoleic,  γ linolenic,  arachidonic  and  eicosapentaenoic  acids. 
Eicosanoid  metabolites  produce  the  agonists  15 deoxy ∆
12,14 prostaglandin  J2 
(15d PGJ2), 9 hydroxyoctadecanoic acid (9 HODE), and 13  hydroxyoctadecanoic 
acid (13 HODE). 15d PGJ2 is formed from PGD2 and has been demonstrated to 
bind  to  PPARγ and  has  been proposed to be  the  principle  endogenous  PPARγ 
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through  more  than  just  PPARγ  stimulation  (119 124).  Examples  include 
experiments where saturating concentrations of synthetic PPARγ ligands fail to 
block the effects of 15d PGJ2 in-vitro (125) and different concentrations of 15d 
PGJ2  have  been  observed  to  exert  differing  effects  (126).  Therefore 
interpretation  of  results  from  experiments  using  15d PGJ2  as  a  pure  PPARγ 
agonist effect has been criticised (127). 
1.8.5 PPARγ-Synthetic Ligands 
Commonly  prescribed  drugs  can  stimulate  PPARγ.  These  include  non steroidal 
anti inflammatory  drugs  (NSAIDs),  fibrates  (128),  retinoids  (129)  and  the 
thiazolidinediones.  Thiazolidinediones  are  potent  PPARγ  agonists  and  were 
designed to exploit the beneficial effect of PPARγ stimulation in the treatment 
of diabetes mellitus. The use of these compounds in PPARγ research has led to a 
better  understanding  of  the  role  of  PPARγ  in  metabolism  and  inflammation.  
Similar  to  15d PGJ2  there  has  been  some  debate  over  whether  the  anti 
inflammatory  effects  of  thiazolidinediones  are  mediated  exclusively  via  the 
PPARγ  receptor  (130 132).  However  an  analogy  can  be  drawn  with 
glucocorticoids which can exert anti inflammatory actions via and independent 
of  the  glucocorticoid  receptor.  Given  the  family  homology  there  are  some 
similarities in the mode of action of PPARγ and the glucocorticoid receptor and 
PPARγ can also reduce inflammation via transactivation and transrepression and 
via a number of non genomic pathways  
1.8.6 Anti inflammatory effects of PPARγ and thiazolidinediones 
Following  the  discovery  of  PPARγ  and  the  evidence  for  its  involvement  in 
resolution  of  inflammation  many  groups  have  investigated  its  role  in  disease 
models  and  patients.  As  a  result  PPARγ’s  role  in  a  variety  of  inflammatory 
conditions such as atherosclerosis (133 135), inflammatory bowel disease (136, 
137),  acute  lung  injury  (138)  and  pulmonary  fibrosis  (139)  has  come  under 
investigation.  A  large  body  of  evidence  also  exists  for  PPARγ  agonists  having 
anti inflammatory  effects  in  in-vitro  and  animal  models  of  asthma  and 
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Specific examples include: 
•  Eosinophils.  Reduced  eosinophilic  inflammatory  response  in  ovalbumin 
allergen challenge models (140 142). 
•  Neutrophils.  Reduced  neutrophilic  response  to  LPS  in  an  animal  model 
designed  to  simulate  neutrophilic  ling  disease  (143)  and  reduced 
neutrophil chemotaxis (144). 
•  T lymphocytes. Inhibition of T lymphocyte clonal proliferation (119, 145 
148) and induction of T lymphocyte apoptosis (149). 
•  Dendritic  cells.  Altered  dendritic  cell  maturation  and  behaviour  in 
response to stimulation (141, 150, 151). 
•  Macrophages. Altered macrophage maturation (119, 123, 128, 152 155), 
cytokine  production  (119,  123,  152,  156,  157)  and  evidence  of  PPARγ 
stimulation  resulting  in  increased  phagocytic  potential  for  apoptotic 
neutrophils (154). 
•  Airway Epithelial cells.  Increased expression of PPARγ in human asthma 
(117)  and  animal  models  (158)  and  reduction  in  airway 
hyperresponsiveness  and    mucus  production,  collagen  deposition, 
basement membrane thickness and transforming growth factor β (TGFβ) 
synthesis (158) and reduced epithelial cell cytokine expression (159, 160). 
•  Airway Smooth muscle. Reduced smooth muscle cell proliferation (124) 
and cytokine expression (38, 161). 
•  Airway  Fibroblasts.  Inhibition  of  differentiation  to  myofibroblasts  and 
cytokine production (162). 
1.8.7 PPARγ modes of action 
There are similarities between corticosteroids and PPARγ agonists in their ability 
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asthma. Similarities also exist in their multiple modes of action. PPARγ has been 
demonstrated  to  exert  its  anti inflammatory  effects  using  the  following 
mechanisms. 
1.8.7.1  Transactivation  
The binding of an agonist to PPARγ induces a conformational change. This allows 
dissociation of co repressor molecules and association with co activators. PPARγ 
then forms heterodimers with retinoic X receptor (RXR) and binds to peroxisome 
proliferator  response elements  (PPREs) in DNA  altering  gene  expression. As  a 
result PPARγ exerts control over a wide number of overlapping but distinct genes 
from the glucocorticoid receptor (163). 
1.8.7.2  Transrepression 
PPARγ stimulation may produce its effects via inhibition of inflammatory gene 
transcription (transrepression) and there are a number of ways that this may 
occur (115, 164, 165):  
•  Sequestration of shared co-activators. PPARγ activation may reduce the 
supply  of  common  co activators  reducing  their  availability  to 
inflammatory transcription factors. 
•  Control of IκB kinase (IΚΚΒ kinase). IKKB releases NF κB from inhibition 
by phosphorylating its inhibitory protein IκB (which subsequently leads to 
its degradation and increased NF κB activity)(120). 
•  SUMOylation of the PPARγ ligand-binding domain. SUMOylation of PPARγ 
facilitates  PPARγ  mediated  transcriptional  suppression  of  inflammatory 
genes (165, 166) 
•  Inhibition of inflammatory transcription factors. Examples exist for NF κB 
(167), NFAT (128, 164, 168) & AP1 (146). 
•  Upregulation  of  anti-inflammatory  genes.  The  tumour  suppressor 
molecule PTEN (phosphate and tensin homologue deleted on chromosome Chapter 1    57 
ten)  is  a  phosphatase  known  to  be  downregulated  in  asthma.  PPARγ 
stimulation increases its concentration in animal models of asthma with 
associated reduced inflammation (142). 
1.8.7.3  Non genomic effects 
•  MAPK  stimulation.  PPARγ  agonists  exert  some  of  their  effects  far  too 
rapidly to be working via gene transcription or suppression, and recent 
evidence has suggested that they can produce some of these rapid effects 
via mitogen associated protein kinases (MAPK) (128, 157, 169 172). 
•  Intracellular  organelles.  PPARγ  agonists  exert  some  effects  via 
intracellular organelles independent of PPARγ: 
o  Endoplasmic  reticulum.  Ciglitazone  and  troglitazone  have  been 
demonstrated  to  increase  intracellular  calcium  by  directly 
stimulating its release from the endoplasmic reticulum (173). 
o  Mitochondria.  Other  groups  have  demonstrated  interaction 
between  mitochondria  and  PPARγ  agonists  (132,  174,  175). 
Thiazolidinediones  alter  mitochondrial  respiration  but  appear  to 
have effects beyond this as illustrated by their ability to increase 
the heat shock response (132). 
1.8.7.4  Modulation and utilisation of the glucocorticoid receptor by PPARγ  
Two independent groups have demonstrated a functional interaction between 
PPARγ and the glucocorticoid receptor (GR). Nie et al (38) demonstrated direct 
physical interaction between PPARγ and the dominant glucocorticoid receptor, 
GRα, following 15d PGJ2 application in human airway smooth muscle cells. This 
interaction was functional as it resulted in the inhibition of eotaxin production 
by  the  cells  following  stimulation  with  TNF α.  Ialenti  et  al  (176)  have  also 
examined PPARγ and GR interaction in a model of inflammation.  Glucocorticoid 
receptor blockade with RU486 (a glucocorticoid receptor antagonist) removed a 
substantial  portion  of  the  anti inflammatory  effect  of  the  PPARγ  agonists 
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was necessary to remove all the anti inflammatory effects.  In the same paper 
rosiglitazone  and  ciglitazone  were  observed  to  stimulate  GR  nuclear 
translocation in a PPARγ deficient cell line leading to the conclusion that PPARγ 
agonists could produce anti inflammatory effects via GR activation. This work 
suggests that PPARγ agonists may be able to modulate existing glucocorticoid 
receptor activity to reduce inflammation and that combined therapy with PPARγ 
agonists  and  corticosteroids  may  produce  a  greater  degree  of  control  over 
inflammation than corticosteroids can achieve alone. 
A  recent  paper  has  demonstrated  evidence  for  direct  stimulation  of  the 
glucocorticoid receptor by thiazolidinediones (177). In this study rosiglitazone 
was  found  to  induce  glucocorticoid  receptor  phosphorylation,  nuclear 
translocation and increased expression of a glucocorticoid receptor dependent 
gene. The authors also demonstrated similar effects for other thiazolidinediones 
and  suggested  that  thiazolidinediones  may  be  exerting  some  of  their  anti 
inflammatory and anti diabetic actions through stimulation of the glucocorticoid 
receptor as a partial agonist. 
1.8.7.5  PPARγ & HDAC 
PPARγ appears to mediate part of its transrepressive actions via HDAC containing 
multiprotein  complexes  (165).  A  murine  model  of  inflammation  based  on 
macrophage  stimulation  by  lipopolysaccharide  and  production  of  iNOS 
demonstrated  that  the  multiprotein  complex  NCoR,  which  contains  HDAC3, 
suppresses transcription of a number of inflammatory genes in unstimulated cells 
by binding to gene promoters. Upon stimulation of the cell with LPS, NCoR was 
removed permitting NF κB responsive inflammatory gene production. However 
addition of the PPARγ agonist rosiglitazone was found to result in SUMOylation of 
PPARγ  on  its  ligand  binding  domain  followed  by  PPARγ  binding  to  the  NCoR 
complex  localised  at  the  iNOS  promoter.  This  prevented  NCoR  removal  and 
transcription  of  NF κB  responsive  inflammatory  genes.  This  prolongation  of 
transrepression was dependent on the HDAC activity of the NCoR complex, as 
rosiglitazone  mediated  transrepression  was  abolished  through  the  use  of  the 
HDAC inhibitor Trichostatin A and siRNAs for HDAC3. 
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1.8.8 PPARγ & asthma 
Few researchers have addressed the relevance of PPARγ to humans with asthma. 
One  study  has  examined  PPARγ  expression  in  bronchial  biopsies  from 
corticosteroid  naive  asthmatic  patients  (117).  The  authors  demonstrated  that 
PPARγ  expression  was  increased  in  corticosteroid  naive  asthmatic  subjects 
compared  to  controls.  This  increased  expression  was  evident  in  all  epithelial 
compartments (epithelial cells, smooth muscle cells and bronchial mucosal cells) 
and PPARγ expression was reduced towards normal levels following treatment 
with inhaled corticosteroids. 
 
What is the role played by PPARγ in asthma and what could be the reason behind 
its suppression following corticosteroid treatment? PPARγ is upregulated by IL 4, 
due to IL4 response elements within the PPARγ gene. A reciprocal relationship 
exists as PPARγ stimulation also inhibits IL 4 and this and similar work has led to 
a discussion over PPARγ having a role as an innate mechanism for resolution of 
inflammation  (128).  PPARγ  stimulation  also  suppresses  a  number  of  other 
inflammatory cytokines of relevance to asthma and its upregulation by cytokines 
would support a role in the resolution of inflammation. 
 
Variations in PPARγ also appear to be relevant to asthma control. A recent study 
examined single nucleotide polymorphisms (SNPs) in PPARγ in a large cohort of 
young  subjects  with  asthma  (178).  Three  previously  characterised  haplotypes 
were examined, Pro12Ala, C1431T & C 681G, using buccal cells. The subjects 
homozygous for the Pro12 and C1431 SNPs had increased asthma exacerbations 
and the combination of Pro12 and C1431 was associated with increased school 
absences and hospital admissions. Subjects homozygous for the Ala12 and T1431 
SNPs in contrast had better asthma control. In summary the human research so 
far supports the animal and in-vitro data suggesting that PPARγ may have a role 
in the control of inflammation in asthma. 
 
1.8.9 PPARγ and smokers with asthma 
A  central  theme  to  this  thesis  is  that  smokers  with  asthma  fail  to  gain  the 
expected benefits from inhaled corticosteroids and require new therapies. The Chapter 1    60 
presented evidence for PPARγ suggests that it has a role to play in the control of 
inflammation and as such may offer an alternative approach for the treatment of 
smokers with asthma. PPARγ expression is upregulated in asthma and reduces in 
response to corticosteroids. It is tempting to speculate that PPARγ expression is 
upregulated  in  smokers  with  asthma  in  correlation  with  their  reduced 
corticosteroid  response  and  as  a  result  PPARγ  stimulation  could  provide  an 
alternative  method  for  the  reduction  of  inflammation  in  this  group.  Whilst 
evidence in support of this particular hypothesis is not available for smokers with 
asthma there is sufficient evidence to justify examination of a PPARγ agonist in 
smokers with asthma in an exploratory clinical trial. 
 
1.9  Non-invasive assessment of inflammation  
1.9.1 Rationale for use of non-invasive methods 
Previous research investigating asthma has utilised autopsy tissue from cases of 
fatal asthma and samples obtained by bronchoscopic  biopsies. Whilst autopsy 
samples are obviously not reflective of normal asthma, bronchoscopy does allow 
sampling of airway cells and bronchial tissue from a variety of subjects over a 
number of timepoints. Unfortunately bronchoscopy is associated with a degree 
of risk, albeit small in most, but significant in those with poor lung function. 
Bronchoscopy is also expensive both for the research unit due to the number of 
staff required to perform the test and for the patient given the amount of time 
required to recover. Therefore whilst bronchoscopy provides useful insights into 
asthma,  concern  over  the  high  cost  and  validity  of  extrapolation  to  other 
subjects has resulted in the development of a number of non invasive measures 
for  the  assessment  and  phenotyping  of  asthma  and  to  follow  treatment 
responses. 
1.9.2 Induced sputum 
The examination of patient's sputum for infective organisms is a well established 
diagnostic tool. The examination of sputum from asthmatics with respect to the 
cellular  profile  led  to  several  important  early  observations  including  the 
association between sputum eosinophilia and good corticosteroid response (179). Chapter 1    61 
However  the  use  of  spontaneous  sputum  is  not  ideal.  Not  all  patients  can 
produce  sputum  spontaneously  and  even  when  possible  spontaneous  sputum 
specimens can be difficult to use due to the high squamous cell contamination 
and  a  high  proportion  of  necrotic  cells  (180).  Induced  sputum  has  risen  in 
popularity as it is felt to reflect inflammation of the main airways and therefore 
provides  similar  but  not  identical  information  to  bronchial  washes  and 
bronchoalveolar lavage (181 183). However induced sputum does not correlate 
well with bronchial biopsy findings (181, 182). With increasing recognition of the 
potential  of  induced  sputum  as  a  non invasive  measure,  methods  for  the 
technique have been refined with the aim of employment in clinical trials (180, 
181, 184, 185). There is currently a debate as to the role for induced sputum 
monitoring  in  the  management  of  asthma  but  it  is  unlikely  to  be  employed 
outside specialist secondary care asthma clinics (48). 
1.9.3 Induced sputum methodology 
1.9.3.1  Induction method 
The  common  thread  in  all  sputum  induction  protocols  is  the  inhalation  of 
nebulised sterile saline from a high output ultrasonic nebuliser, the need for the 
administration of pre induction bronchodilator and for regular monitoring of the 
participant’s symptoms and FEV1 during the induction period (181, 184). Beyond 
this there is a difference in opinion as to the optimal method. A range of time 
periods and concentrations of sterile saline have been employed by different 
centres and by multicentre studies. Some centres expose subjects to nebulised 
saline  for  periods  of  five  minutes  and  others  use  periods  of  seven  or  more 
minutes. There is also some variation with regards the concentration of saline 
used  with  some  groups  increasing  the  saline  concentration  with  each  new 
inhalation  period  and  others  keeping  a  constant  concentration.  Our  group 
currently employs seven minute inhalation periods and 3, 4 & 5% saline. The 
subject moves onto the next highest concentration if their lung function allows 
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1.9.3.2  Sputum processing 
The  processing  of  induced  sputum  samples  has  also  been  the  cause  of  some 
debate with some groups advocating the use of the whole sample and others 
selection of sputum plugs (186). A recent working group concluded that both 
methods of selection are useful for differentiating health and disease but were 
felt to not be interchangeable and it was advised to keep to one method for the 
duration of a trial (186). Our group currently employs the whole sample method. 
Once processed a sample of the sputum is added to a slide and processed for 
counting. The current consensus is that a minimum number of 400 non squamous 
cells are required for a representative count (186). The count should consist of a 
total cell count, squamous cell count and a differential of non squamous cells 
with samples being discarded when the percentage of squamous cells is greater 
than  80%  (187).  Induced  sputum  results  expressed  as  a  percentage  of  non 
squamous cells bypasses concerns about dilution in the whole sample method 
and allows for good reproducibility (187, 188).  
1.9.4 Induced sputum-Clinical trials 
Induced  sputum  has  been  demonstrated  to  be  highly  reproducible  in  asthma 
(180),  to  respond  appropriately  to  allergen  challenge  and  corticosteroid 
treatment (181) and to correlate with bronchial provocation testing and exhaled 
nitric oxide levels in adults (189) and children (190) (although these findings are 
not consistent (191, 192)).  
1.9.4.1  Induced sputum-Eosinophilia 
Induced sputum facilitates sub categorisation of asthma into groups that respond 
to  conventional  treatments  based  on  the  predominance  of  certain  cell  types 
(essentially  as  an  extension  of  previous  work  in  spontaneous  sputum  (179)). 
Therefore induced sputum has become employed as a study endpoint in cross 
sectional and intervention trials. Treating subjects with sputum eosinophilia with 
corticosteroids to reduce the percentage of eosinophils below a pre set target 
has been demonstrated to result in a greater improvement in asthma control 
relative  to  standard  clinical  measures  (193)  whilst  the  absence  of  sputum 
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(193). The degree of sputum eosinophilia also negatively correlates with FEV1 
(194).  
1.9.4.2  Induced sputum-Neutrophilia and paucicellular sputum 
Sputum  neutrophilia  is  associated  with  a  reduced  response  to  corticosteroid 
treatment in asthma as a raised sputum neutrophil count has been described in 
smokers  with  asthma  (41,  42)  and  subjects  with  severe  asthma  (195 199).  In 
prospective clinical trials  sputum  neutrophilia  has  also  been  demonstrated  to 
correlate with steroid resistant inflammation (44, 46). 
In  subjects  with  raised  sputum  neutrophils  there  is  evidence  of  an  inverse 
correlation with FEV1 (194, 200) and irreversible airflow obstruction (200). In 
some  subjects  with  asthma  an  induced  sputum  profile  is  observed  which  has 
neither a raised eosinophil nor neutrophil count. This group has been described 
as ‘paucicellular’ or ‘paucigranulocytic’ and appears to indicate a milder form of 
asthma as it is associated with better asthma control (46).  
1.9.4.3  Induced sputum-Definition of eosinophilia and neutrophilia  
The  definition  of  sputum  eosinophilia  has  been  developed  through  research 
examining sputum profiles from normal subjects. This work has resulted in the 
current consensus for the cut off being an eosinophil percentage of >2% (44, 46, 
201,  202).  The  definition  of  neutrophilia  is  slightly  more  problematic  as  the 
sputum neutrophil percentage increase with age (200, 202). A correction based 
on subject age may enable further examination of the importance of sputum 
neutrophilia (194). A pragmatic approach that has been advocated is to define 
neutrophilia as a sample with greater than 50% neutrophils. However the need 
for research addressing normal ranges for induced sputum is clear and a call for 
further work has recently been made (203). 
1.9.4.4  Induced sputum-Reproducibility 
Induced  sputum  demonstrates  good  reproducibility  with  intraclass  correlation 
co efficients (ICC) for eosinophils of 0.85 and neutrophils of 0.57 (187) for whole 
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0.63 for eosinophils and 0.57 for neutrophils (204) in one study and 0.94 for 
eosinophils and 0.81 for neutrophils in another (180). 
1.9.5 Sputum supernatant cytokines 
Investigation  of  the  possible  mechanisms  responsible  for  the  development  of 
asthma and allergy in animal models, in-vitro systems and clinical studies has 
led to the identification of pathways in the innate and adaptive immune system 
that may be activated in asthma. The cytokines and chemokines associated with 
these pathways can be detected in the supernatant phase of sputum samples 
obtained from patients using immunological techniques.  
In recent years the number of antibodies available for the cytokine/chemokine 
of interest has increased and it is now possible to detect multiple signals within 
the same sample using commercially available systems. Therefore researchers 
are able  to  examine the  symphonic  orchestration  of  the immune  response  in 
contrast to the limited and potentially biased examinations in the past. Using 
these  new  approaches  it  should  be  possible  to  determine  the  relative 
contribution from the innate and adaptive immune arms of the immune system.  
1.9.5.1  Effect of sputum processing on supernatant cytokines 
However  the  examination  of  cytokines  and  chemokines  in  induced  sputum 
presents  some  unique  difficulties  due  to  the  use  of  the  reducing  agent 
dithiothreitol (DTT) (181, 205 207). DTT is routinely employed in the preparation 
of  induced  sputum  as  it  reduces  the  viscosity  of  the  sample  enabling  easy 
removal of sputum plugs. An unfortunate side effect is loss of antigenicity of 
some cytokines due to the disruption of thiol bonds within their structure (205, 
206).  Recent  work  employing  removal  of  DTT  post  sputum  processing  using 
dialysis cassettes (206), removal of sputum supernatant prior to addition of DTT 
or  use  of  lower  concentrations  have  been  attempted  with  improvements  in 
detection levels. Despite the availability of techniques to examine cytokines in 
induced  sputum  the  identification  of  a  consistent  sputum  cytokine  profile 
predictive of a treatment response remains elusive perhaps as a result of this 
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1.9.6 Exhaled markers of inflammation-Nitric oxide 
Nitric  oxide  (NO)  is  abundant  in  the  human  body,  where  it  has  many  roles 
including  vasomotor  control  and  neurotransmission.  NO  is  produced  from  L 
arginine  by  nitric  oxide  synthases  (NOS)  through  oxidative  conversion  (208). 
There are three forms of NOS and two of the three are constitutively expressed 
neuronal  nitric  oxide  synthase  (nNOS)  and  endothelial  nitric  oxide  synthase 
(eNOS). Both nNOS and eNOS are activated by increased intracellular calcium as 
a result of their calmodulin binding region. nNOS has a role in non cholinergic 
non adrenergic  bronchial  smooth  muscle  relaxation  and  eNOS  in  bronchial 
epithelial  ciliary  beat  frequency  (208).  The  third  NOS,  inducible  nitric  oxide 
synthase (iNOS), is upregulated by immunological and inflammatory stimulation, 
is relatively insensitive to intracellular calcium levels and produces much larger 
amounts of NO compared to nNOS and eNOS (208).  
NO is present in exhaled breath and was first detected in humans in 1991 (209) 
and in subjects with asthma soon after (210). Expelled air from the lungs does 
contain NO but it is present at much higher levels in the nose and paranasal 
sinuses (210). However with adherence to good measurement techniques nasal 
NO  can  be  excluded  through  closure  of  the  soft  palate  in  the  majority  of 
subjects (47). Bronchial epithelial cells, airway smooth muscle, macrophages, 
neutrophils and alveolar cells all express iNOS and contribute to the production 
of exhaled NO but the bronchial epithelium is responsible for the lion’s share 
(208, 211, 212). The role of nitric oxide in the lung is complex as it is highly 
reactive and it can form reactive nitrogen species such as peroxynitrite, react 
with cysteine residues on proteins to form S nitrosothiols and hence interfere 
with zinc finger motifs of transcription factors, interact with guanylate cyclase 
synthase  to  increase  intracellular  cGMP  levels  and  alter  mitochondrial 
metabolism (208, 211, 212). 
1.9.7 Nitric oxide in asthma 
The  ability  of  iNOS  to  be  induced  by  inflammation  coupled  to  the  effect  of 
increased nitric oxide on cellular processes and the observations that exhaled 
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treatment has led to an interest in the monitoring  of exhaled NO in asthma. 
Exhaled  NO  has  subsequently  become  established  as  an  endpoint  for  the 
assessment of new therapies targeted against inflammation. In recognition of 
this  recent  consensus  guidelines  have  provided  expert  guidance  aiding  both 
comparison of studies and avoidance of errors in assessment (47). Unfortunately 
the specificity of raised single flow measurement of NO for asthma is less than 
desired as production is increased in other inflammatory conditions, for example 
cirrhosis  (213),  systemic  lupus  erythematosis  (214),  COPD  (215)  and  lung 
transplant rejection (216). 
1.9.7.1  Employment in asthma control algorithms 
However  there  are  also  problems  with  exhaled  NO  and  its  utilisation  in  the 
management of asthma which has led to questions over its usefulness in clinical 
research.  Several  groups  have  explored  the  utility  of  exhaled  NO  in  the 
management  of  asthma  (217 219)  but  no  reduction  in  asthma  exacerbations 
occurred  when  exhaled  NO  was  used  to  guide  management.  In  the  largest 
management  trial  to  date  (219)  the  use  of  NO  in  conjunction  with  clinical 
assessment  resulted  in  increased  inhaled  corticosteroid  usage  without 
improvement in asthma control, lung function, unscheduled visits or need for 
hospitalisation. 
1.9.7.2  Reference ranges 
Measurement of NO using one standard exhaled flow rate also suffers from less 
than ideal sensitivity and specificity. There is difficulty with cut offs given the 
degree  of  overlap  that  exists  between  subjects  with  asthma  and  normal 
subjects.  However a NO  level  of  <16ppm  (measured  at  50ml/sec) appears  to 
indicate  of  an  absence  of  eosinophilia  and  >26ppm  correlates  with  sputum 
eosinophilia  (albeit  weakly)  (213,  215).  However  other  cut  offs  have  been 
employed (219) and one manufacturer suggests that a value of greater than 50 
ppb in adults is suggestive of eosinophilic inflammation (Aerocrine AB, Sweden). 
I  would  agree  that  similar  to  induced  sputum  there  is  an  urgent  need  for 
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1.9.7.3  Effects of cigarette smoking 
Another  major  problem  for  the  employment  of  exhaled  NO  in  research  and 
clinical practice is the effect of current smoking on exhaled NO levels. Smoking 
acutely  increases  exhaled  nitric  oxide  levels,  reflecting  the  concentration  of 
nitric  oxide  within  the  cigarette  (51,  54)  and  chronic  smoking  results  in  a 
reduction  of  exhaled  NO  with  measurements  in  smokers  with  asthma  usually 
being in the normal range (50, 220). However a recent study does suggest that a 
percentage  change  in  the  exhaled  NO  concentration  may  reflect  changes  in 
asthma control and therefore may overcome some of the problems with the use 
of this endpoint in smokers with asthma (221).  
The mechanism responsible for the reduced exhaled NO concentration displayed 
by  this  group  has  been  debated.  Some  authors  propose  that  the  high 
concentration of NO in cigarette smoke could be inhibiting iNOS (52, 54) and 
others that the increased oxidative stress results in consumption of airway NO 
(51, 52). A recent study comparing smokers with asthma to non smokers with 
asthma demonstrated equal levels of iNOS in the smokers and non smokers with 
asthma but raised arginase 1 and ornithine de carboxylase expression in smokers 
suggesting that substrate competition may be contributing to the reduced NO 
levels in smokers with asthma (53).  
1.9.7.4  Extended flow nitric oxide analysis 
Early  work  examining  exhaled  nitric  oxide  noted  that  the  nitric  oxide 
concentration level in exhaled breath varied with the flow rate of exhalation 
with an inverse exponential relationship between flow rate and exhaled nitric 
oxide concentration being evident (222). The production rate of NO (VNO) also 
increases linearly with the rate of exhalation similar to heat exchange in a pipe. 
These characteristics of exhaled NO led researchers to develop models based on 
the principle that the lungs could be divided into two compartments or phases; a 
fixed volume conducting airways region and an expandable alveolar region. 
This two compartment model allows for the derivation of estimates for alveolar 
NO levels (Calv, ppb), airway wall NO diffusion (Daw, pl/s/ppb), airway wall nitric 
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the flow rates used and the regression model employed. Plotting nitric oxide 
production against flow rate for a variety of flow rates allows derivation of these 
parameters using linear and non linear regression. This alternative approach to 
the assessment of exhaled NO has led to hopes that extended flow analysis will 
increase the sensitivity and specificity of exhaled NO. Alveolar NO levels may 
reflect inflammation in the smaller airways (223) and recent work has employed 
this endpoint in the examination of new formulations of inhaled corticosteroids 
in the hope of detecting a reduction in small airway inflammation (224). Alveolar 
NO also appears to be unaffected by smoking so could be useful as a measure of 
inflammation in COPD and smokers with asthma (225, 226). The technique may 
also be able to improve the specificity of exhaled NO through the definition of 
extended  flow  profile  ‘signatures’  for  different  conditions.  For  example, 
different  conditions  may  have  different  rates  of  airway  wall  NO  production, 
airway  wall  diffusion  and  alveolar  and  airway  NO  levels.  Steroid  naïve  non 
smoking  asthmatics  have  raised  alveolar  NO,  diffusion  and  flux  compared  to 
steroid treated asthmatics who display raised diffusion only (227). Extended flow 
rate nitric oxide measurement has not been studied in smokers with asthma and 
given the absence of an impact of smoking on alveolar NO in normal smokers and 
smokers with COPD extended profile analysis may provide a useful non invasive 
marker of inflammation in smokers with asthma. 
1.9.8 Exhaled breath condensate  
Exhaled breath contains vapours and aerosols that can be analysed by collecting 
via cooling and precipitation (228, 229). This phase of exhaled breath, known as 
exhaled  breath  condensate  (EBC),  has  been  utilised  since  the  early  nineteen 
eighties  as  a  non invasive  method  of  examining  airway  lining  fluid  and  its 
chemical environment composition. EBC has been demonstrated to contain non 
volatile  compounds  such  as  cytokines,  lipids,  surfactant,  ions,  oxidation 
products,  adenosine,  histamine,  acetylcholine  and  serotonin  and  over  200 
volatile compounds such as ammonia, H2O2 and ethanol can be detected (229, 
230). EBC has subsequently been used to examine a number of disease states 
(for example asthma, cystic fibrosis and bronchiectasis) and their response to 
treatment (228, 231 233). Chapter 1    69 
1.9.8.1  Exhaled breath condensate-methodological considerations 
EBC gained interest as it was initially thought to have the potential to obtain 
equivalent samples to invasive procedures such as bronchoscopy and broncho 
alveolar lavage and non invasive procedures that require specialist processing 
such as induced sputum. However there are methodological issues that need to 
be  addressed  and  hence  concerns  over  the  applicability  of  EBC  data.  For 
example,  EBC  has  recently  been  demonstrated  to  have  poor  correlation  with 
bronchoalveolar  lavage  for  a number  of  measurements  (234).  There is  also a 
need  for  a  reliable  marker  to  calculate  the  degree  of  dilution  of  exhaled 
biomarkers by water in the EBC (235 237). Work is currently ongoing to develop 
a suitable reference marker. 
1.9.8.2  Exhaled breath condensate pH 
Another avenue of examination in exhaled breath condensate is EBC pH. Hunt et 
al have demonstrated that asthmatics admitted with acute exacerbations have a 
reduced EBC pH that normalises within forty eight hours of treatment (228). EBC 
pH has subsequently been examined in a number of conditions including COPD 
(232),  bronchiectasis (238)  and  cystic  fibrosis  (239,  240).  Measurement  of  pH 
after de aeration with argon has been demonstrated to be consistent day to day, 
week  to  week  and  person  to  person  and  to  be  stable  over  a  range  of 
temperatures of collection and for 2yrs in storage (232, 241). Similarly EBC pH is 
unaffected  by  hyper  and  hypoventilation  (242)  and  methacholine  induced 
bronchoconstriction (241).  
1.9.8.3  Mechanisms responsible for EBC acidification 
What causes the airway acidification demonstrated by EBC pH? One potential 
mechanism  is  alteration  of  airway  cell  numbers  and  proportions.  Both 
neutrophils and eosinophils can cause airway acidification. Neutrophils can form 
hypochlorous acid via the myeloperoxidase catalysed reaction between H2O2 and 
chloride. Eosinophils can produce acid via eosinophil peroxidase which catalyses 
a reaction between H2O2 and halides to form hypohalous acids. Hunt et al did not 
examine  induced  sputum  in  their  study  so  we  do  not  know  the  relative 
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induced  sputum  neutrophilia  has  demonstrated  a  strong  negative  correlation 
with EBC pH in subjects with COPD and bronchiectasis and a strong negative 
correlation between sputum eosinophilia and pH in subjects with asthma (238). 
Further  research  comparing  smokers  and  non smokers  with  asthma  has 
demonstrated that smoking is associated with a lower EBC pH (58). No difference 
was  present  in  percentage  neutrophil  counts  between  the  two  groups  in  this 
study. 
An alternative mechanism for airway acidification in asthma could be alterations 
in the airway epithelium. Activation of cell surface exchange pumps such as Na
+ 
H
+ exchange protein 1 and anion exchange proteins 1 and 3 in the context of 
reduced airway lining fluid buffering have been suggested as potential causes of 
acidification  of  inflamed  airways  (243).  Other  potential  mechanisms  for  EBC 
acidification include inappropriate collection of gastric air & micro aspiration of 
gastric contents. 
1.10 Hypotheses and aims 
The overall aim of this thesis was to examine two potential new therapies for 
smokers  with  asthma  and  to  gain  understanding  of  the  altered  inflammatory 
processes present in this group.  
The following hypotheses were examined in the two studies conducted for this 
thesis: 
1.10.1  Theophylline & Rosiglitazone 
•  Low dose theophylline will restore corticosteroid sensitivity in smokers 
with asthma due to a restoration of HDAC activity 
•  The oral PPARγ agonist rosiglitazone will demonstrate superiority to low 
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1.10.2  Corticosteroid sensitivity study 
•  Smokers with asthma display a muted lung function response to an oral 
corticosteroid trial compared to non smokers with asthma 
•  Smokers with asthma have an altered pulmonary and systemic cytokine 
environment compared to non smokers with asthma 
•  Smokers  with  asthma  display  a  reduced  sputum  and  blood  total  HDAC 
activity compared to non smokers with asthma 
•  Smokers with asthma display alterations in flow independent nitric oxide 
parameters compared to non smokers with asthma 72 
2  Methods 
2.1 Regulatory approval 
The studies presented in this thesis were reviewed and approved by the West 
Glasgow Ethics Committee. The study examining the efficacy of rosiglitazone in 
smokers  with  asthma  was  also  submitted  for  review  and  approval  by  the 
Medicines and Health Regulatory Authority. All subjects received an information 
sheet and attended for a discussion of the associated study protocol prior to 
consent and enrolment. 
2.2 Recruitment methods 
The majority of patients that took part in the studies presented in this thesis 
were recruited from general practices in the Greater Glasgow and Clyde and 
North and South Lanarkshire Health Board areas. The practices were approached 
by letter and those willing to participate were visited by a member of the study 
team  who  undertook  a  search  of  the  practice  records  to  identify  potential 
recruits, taking care to exclude subjects who failed to meet entry criteria. A list 
of potential recruits was then left with the practice for review and vetting to 
prevent inappropriate approaches. Once this process was completed a further 
visit to the practice was arranged where the study team member produced an 
approach pack containing an invitation letter, a response form and a stamped 
address envelope. The practice then posted the approach pack to the potential 
recruits  in  their  normal  mail.  Interested  subjects  who  contacted  the  asthma 
research unit were vetted by phone call and those who were deemed suitable 
were invited to discuss the study. 
Commercial adverts approved by the local ethics committee were also used to 
help  recruitment  to  the  theophylline  and  rosiglitazone  study.  Two  radio 
advertisement campaigns were utilised along with a month of posters placed at 
major transport hubs in the Glasgow area. A small number of subjects who had 
previously  participated  in  trials  run  by  the  Asthma  Research  Unit  were  also 
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2.3 Study design 
2.3.1 Efficacy of theophylline and rosiglitazone in smokers with 
asthma 
This study was a randomised, prospective, double blind, double dummy, active 
comparator, parallel group design. Mild to moderate (2) stable asthmatics aged 
18 to 60 on ≤1000 mcg beclometasone (or equivalent) per day who were regular 
smokers of ≥5 cigarettes per day and with a pack year history of ≥5 pack years 
were  eligible  for  enrolment.  Subjects  who  were  willing  to  participate  were 
offered smoking cessation advice and those unwilling to quit smoking at that 
time and did not have conditions excluding participation were enrolled.  
All  subjects  had  to  demonstrate  reversible  airflow  obstruction  with  a  FEV1 
bronchodilator response of ≥12% (and >200ml). Subjects were also monitored for 
asthma stability for up to six weeks and underwent a corticosteroid weaning and 
monitoring  phase  that  lasted  one  month  within  this  period.  Subjects  were 
excluded from randomisation if they experienced an exacerbation of asthma at 
any point during this run in phase. An asthma exacerbation was defined as a 
reduction in morning peak flow (PEF) of 30% or more from baseline or asthma 
exacerbation  requiring  oral  corticosteroids  or  hospitalisation  or  emergency 
department/general practice visit or the presence of asthma symptoms deemed 
unacceptable to either the study co ordinator or study subject.  
Other exclusion criteria included: 
•  Asthma  exacerbation  or  respiratory  tract  infection  within  six  weeks  of 
screening  
•  Additional respiratory condition e.g. bronchiectasis 
•  Plan to reduce or stop cigarette smoking 
•  Pregnancy or plan to conceive 
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•  Recent  myocardial  infarction/unstable  angina  or  any  history  of  cardiac 
failure (past 6 months) 
•  Anaemia or abnormal renal or hepatic laboratory values 
•  Contraindication to treatment with either theophylline, rosiglitazone or 
inhaled corticosteroid 
•  Recent drug or alcohol abuse 
•  Morbid obesity (defined as BMI>40) 
•  Inability to perform spirometry 
•  Requirement for treatment with any other asthma medications (except 
inhaled salbutamol and allocated trial medication) from screening until 
study completion. 
At  the  end  of  a  two week  inhaled  corticosteroid  free  period  each  subject 
attended  for  a  randomisation  visit,  which  comprised  spirometry  and  PEF 
recordings, completion of an asthma control questionnaire (ACQ)(244), induced 
sputum  for  differential  count,  supernatant  and  sputum  macrophage  HDAC 
activity assay and routine bloods for safety (full blood count, renal and liver 
function testing) and characterisation (total and specific IgE, total cholesterol, 
LDL, HDL and triglycerides levels). 
Subjects  were  then  randomised  to  either  100mcg  twice  a  day  inhaled 
hydrofluoroalkane beclometasone dipropionate (Qvar©, IVAX, Runcorn, Cheshire, 
UK)  [Equivalent  to  approximately  400mcg  per  day  chlorofluorocarbon 
beclometasone]  (245),  4mg  twice  daily  oral  rosiglitazone  (Avandia®,  GSK, 
Greenford,  Middlesex,  UK),  200mg  twice  daily  oral  theophylline  (Uniphyllin® 
Continus®,  NAPP,  Cambridge,  UK)  or  200mg  twice  daily  oral  theophylline  in 
combination with 100mcg twice a day inhaled hydrofluoroalkane beclometasone 
dipropionate.  Subjects  returned  for  pre bronchodilator  lung  function  at  two 
weeks and repeated the assessments carried out at the baseline visit (spirometry 
pre and post bronchodilator, peak flow, induced sputum and supernatant, blood 
and serum & ACQ) after four weeks. This visit was performed at the same time 
of  day  (+/   2  hours)  as  the  baseline  visit.  Continued  regular  smoking  was 
confirmed through the measurement of exhaled carbon monoxide and urinary 
cotinine metabolites. Subjects were instructed to omit smoking for three hours Chapter 2    75 
prior to each study visit and were informed that if they did not adhere to this 
request their visit would be re scheduled and where this was not possible they 
would be excluded from the study for non compliance. If an excessively raised 
carbon  monoxide  level  was  detected  subjects  were  challenged  over  their 
compliance with abstinence from smoking. 
The primary endpoint was change in pre bronchodilator FEV1 from baseline to 
day  28.  Secondary  endpoints  were  change  from  baseline  to  day  28  in  pre 
bronchodilator PEF, FVC, FEF25 75, FEF75 & asthma control questionnaire score. 
Exploratory  endpoints  included  sputum  differential  count,  sputum  cytokine 
profile & sputum macrophage histone deacetylase activity (HDAC). 
2.3.2 Determinants of corticosteroid insensitivity in smokers with 
asthma 
The study was a cross sectional design with open label, unblinded use of oral 
dexamethasone. Smokers, ex smokers and non smokers with mild to moderate 
asthma were recruited to the study. Subjects were allowed treatment with up to 
a maximum of 2000 mcg beclometasone (or equivalent), long acting β2 agonists 
and  leukotriene  receptor  antagonists.  Theophylline  was  withdrawn  (if 
prescribed) for 6 weeks prior to the start of the steroid trial and restored at the 
end  of  the  study.  Smokers  with  asthma  were  eligible  if  they  were  currently 
smoking ≥5 cigarettes per day and had a ≥5 pack year history. Ex smokers with 
asthma were eligible if they had ceased smoking 2 or more years from the date 
of  recruitment  and  had  a  ≥5  pack  year  history.  Non  smoking  subjects  were 
required to have no history of regular smoking and to be current non smokers. 
All subjects performed urine cotinine and exhaled carbon monoxide testing at 
each visit to confirm smoking status. Smokers with asthma were instructed to 
omit smoking for 3 hours prior to each visit and were informed that if they did 
not  adhere  to  this  request  their  visit  would  be  re scheduled  and  when  not 
possible  they  would  be  excluded  from  the  study  for  non compliance.  If  an 
excessively raised carbon monoxide level was detected subjects were challenged 
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All recruited subjects had to demonstrate either reversible airflow obstruction 
with  a  FEV1  bronchodilator  response  of  ≥12%  (and  >200ml),  PEF  lability  or  a 
positive methacholine test to be eligible to perform the oral corticosteroid trial. 
If  subjects  did  not  demonstrate a  positive  FEV1  bronchodilator response  then 
they  returned  after  completing  a  PEF  diary.  If  this  did  not  demonstrate  PEF 
lability  then  a  methacholine  test  was  performed.  Baseline  measurements 
included spirometry and PEF, exhaled nitric oxide measurement, exhaled breath 
condensate and induced sputum collection, asthma control questionnaire score 
and blood for HDAC activity and cytokine assessment. Corticosteroid sensitivity 
was assessed using a two week trial of oral dexamethasone, adjusted for body 
surface  area.  Each  subject  was  allocated  a  daily  dose  of  6mg/1.74  m
2  oral 
dexamethasone  and  steroid  response  was  assessed  as  the  change  in  pre 
bronchodilator FEV1 at two weeks. The assessments carried out at baseline were 
also  repeated  with  the  inclusion  of  blood  cortisol  to  check  compliance  with 
corticosteroids. If blood cortisol was suppressed below 50nmol/l then subjects 
were deemed to be compliant with therapy and their post steroid trial data was 
assessed. This visit was performed at the same time of day (+/  2 hours) as the 
baseline visit. A subset of subjects returned at one month to repeat some of the 
assessments to determine the duration of oral corticosteroid effect. 
Exclusion criteria were: 
•  Patients with unstable asthma; defined as the presence of 1 or more of 
the  following  events  in  the  month  prior  to  study  [Emergency/’out  of 
hours’ visit to GP for asthma exacerbation; GP visit to patient at home for 
asthma exacerbation or A & E attendance/hospital admission for asthma 
exacerbation] 
•  Treatment with oral corticosteroids in the past month 
•  Need for maintenance oral corticosteroid therapy 
•  Need for treatment with theophylline for course of study 
•  Pregnancy or planning to become pregnant over course of study Chapter 2    77 
•  Presence of medical condition likely to be exacerbated by treatment with 
oral corticosteroids 
•  Plan for smoking cessation or reduction during course of study 
2.4 Demonstration of eligibility for recruitment to trials 
2.4.1 Reversibility testing 
Improvement in airflow obstruction in response to inhaled bronchodilator in a 
subject with a history consistent with asthma is accepted as diagnostic for the 
condition (1, 2) and is a frequently used entry criteria for clinical trials. 
In both trials reversibility testing was performed in all subjects by administering 
2.5mg  of  nebulised  salbutamol  for  five  minutes  following  suitable  baseline 
spirometric  recordings.  Subjects  then  performed  spirometry  from  30  minutes 
post  nebuliser.  A  minimum  of  three  acceptable  efforts  were  obtained  and  a 
maximum of eight efforts was allowed to meet this criterion. The highest FEV1 
and  FVC  obtained  were  used  for  analysis.  Subjects  were  asked  to  withhold 
inhaled and oral treatments according to consensus recommendations (table 2.1) 
(246). Reversible airflow obstruction was defined as an improvement in FEV1 of 
12%  or  greater (and 200ml  or  more  in  volume) and  was  calculated  using  the 
formula: 
% reversibility  =  ((post bd FEV1 – pre bd FEV1)/ pre bd FEV1) * 100 
where bd = bronchodilator 
 
Treatment  Withdrawal period 
Short acting inhaled bronchodilator  4 hours 
Long acting inhaled bronchodilator  24 hours 
Oral bronchodilator  24 hours 
Table 2.1 Withdrawal periods for bronchodilators prior to reversibility testing.  
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2.4.2 Peak flow lability 
Spontaneous variation in peak flow is recognised as a defining characteristic of 
asthma and is a reflection of the variable nature of the dyspnoea experienced by 
some subjects with asthma (1). Entry to the trial examining the corticosteroid 
responses of smokers, ex smokers and non smokers with asthma was therefore 
permitted if variable airflow obstruction was demonstrated through peak flow 
recordings if spirometric reversibility testing was negative at the first visit.  
Subjects were issued with a diary card and peak flow meter (EN 13826, Clement 
Clarke, Harlow, UK) and were instructed to perform three adequate efforts in 
the morning and evening and to record the highest recording in their diary for 
one to two weeks prior to review. The threshold of peak flow lability required 
for  entry  to  the  trial  followed  published  methodology  i.e.  20%  variation  in 
amplitude over 3 days in the period of diary recording (with a minimum change 
of 60 litres)(1). 
2.4.3 Bronchial provocation testing 
The demonstration of bronchial hyperreactivity in a subject with a high pre test 
probability of asthma is accepted as diagnostic for the condition (247) and this 
approach is frequently applied as an eligibility criteria in clinical research where 
subjects cannot demonstrate peak flow lability or significant FEV1 improvement 
post  nebulisation  due  to  good  asthma  control.  Testing  for  the  presence  of 
bronchial hyperreactivity centres on the administration of a challenging agent, 
most  commonly  histamine  or  methacholine,  in  serial  doubling  doses  via  a 
modified  Wright’s  nebuliser  (Airlife  Sidestream®  high  efficiency  nebuliser, 
Cardinal Health, UK) calibrated to supply 0.13ml/min of solution. 
In the study examining the corticosteroid responses of smokers, ex smokers and 
non smokers with asthma participation was allowed if subjects had a positive 
methacholine test and a history compatible with asthma. Non smokers and ex 
smokers with asthma were allowed to perform methacholine testing if their FEV1 
was greater than or equal to 60% predicted.  However smokers with asthma were 
required  to  have  a  pre  bronchodilator  FEV1  of  greater  than  or  equal  to  80% Chapter 2    79 
predicted  to  minimise  recruitment  of  subjects  with  chronic  obstructive 
pulmonary disease. 
In preparation for the test subjects were asked to  omit asthma medications, 
anti histamine  medications  and  foods  and  drinks  containing  caffeine  as  per 
recommendations  (247)(table  2.2).  Female  subjects  underwent  pregnancy 
testing and were only allowed to perform methacholine testing if not pregnant. 
Treatment  Duration of withdrawal (hours) 
Short acting β2 agonist  8 
Long acting β2 agonist  48 
Short acting anti muscarinic  24 
Long acting anti muscarinic  48 
Leukotriene receptor antagonists  24 
Theophylline  48 
Anti histamines  48 
Caffeine containing food or drinks 
(chocolate, tea, coffee, soft drinks)  Day of study 
Table 2.2 Advised durations of withdrawal from medications and foods.  
Table adapted from (247). 
 
Subjects  initially  performed pre challenge spirometry  to determine their best 
pre challenge  FEV1.  Nebulised  saline  was  then  administered  as  an  initial 
challenge  for  two  minutes.  The  target  drop  of  20%  was  calculated  from  the 
highest post saline FEV1 following repeat spirometry. The subject then inhaled 
increasing doses of methacholine in two minute dosing periods by tidal breathing 
whilst wearing a nose clip. On completion of each nebulisation phase spirometry 
was performed at 30, 90 and 180 seconds. If the subject’s FEV1 did not drop by 
20% or more in response to the methacholine dose then this was followed by a 
subsequent dose of methacholine until the subjects FEV1 declined by 20% from 
their  highest  post  saline  measurement  or  the  final  dose  (16mg/ml)  was 
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followed  by  0.0625mg/ml,  0.125mg/ml  and  then  on  in  doubling  doses  up  to 
16mg/ml.  Three  millilitres  of  each  methacholine  solution  was  placed  in  the 
nebuliser  just  prior  to  administration.  Methacholine  was  obtained  from  the 
hospital  pharmacy  (Western  Infirmary  &  Gartnavel  General  Hospital,  Sterile 
Production Unit) and was kept refrigerated to maintain stability. New stock was 
supplied every six months.  
The provoking concentration of methacholine required to produce a fall in FEV1 
by 20% (PC20) for each subject was calculated by linear interpolation using the 
formula: 
 
C1 = second to last methacholine concentration, C2 = last methacholine concentration, R1 = 
% fall in FEV1 after C1, R2 = % fall in FEV1 after C2 
Figure 2.1 Methacholine calculation method. Table adapted from (247) 
 
A PC20 of <8mg/ml in the context of a clinical history consistent with asthma, 
appropriate  symptoms  during  the  test  (chest  tightness,  dyspnoea)  and  good 
quality spirometric efforts was considered to confirm the diagnosis of asthma 
and eligibility for entry to the trial. 
2.4.4 Urine cotinine 
Smoking  history  was  confirmed  by  measurement  of  nicotine  metabolites  in  a 
specimen of the subjects urine using the SmokeScreen
TM sampling system (GFC 
Diagnostics,  Stourbridge,  UK).  The  SmokeScreen
TM  system  detects  the 
metabolised  derivatives  of  nicotine  through  their  reaction  with 
diethylthiobarbituric acid in the sampling system as this turns the urine pink. 
This method removes the problems associated with the measurement of urine 
cotinine alone such as conversion to other metabolites. 
The  level  of  nicotine  metabolites  present  was  objectively  assessed  using  the 
SmokeScreen
TM colorimeter (GFC Diagnostics, Stourbridge, UK). The colorimeter 
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measurement  5  minutes  later.  Previous  research  has  demonstrated  that  the 
reaction of nicotine metabolites occurs in a predictable linear fashion and hence 
the change in colour over time can be converted to concentration of nicotine 
metabolites  (248).  The  colorimeter  performs  this  calculation  and  displays  a 
‘cotinine equivalent’  concentration  (0 20   g/ml)  and  a  category  of  ‘smoking’ 
(non smokers, passive smoker, mild, moderate and severe smoker). The cotinine 
equivalent  concentration  ranges  for  each  category  are  non smokers  (0.0 0.3 
 g/ml), passive smoker (0.4 1.0), light smoker (1.1 5.0), medium smoker (5.1 
10.0), heavy smoker (10.1 15.0) and v heavy smoker (15.1 21.0). 
2.4.5 Exhaled Carbon Monoxide measurement 
All  subjects  performed  exhaled  carbon  monoxide  at  each  timepoint  in  both 
studies to provide substantiation to their assertion that their smoking history was 
unchanged. Exhaled carbon monoxide was detected using a Pico Smokerlyser® 
(Bedfont  Scientific  Ltd,  Rochester,  UK).  The  Smokerlyser®  detects  exhaled 
carbon monoxide using an incorporated electrochemical sensor and presents the 
result as percentage carboxyhaemoglobin, parts per  million and as a ‘traffic 
light’  read  out.  The  concentration  range  was  0 80  parts  per  million  with  an 
accuracy of +/  2%. The non smoking range was defined as 0 7 parts per million 
and current smoking 8 parts per million and above (249).  
Previous  research  has  demonstrated  that  it  takes  2 8  hours  for  the  carbon 
monoxide level to reduce by half (250 252) and at least 24 hours of smoking 
cessation is required for a smoker’s carbon monoxide level to return to that of a 
non smoker  (252).  A  grossly  elevated  level  of  carbon  monoxide  resulted  in 
questioning  of  the  volunteer  with  regards  their  compliance  with  omission  of 
smoking for the visit. Non smokers and ex smokers had to demonstrate levels 
consistent with no current smoking. Smokers had to demonstrate elevation of 
their carbon monoxide level consistent with current smoking. 
Subjects performed three readings and the mean was used for analysis. Subjects 
inhaled  and  held  their  breath  for  15  seconds  and,  when  prompted  by  the 
Smokerlyser®,  exhaled  completely  into  the  D piece  valve  via  a  cardboard 
mouthpiece.  Both  the  valve  and  mouthpiece  are  single  use  only.  The  valve 
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compounds.  Calibration  was  carried  out  every  six  months  using  a  cylinder  of 
carbon  monoxide  certified  at  20  parts  per  million  (Bedfont  Scientific  Ltd, 
Rochester, UK). 
2.5 Clinical endpoints 
2.5.1 Spirometry 
Spirometric  recording  was  performed  in  all  subjects  using  electronic 
pneumotachograph  spirometers  (Vitalograph  Ltd,  Maids  Moreton,  Buckingham, 
UK) to the standards set by the joint ATS/ERS guidelines on spirometry (253). 
Calibration of each spirometer was carried out every day prior to first use with a 
3  litre  reference  syringe  with  adjustment  for  ambient  temperature  (253). 
Servicing was also carried out on an annual basis by Vitalograph technicians. 
Spirometric manoeuvres were consistent with published recommendations (253). 
To ensure consistent and valid performance of spirometry subjects observed a 
demonstration by the study doctor or research nurse prior to their first attempt. 
The  subject  was  then  instructed  to  take  a  maximum  breath  in  and  to  then 
immediately place the mouthpiece in their mouth and blow out with maximum 
effort  into  the  mouthpiece  until  no  further  air  could  be  expelled.  Active 
encouragement  to  continue  exhalation  until  a  suitable  effort  had  been 
performed was provided by the supervising staff member. The procedure was 
repeated  until  three  acceptable  manoeuvres  were  available  ensuring  proper 
understanding of the technique and consistency in performance. A maximum of 
eight efforts was allowed to facilitate this process. An acceptable exhalation 
manoeuvre was defined as one which demonstrated a good rapid start, was free 
from artefact (cough, sub maximal effort, glottis closure etc) and that had a 
satisfactory duration of exhalation. The duration was satisfactory if a plateau 
was reached and a minimum of six seconds of exhalation had been performed. 
Inter manoeuvre variability was reduced by accepting efforts where the last two 
FEV1 results did not vary by more than 5% or 150ml.The highest FEV1, FVC, FEF25 
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2.5.2 Peak expiratory flow 
All patients were required to perform peak flow measurement at visits where 
spirometry was performed. Clement Clarke meters with EU scale EN 13826 were 
used for all measurements (Clement Clarke, Harlow,  UK). PEF procedure was 
first demonstrated by the study nurse or doctor and subjects were then asked to 
stand  upright  and  blow  with  maximum  effort  into  the  peak  flow  meter.  The 
highest of three acceptable readings was recorded. 
2.5.3 Asthma Control Questionnaire  
The  Juniper  Asthma  Control  Questionnaire  (ACQ)  is  a  simple,  reliable  and 
sensitive questionnaire that was developed to allow quick assessment of asthma 
control  in  all  severities  of  asthma  and  has  been  demonstrated  to  effectively 
demonstrate the impact of asthma treatment interventions (244).  
The score produced by the questionnaire is based on a series of seven questions. 
The first six questions cover the symptoms that the respondent has experienced 
in the past week with regards night time wakening, limitation of normal daily 
activities, early morning wakening, dyspnoea and wheeze and frequency of use 
of inhaled β2 agonist. Each question is answered by the respondent selecting one 
choice from six and the severity of choices ranging from responses which signal 
no symptoms or none to maximum severity for that particular symptom. The 
final question is answered by the clinic staff using the respondent’s FEV1 result 
from spirometry performed on the day of the assessment.  
The respondent’s score is the mean for all seven fields, resulting in maximum 
control being represented by a score of zero and the worst level of control a 
score  of  six.  Recent  research  has  determined  that  a  score  less  than  0.75  is 
indicative  of  good  asthma  control,  a  score  of  greater  than  1.5  indicative  of 
inadequate  control  and  a  change  in  subjects  ACQ  score  of  0.5  or  more  is 
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2.5.4 Exhaled Nitric Oxide 
Exhaled nitric oxide (FENO) was measured at multiple flow rates (30, 50, 100, 150, 
200,  250  &  300ml  sec
 1)  using  a  Niox Flex  analyser  (Aerocrine  AB, 
Sundbybergsvägen  9,  SE 171  73  Solna,  Sweden)  which  meets  joint  ATS/ERS 
criteria for the measurement of on line FENO (47). 
The  Niox Flex  measures  FENO  by  chemiluminescence.  Briefly  the  principle  of 
detection involves the subject’s FENO reacting with ozone produced within the 
machine. This generates nitrogen dioxide with electrons in an excited state i.e. 
that are occupying a higher energy level than normal. Subsequent return of the 
electrons  to  their  normal  excitation  level  is  associated  with  the  discharge of 
electromagnetic radiation at a wavelength of 600 3000nm. This is detected by a 
photomultiplier  tube  incorporated  within  the  machine  and  as  a  linear 
relationship exists between the level of radiation emitted and the FENO exhaled 
enables derivation of FENO. The Niox Flex has a published measuring range of 0 
200 ppb, a detection limit of 1 ppb, a sampling frequency of 20Hz, a response 
time of <1.5 seconds and an accuracy of +/  2.5 ppb for levels < 50 ppb and +/  5 
% of values >50 ppb. Calibration was carried out every two weeks or as required. 
Prior  to  performing  the  test  subjects  received  an  explanation  on  how  to 
correctly perform the test from the supervising doctor or nurse. Following this 
the subject performed the test according to consensus guidelines (47). The Niox 
Flex requires subjects to take a deep inspiration both in and then exhale out 
through the machine’s mouthpiece. This ensured scrubbing of inhaled air which 
passed  through  the  mouthpiece  to  the  subject.  The  Niox Flex  automatically 
calculates  nitric  oxide  output  (VNO)  and  exhaled  nitric  oxide  concentration, 
discarding measurements inconsistent with previous results at that flow rate and 
which  did  not  demonstrate  a  plateau.  Visual  feedback  was  provided  by  the 
machine to maintain exhalation pressure above that required for closure of the 
velum, reducing nasal nitric oxide contamination.  
The results obtained from the multiple flow rates performed by the subjects in 
the Niox Flex were used to calculate estimates for extended flow parameters for 
each subject based on modelling equations from previously published research 
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of nitric oxide metabolism including alveolar nitric oxide as a result of modelling 
of the lung as a compartment divided into two parts. The first consists of a non 
expandable conducting airway which corresponds to the trachea to division 16 of 
Weibel’s model of the airways and an expandable alveolar region that comprises 
division 17 of the same system onwards (figure 2.2). 
The tissue surrounding the airway and the alveolus is assumed to produce nitric 
oxide at a constant rate and that this can either: 
•  Diffuse into the blood, which acts as an infinite sink 
•  Diffuse into the airway 
•  Be consumed by  reactions  with  substances  within the  cell  (superoxide, 
metalloproteins, thiols, oxygen)  
Therefore nitric oxide is diffusing into and out of the airway and alveolus at a 
rate  dependent  on  the  level  of  nitric  oxide  in  the  airway,  the  rate  of  NO 
production and NO diffusion into the bloodstream. Using these assumptions it is 
possible to use the exhaled nitric oxide concentration, rate of NO production 
and flow rate of exhalation to estimate the alveolar nitric oxide level and a 
number of other parameters. 
Tsoukias and George’s method (222) involves plotting the rate of NO production 
(VNO) against the rate of exhalation and performing linear regression to fit a line 
to the points obtained. This results in the intercept of the Y axis providing an 
estimation  of  airway  nitric  oxide  flux  and  the  gradient  of  the  derived  line 
providing an estimate of alveolar NO from the equation: 
VNO = Calv.VE + J’awNO 
Where VNO= elimination rate of exhaled nitric oxide (ml/s), VE = exhalation flow rate (ml/s), 
Calv= alveolar NO concentration (ppb), J’awNO=maximum NO flux (pl/sec). 
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Figure 2.2 Schematic of 2-compartment model for nitric oxide pulmonary exchange.  
First  compartment  represents  relatively  nonexpansile  conducting  airways;  second 
compartment  represents  expansile  alveoli.  Each  compartment  is  adjacent  to  a  layer  of 
tissue that is capable of producing and consuming nitric oxide (NO). Exterior to tissue is a 
layer of blood that represents bronchial or pulmonary circulation and serves as an infinite 
sink for NO. VE and VI, expiratory and inspiratory flow, respectively; CE and CI, expiratory 
and  inspiratory  concentration,  respectively;  Cair  and  Calv,  airway  and  alveolar 
concentration,  respectively;  VAIR  and  VALV,  airway  and  alveolar  volume,  respectively; 
Jt:g,air and Jt:g,alv, total flux of NO from tissue to air and from alveolar tissue, respectively; 
t, time; V, volume. Adapted from (227). 
 
Silkoff  and  colleagues  developed  a  non linear  regression  method  (255)  that 
correlated well with measurements of exhaled NO at 9 flow rates (4.2, 8.5, 10.3, 
17.2,  20.7,  38.2,  75.6,  850  &  1550  ml/sec)  and  enabled  calculation  of  the 
parameters  above.  Solving  for  the  following  equation  provides  estimates  for 
alveolar nitric oxide, nitric oxide flux and airway wall nitric oxide concentration 
and diffusion: 
FENO = CawNO + (Calv   CawNO)e
( DawNO/VE) 
Where  FENO=exhaled  NO  concentration  (ppb),  CawNO=airway  wall  concentration  (ppb), 
DawNO=diffusion  from  airway  wall  to  airway  (pl/s/ppb),  Calv  =alveolar  NO  level  (ppb), 
VE=flow rate of exhalation (ml/sec) 
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Nitric oxide flux and airway wall nitric oxide diffusion and concentration can 
also be obtained by linear regression using the VNO and FENO results from the 30 
and 50ml/sec flow rates (255). VNO is plotted against FENO and linear regression 
carried out through the points. Nitric oxide flux can then be obtained from the 
y intercept and nitric oxide diffusion from the reciprocal of the slope gradient. 
Airway wall concentration is obtained from the relationship (255): 
 
J’awNO = CawNODawNO 
Where  J’awNO=maximum  NO  flux  (pl/sec),  CawNO=airway  wall  concentration  (ppb), 
DawNO=diffusion from airway wall to airway (pl/s/ppb) 
 
Extended flow analysis has demonstrated elevated levels of alveolar nitric oxide 
in subjects with severe asthma (compared to subjects with mild asthma) (256, 
257) and subjects with COPD (225, 258) although this finding is not consistent 
(52). Smoking does not appear to reduce alveolar nitric oxide levels in normal 
subjects (226, 259) and alveolar nitric oxide levels are equivalent in smokers and 
ex smokers with COPD (52, 225). This suggests that extended flow analysis may 
provide  useful  insights  into  nitric  oxide  metabolism  in  smokers  with  asthma. 
Given  the  uncertainties  as  to  the  best  method  for  calculating extended  flow 
nitric oxide parameters and the potential that smokers with asthma may have 
alterations in some or all extended flow nitric oxide parameters both linear and 
non linear  models  were  employed.  The  inherent  variability  of  the  presented 
parameters was not determined in this thesis. 
2.5.5 Exhaled breath condensate pH 
Exhaled  breath  condensate  (EBC)  collection  was  performed  using  a  Jaeger 
EcoScreen®  (VIASYS  GmbH,  Leibnizstrasse  7,  D 97204  Hoechberg,  Germany) 
which  complied  with  expert  opinion  (56).  Subjects  performed  tidal  breathing 
into the apparatus mouthpiece for a minimum of ten minutes whilst wearing a 
nose clip. Subjects were allowed brief rests if required and were instructed to 
cease breathing into the mouthpiece prior to removal of nose clip and to avoid 
expelling  flatus  into  the  mouthpiece.  If  an  insufficient  amount  of  EBC  was 
collected after ten minutes the subjects were asked to continue for a further 5 
minutes. A final further five minutes were allowed if there was still insufficient 
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The EBC sample obtained was processed as per expert opinion (56, 232). One ml 
of  the  sample  was  aliquoted  into  a  1.5ml  eppendorf  and  de aerated  for  ten 
minutes with argon resulting in the removal of carbon dioxide from the solution 
and  stabilisation  of  pH.  Recordings  of  pH  were  taken  using  a  MINITRODE  P 
electrode  (VWR  International,  Lutterworth,  UK)  and  HANNAH  pH  210  digital 
meter (VWR International, Lutterworth, UK) which had been calibrated prior to 
use using pH 4 and 7 buffers. Reproducibility of EBC pH measurement was not 
addressed in this thesis. 
2.5.6 Sputum induction 
Sputum was obtained using a procedure modified from that of Pin et al (184) and 
Pavord et al (181). Subjects performed spirometry and then were pre treated 
with  nebulised  salbutamol  followed  by  spirometry  after  thirty  minutes.  The 
highest post salbutamol FEV1 obtained was recorded for post saline evaluation. 
Subjects  inhaled  nebulised  saline  using  an  ultrasonic  nebuliser  (Sonix  2000, 
Medix  Ltd,  Harlow,  Essex,  UK)  for  three  seven  minute  periods  resulting  in  a 
maximum of 21 minutes of nebulisation. Hypertonic saline at concentrations of 
3, 4 and 5% (Western Infirmary & Gartnavel General Hospital, Sterile Production 
Unit) were employed. 
To  ensure  no  bronchospasm  had  occurred  during  the  procedure  all  subjects 
performed spirometry after each nebulisation period. If no change in FEV1 was 
detected (defined as a drop in FEV1 of less than 10% from post nebuliser values, 
an  increase  in  FEV1  or  no  change)  then  the  subject  continued onto the  next 
concentration  of  saline.  However  if  a  drop  of  more  than  20%  from  the  post 
nebuliser level was observed the procedure was terminated and the subject was 
treated with nebulised salbutamol. A drop in FEV1 of less than 20% and greater 
than  10%  resulted  in  the  subject  repeating  nebulisation  at  the  same 
concentration of saline. Subjects were encouraged to expectorate into a sterile 
container at any time during the procedure. The sterile containers were kept in 
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2.6 Processing of biological samples 
2.6.1 Sputum processing 
The sputum obtained was processed using the method of Popov et al (260) with 
some  modifications.  Upon  arrival  in  the  laboratory  the  whole  sample  was 
decanted, weighed and examined by the technicians. Macroscopic appearances 
were recorded (quality, obvious salivary contamination etc). The volume of the 
sample dictated the volume of dithiothreitol (DTT) (‘Sputolysin’, Calbiochem 
Novabiochem (UK) Ltd, Nottingham, UK) diluted in Hanks Balanced Salt Solution 
(HBSS) (Invitrogen, Paisley, UK) to be added to the sample. For samples less than 
5ml,  250 l  of  0.1%  DTT  diluted  in  750 l  HBSS  was  added  to  the  sample. 
Thereafter for every 1ml increase in sample volume a further 50 l was added 
and the HBSS reduced by 50 l i.e. for samples of 6ml 300 l of 0.1% DTT and 
700 l HBSS was added. This increase in DTT concentration continued until the 
samples were greater than 10ml in volume and then 500 l of DTT and 500 l of 
HBSS was added to the sample regardless of increase in volume. 
Mechanical  separation  of  the  sample  was  then  performed  for  at  least  ten 
minutes  using  a  sterile  Pasteur  pipette  to  ensure  proper  separation  of  the 
specimen. Once this was achieved the sample was then diluted to 30ml using 
HBSS and forced through a 70 m cell strainer (VWR International, Lutterworth, 
UK) into a pre weighed 50ml sterile tube. The tube was then re weighed and the 
volume of filtrate obtained was recorded. A total cell count was then performed 
using a Neubauer haemocytometer with 20 l of the sample diluted 1:1 in Trypan 
blue (Sigma Aldrich, Gillingham, UK). The total number of cells, number of dead 
and alive and squamous cells were recorded and the total number of viable cells 
(excluding  squamous  cells)  obtained  was  then  calculated.  500 l  of  a  1x10
6 
concentration of sputum cells was aliquoted off for cytospin slides and the rest 
of the sample was then centrifuged at 1500 rpm for 10 minutes at 4˚C. Four 1ml 
samples  of  supernatant  were  aspirated  off  and  stored  for  future  cytokine 
analysis and the sample pellet was washed and re suspended in Roswell Park 
Memorial Institute medium (RPMI 1640) with 10% Foetal Calf Serum added (RPMI 
FCS,  SIGMA ALDRICH  Ltd,  Gillingham,  UK)  for  measurement  of  sputum 
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2.6.2 Sputum differential counting 
Three  cytospin  slides  were  produced,  air  fixed  and  stained  (Romanowsky 
staining;  Lamb  Quick stain  kit,  Thermo  Fisher  Scientific  Ltd,  UK).  The 
differential cell count was performed by counting 400 non squamous cells from a 
representative area of the slide and the total and relative percentage of each 
cell type recorded. Two technicians examined two of the slides independently 
and the mean of the counts was used for analysis.  The third slide was kept in 
reserve in case of damage to one of the main slides. 
2.6.3 Measurement of HDAC activity in sputum macrophages  
HDAC  activity  was  assessed  using  the  Fluor de Lys
TM  HDAC  activity  kit  from 
BIOMOL (BIOMOL Int, Exeter, UK). The cell suspension obtained at the end of 
sputum  processing  was  plated  out  in  a  six  well  plate  (VWR  International, 
Lutterworth, UK) with three wells being used per patient and 1ml of suspension 
per well. The plate was incubated at 37˚C with 5% CO2 supplementation for 1 
hour to stimulate adherence of macrophages. 
HDAC substrate was then added to two wells at a concentration of 200 M per 
well. The HDAC inhibitor Trichostatin A (TSA) was also added to one of the wells 
containing  HDAC  substrate  at  a  concentration  of  1 M.  The  wells  were  then 
labelled TSA + and TSA  depending on which had TSA in addition to substrate. 
The  plate  was  again  incubated  for  one  hour  at  37˚C  with  5%  CO2 
supplementation. After one hour the non adherent cells were removed and the 
adherent  cells  washed  with  RPMI FSC  and  lysed  with  HDAC  lysis  buffer.  The 
adherent cells were not inspected or subject to a differential count. The cell 
lysate was then aspirated into labelled eppendorfs which were stored at  80˚C 
until development. The remaining well was used for cell counting. HDAC activity 
of the samples was determined through the addition of Fluor de Lys
TM developer 
(BIOMOL Int, Exeter, UK) to 10 L of each of the samples in a white 96 well plate. 
The plate was covered in tin foil and placed in the dark at room temperature for 
30 minutes. The samples were then excited in a fluorimeter and the emitted 
light was then recorded. The HDAC activity of the sample was calculated using 
this result, the result from the blank and control wells and the standard curve. Chapter 2    91 
Correction was performed for the cell count obtained from the third well of the 
six well plate for each sample. Assay variability testing was not performed. 
2.6.4 Measurement of sputum supernatant and plasma cytokines 
The  sputum  supernatant  and  plasma  obtained  in  the  study  examining  the 
corticosteroid responses of smokers, ex smokers and non smokers with asthma 
was examined for a number of cytokines and chemokines using a commercially 
available multiplex immunodetection system (25 plex cytokine assay, Invitrogen 
Ltd, 3 Fountain Drive, Inchinnan Business Park, Paisley, UK) and a Luminex 100
TM 
analyser (Luminex Corporation, 12212 Technology Blvd, Austin, Texas, USA). This 
system enables the detection of multiple cytokines and chemokines of interest in 
small volumes through the use of antibody labelled microspheres in a solid phase 
sandwich immunoassay. The microspheres bind to the analyte of interest due to 
their  conjugated  antibody  and  the  microspheres  enable  detection  of  the 
concentration of analytes due to their internal dyes which when excited by the 
lasers  incorporated  within  the  Luminex  100
TM  emit  specific  wavelengths  of 
radiation. The emitted radiation is detected by the analyser and due to each 
bead having a different ‘signature’, the detected radiation is converted to a 
concentration of cytokine/chemokines for each analyte using results obtained 
from standard curves. The cytokines detected using this approach were eotaxin, 
granulocyte/monocyte colony stimulating factor (GM CSF), interferon α (IFN α), 
interferon γ (IFN γ), interleukin (IL) 1 receptor antagonist (IL 1RA), IL 1β, IL 2, 
IL 2 receptor (IL 2R), IL 4, IL 5, IL 6, IL 7, IL 8 (CXCL8), IL 10, IL 12 (p40/p70 
form),  IL 13,  IL 15,  IL 17,  Interferon inducible  Protein  of  10  kDa  (IP 10  aka 
CXCL10), Monocyte Chemotactic Protein 1 (MCP 1), Monokine Induced by IFN γ 
(MIG aka CXC9), Monocyte Inflammatory Protein 1α (MIP 1α aka CCL3), Monocyte 
Inflammatory Protein 1β (MIP 1β aka CCL4), Regulated upon Activation, Normal 
T cell Expressed and Secreted (RANTES aka CCL5), and Tumour Necrosis Factor α 
(TNF α). 
Validation of the Luminex technique was carried out using a 30 plex cytokine 
and supplied cytokine standards. Serial dilutions confirmed the linearity of the 
assay for all cytokines in the working range (figure 2.3 IL 6 result). Addition of 
the reducing agent DTT at concentrations of 0.05 and 0.00125% had no effect on Chapter 2    92 
antigenicity (figure 2.3 IL 6 result). Spiking of samples also demonstrated good 
correlation  between  the  spiked  concentration  and  sample  concentration  as 
detected by Luminex (r=0.64, p<0.001) (figure 2.4). 
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Figure 2.3 Linearity of IL-6 detection and effect of two concentrations of DTT on antigenicity 
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Figure 2.4 Result of spiking experiment for 30 cytokines 
 
In the studies examining theophylline and rosiglitazone in smokers with asthma 
and the study examining the corticosteroid responses of smokers, ex smokers 
and non smokers with asthma sputum supernatant selected cytokines were also Chapter 2    93 
assessed using pre coated enzyme linked immunosorbent assays (ELISAs). Sputum 
supernatant  from  the  study  examining  theophylline  and  rosiglitazone  was 
examined  for  interleukin  (IL) 8,  myeloperoxidase  (MPO)  and  Regulated  on 
Activation, Normal T Expressed and Secreted (RANTES)/CCL5 levels (IL 8, R&D 
Systems, Abingdon, UK, MPO, Immundiagnostik, Oxford Biosystems, Oxford, UK, 
RANTES/CCL5, Invitrogen Ltd, Paisley, UK). Sputum supernatant from the study 
examining the corticosteroid responses of smokers, ex smokers and non smokers 
with asthma was examined for IL 6 using a high sensitivity ELISA (Abcam plc, 
Cambridge, UK). Each ELISA plate was processed according to manufacturer’s 
instructions. Briefly the pre coated plates were loaded with samples followed by 
incubation  with  shaking,  washing  with  supplied  wash  buffer  and  then 
streptavidin horse radish peroxidase was then added to the plates. This was then 
followed by a further shaking step and a further wash cycle. Developer was then 
added and the reaction stopped once sufficient colour had developed. The plate 
was then read on a plate reader with the primary and secondary wavelengths 
required for the assay and the output determined using the standards within 
each plate. 
2.6.5 Blood tests 
2.6.5.1  Peripheral blood monocyte selection 
Blood was obtained using lithium heparin vacutainers and the monocyte fraction 
selected by density centrifugation. Whole blood was diluted 1:1 in RPMI 1640, 
carefully layered on top of Histopaque® (SIGMA ALDRICH Ltd, Gillingham, UK) 
and then centrifuged at 1800rpm for 30 minutes at room temperature. The white 
cell  fraction  then  became  obvious  as  a  creamy  white  layer  at  the  interface 
between  the  Histopaque®  and  serum.  This  was  carefully  aspirated  off  and 
washed in RPMI by centrifuging twice for 5 minutes at 1400 rpm at 4˚C. The 
concentration of cells within the pellet was then determined by cell counting 
and diluted as appropriate. The pellet obtained was used for the assessment of 
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2.6.5.2  PBMC HDAC activity 
HDAC activity in peripheral blood borne monocytes was assessed using the Fluor 
de Lys
TM  system  (BIOMOL  Int,  Exeter,  UK).  Briefly  the  PBMC  cell  pellet 
suspension was plated out into three wells of a six well plate and left to adhere 
for one hour. The non adherent cells were removed and the HDAC substrate was 
added to two wells and TSA to one of the two wells. The third well was used for 
cell counting. After one hour incubation the reaction was stopped using lysis 
buffer and the resultant lysate scraped off using a cell scraper and aspirated off 
into three eppendorfs for storage at  80˚C. The HDAC activity of the subjects 
PBMCs  was  then  assessed  by  the  addition  of  Fluor de Lys  developer  to  the 
sample. The result was obtained using a fluorimeter as before with correction 
for cell count. Assay variability testing was not performed. 
 
2.6.5.3  Biochemical assays 
Routine  biochemistry  testing  was  performed  by  the  North  Glasgow  Hospital 
Trust’s Biochemistry laboratory, Gartnavel General Hospital, Glasgow. Samples 
were processed in the study examining theophylline and rosiglitazone for renal 
function  and  electrolytes,  liver  function  tests,  adjusted  calcium,  total 
Cholesterol, glucose and theophylline levels. Serum cortisol concentrations were 
assessed  in  the  study  examining  corticosteroid  response.  All  samples  were 
processed  and  results  generated  using  an  automated  processing  system 
(ARCHITECT c8000, Abbot Diagnostics, Maidenhead, UK). 
2.6.5.4  Differential blood counts 
Differential blood counts were performed in the study examining theophylline 
and  rosiglitazone  by  the  North  Glasgow  and  Clyde  NHS  trust  Haematology 
laboratory at Gartnavel General Hospital, Glasgow using an automated X Class 
SYSMEX  machine  (SYSMEX,  Hamburg,  Germany).  This  provided  haemoglobin 
concentration, total and differential white cell count and platelet concentration 
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2.6.5.5  Serum IgE and IgE antibodies against common allergens 
The serum concentrations of IgE and specific immunoglobulin E (IgE) antibody 
activity  against  allergens  from  cat  dander,  grass  pollen  and  house  dust  mite 
were measured by fluorescent enzyme immunoassay (FEIA, UniCAP 100 System, 
Pharmacia,  Milton  Keynes,  UK)  by  the  North  Glasgow  and  Clyde  NHS  trust 
Immunology  laboratory,  Western  Infirmary,  Glasgow,  in  the  study  examining 
theophylline and rosiglitazone in smokers with asthma.  
The  method  of  FEIA  is  based  on  the  binding  of  the  patient’s  serum 
immunoglobulins  to  the  antigen/s  of  interest,  which  is  bound  to  a  flexible 
cellulose matrix, housed within a small permeable container. This is followed by 
a wash to remove unbound immunoglobulins. IgE bound to the allergen is then 
detected  by  binding  of  beta galactosidase labelled  anti IgE,  and  any  unbound 
secondary antibody is removed by washing. The bound enzyme activity is then 
measured by catalysing the production of a fluorescent product, umbelliferone, 
from a colourless substrate. The fluorescence produced is proportional to the IgE 
antibody concentration, and is quantified by comparison to a standard curve. 
The  assay  system  has  a  working  range  of  0.35 100  arbitrary  units  per  litre 
(AU/L). A level of greater than 0.35 AU/L for specific IgE is considered raised. 
Total serum IgE was measured as above, with the exception that all the serum 
IgE  was  captured  by  anti IgE  bound  to  the  cap  matrix.  Serum  IgE  has  a  log 
normal distribution, and concentrations greater than 120 IU/L are considered 
significantly  raised,  as  values  above  this  level  are  associated  with  atopy  and 
clinical allergy. 
2.7 Data handling and statistical analysis 
2.7.1 Data handling 
All data for the trial examining theophylline and rosiglitazone was entered into a 
specially designed case report form (CRF) provided by GlaxoSmithKline (GSK) and 
sent  to  their  data  entry  team  for  generation  of  the  research  database.  The 
quality of CRF completion was assessed by an independent monitor employed by 
GSK who examined ten per cent of the completed CRFs prior to sending for entry Chapter 2    96 
and  generated queries  for  areas  which  required clarification.  Where  areas  of 
uncertainty  within  the  data  were  identified  I  clarified  and  corrected  where 
required. 
I designed the CRFs and performed all data entry and checking for the study 
examining corticosteroid responses. 
2.7.2 Statistical analysis 
2.7.2.1  Approach and performance of analysis 
The lung function data in the trial examining theophylline and rosiglitazone was 
performed  by  a  professional  statistician  (Dr  Lisa  Sweeney)  employed  by  GSK 
using SAS v 8.2 (SAS Institute Inc., NC, USA) on a UNIX system. I performed all 
other analyses and comparisons in this trial using MINITAB 15 (Minitab Inc. State 
College, PA, USA). The study analysis was performed with an intention to treat 
approach. 
The  majority  of  the  analysis  for  the  trial  examining  the  oral  corticosteroid 
responses of smokers, ex smokers and non smokers with asthma was performed 
by a professional statistician (Dr Chris Weir, Robertson Centre for Biostatistics, 
University of Glasgow) using SAS v 9.1 (TS1M3) for Windows (SAS Institute Inc., 
NC, USA). I performed all additional analyses and comparisons using MINITAB 15 
(Minitab Inc. State College, PA, USA). This study was analysed as a per protocol 
study.  Subjects  non compliant  with  oral  corticosteroids  formed  part  of  the 
baseline comparisons but their post oral corticosteroid data was not utilised. 
In  both  studies  parametric  data  was  analysed  by  t–testing  and  ANOVA  as 
appropriate.  Non parametric  data  was  assessed  by  Mann  Whitney  or  log 
transformed prior to normality testing (using Anderson Darling) and if parametric 
as  a  result  was  analysed  by  t testing.  Difference  of  adjusted  means  analysis 
(ANCOVA)  was  performed  for  the  lung  function  data  in  the  theophylline  and 
rosiglitazone trial due to differences in the baseline characteristics of the groups 
which  were  deemed  by  the  statistician  to  influence  the  result.  All  analyses 
performed for the thesis were two sided with alpha set at 5%. Chapter 2    97 
2.7.2.2  Power calculations 
The theophylline and rosiglitazone study did not have a formal power analysis 
performed due to a lack of information on responses to both drugs in the study 
population.  However  the  study  was  informed  by  the  confidence  intervals 
observed in the response of smokers with asthma to an oral corticosteroid trial 
(23). This resulted in the estimation that 22 subjects were required per group to 
detect a 230ml difference in FEV1 between the treatment arms and to allow for 
a 10% drop out rate. 
The study examining oral corticosteroid responses was informed by a previous 
trial  (23).  This  resulted  in  the  estimate  that  22  subjects  were  required  to 
provide 80% power to demonstrate a difference of 336ml in FEV1 response to oral 
corticosteroids between smokers and non smokers with asthma and to allow for 
a 10% drop out rate. 
2.7.2.3  Multiple comparison issues 
Both  of  the  studies  presented  in  this  thesis  are  susceptible  to  false  positive 
results due to multiple comparison issues. These have arisen for several reasons.  
In the study examining theophylline and rosiglitazone there is the possibility of a 
type 1 error despite the use of a pre defined primary endpoint and alpha level. 
This is due to the use of four treatment groups and a failure to adjust the alpha 
level  to  conserve  the  family wise  error  rate  for  the  trial  design.  However 
correction for this issue would have resulted in the study becoming unfeasible 
for a thesis and for one site to conduct in a reasonable time. The pre defined 
secondary  endpoints  are  used  to  support  and  confirm  the  primary  endpoint 
findings  in  an  attempt  to  reduce  erroneous  conclusions.  Finally  a  number  of 
exploratory  endpoints  are  permitted  for  examination  of  the  database  to 
generate future research leads. 
The study examining the oral corticosteroid response of smokers, ex smokers and 
non smokers with asthma is again an exploratory study. Given the nature of the 
study  and  volume  of  data  generated  a  number  of  false  positive  results  are 
possible  given  that  alpha  is  set  at  the  traditional  value  of  5%.  However Chapter 2    98 
established  methods  for  correction  for  multiple  analyses  were  felt  to  be 
unhelpful as they are unnecessarily punitive for a study of this size and would 
obscure potential important observations. 
Therefore the conclusions drawn in this thesis are constrained by the likelihood 
of the presence of false positive results. To compensate, the data is presented 
as exploratory rather than conclusive. This approach is designed to temper the 
conclusions and whilst this cannot correct for possible type 1 errors it reminds 
the reader of the need for confirmation of all findings in adequately powered 
and  informed  trials.  The  final  consideration  is  that  adequately  powered  and 
conclusive clinical trials in smokers with asthma will now be feasible as a result 
of the data presented in the following chapters. 99 
3  Reversal  of  corticosteroid  insensitivity  in 
smokers with asthma 
3.1 Introduction 
Inhaled corticosteroids are recommended as the first line treatment for chronic 
persistent asthma (1, 2). However a significant proportion of individuals with 
asthma fail to establish complete control despite this approach (25).  
Smokers with asthma comprise part of this poorly controlled group and exhibit 
an impaired response to both inhaled and oral corticosteroids compared to non 
smokers  with  asthma  (5 10,  22 24).  Previous  research  has  also  demonstrated 
that smokers with asthma have worse symptoms (11), an accelerated decline in 
lung function (15, 21) and increased frequency of emergency department visits 
for asthma (16, 17) compared to matched non smoking asthmatics. 
The prevalence of smoking in asthma reflects that of the general population and 
therefore smokers with asthma represent a large group of patients with poorly 
controlled disease (261). Smoking cessation is the obvious route for practitioners 
and  smokers  with  asthma  to  pursue  and  has  been  demonstrated  to  be  an 
effective  therapy  in this  group  (49),  but as  sustained  quitting rates  are  low, 
improvements  on  current  treatments,  additional  or  alternative  therapies  are 
required  for individuals with asthma who continue to smoke. 
What mechanisms are responsible for the reduced response to corticosteroids 
displayed by smokers with asthma? Corticosteroids reduce inflammation via a 
number  of  different  mechanisms  including  inhibition  of  pro inflammatory 
transcription  factors  through  both  competition  for  co factors  and  direct 
inhibition,  increased  expression  of  anti inflammatory  genes  and  repression  of 
inflammatory gene expression (27, 32). One mechanism that corticosteroids use 
to  suppress  inflammatory  gene  expression  and  that  may  be  of  relevance  in 
smokers  with  asthma  has  come  to  light  through  the  research  discipline  of 
epigenetics.  Epigenetics  examines  the  effect  of  post translational  covalent 
modifications  of  chromatin  on  the  control  of  gene  expression.  It  has  been 
demonstrated  in-vitro  that  approximately  half  of  the  immunosuppressant Chapter 3    100 
activity of corticosteroids is produced through stimulating the removal of acetyl 
groups  at  areas  of  active  transcription  (36).  Cigarette  smoke  reduces  HDAC 
activity in-vitro (92), which could explain corticosteroid insensitivity in smokers 
with asthma. At standard doses, theophylline produces bronchodilation, whereas 
low  doses  increase  HDAC  activity  with  associated  reductions  in  inflammatory 
gene expression when given in combination with corticosteroids (102, 103). One 
of  the  main  aims  of  this  study  was  to  test  the  hypothesis  that  low  dose 
theophylline  restores  HDAC  activity  in  smokers  with  asthma  leading  to  a 
restoration of corticosteroid sensitivity which when theophylline was given in 
combination  with  inhaled  corticosteroid  would  improve  lung  function  to  a 
greater degree than inhaled corticosteroids alone. 
Therefore, I undertook an exploratory clinical trial to examine the effect of low 
dose theophylline in combination with low dose inhaled corticosteroid on lung 
function and other outcomes in a group of smokers with asthma. 
3.2 Methods 
3.2.1 Subjects 
Subject  characteristics,  inclusion/exclusion  criteria  and  recruitment  methods 
were as described in the general methods chapter. 
3.2.2 Study design 
A full description of the study is provided in the general methods chapter. In 
brief  the  study  was  a  randomised,  prospective,  double blind,  double dummy, 
active comparator, parallel group design. Subjects were randomly allocated to 
one of four treatment groups, three of which are discussed in this chapter. The 
treatments  discussed  in  this  chapter  are;  twice  a  day  100mcg  inhaled 
hydrofluoroalkane  beclometasone  dipropionate  alone,  the  combination  of  low 
dose oral theophylline (200mg bd) and inhaled beclometasone dipropionate and 
theophylline alone (figure 3.1). Chapter 3    101 
 
Figure 3.1 Randomisation schedule 
 
Subjects  performed  a  number  of  assessments  at  baseline  and  repeated  the 
assessments after twenty eight days of treatment. A short visit at fourteen days 
was  performed  to  assess  lung  function.  The  West  Glasgow  Research  Ethics 
Committee approved the study and all patients gave written informed consent. 
3.2.3 Measurements 
A  full  description  of  the  measurements  is  provided  in  the  general  methods 
chapter.  Lung  function  assessments  conformed  to  consensus  guidelines  (246). 
Sputum  induction,  differential  count,  HDAC  measurement  and  supernatant 
analysis were performed as discussed in the general methods chapter.  HDAC 
assay variability testing was not performed. Continuation of smoking during the 
study  was  confirmed  by  history  and  the  detection  of  urinary  nicotine 
metabolites. Subjects were regarded as current smokers if their category was 
mild  smoker  or  greater  and  their  urine  cotinine  level  was  greater  than 
1.1mg/ml. Treatment compliance was assessed by tablet count, inhaler weight 
and serum theophylline level.  
3.2.4 Statistical analysis 
The  reduced  response  to  inhaled  corticosteroids  in  smokers  with  asthma 
prevented standard power calculations. The study was informed by FEV1 changes Chapter 3    102 
from  a  previous  clinical  trial  employing  oral  corticosteroids  in  smokers  with 
asthma (23). This resulted in the estimation that 22 subjects were required per 
group to detect a 230ml difference in FEV1 between the treatment arms and to 
allow for a 10% dropout. A slightly higher dropout rate occurred (13%) during the 
trial resulting in a larger numbers of subjects being randomised to treatment. 
The primary endpoint was difference in pre bronchodilator FEV1 between the 
treatments and beclometasone alone at 28 days. The secondary endpoints were 
change  in  pre  and  post  bronchodilator  PEF,  FVC,  FEF25 75,  FEF75  &  ACQ. 
Exploratory endpoints were change in sputum differential, sputum HDAC activity 
and sputum supernatant. Lung function changes were examined using ANCOVA 
(incorporating Kenward & Roger’s method (262)) using SAS v8.2 (SAS Institute 
Inc, NC, USA). All data obtained after day 1 of treatment was used for analysis. 
The remaining statistical analysis was performed using Minitab 15 (Minitab Inc. 
State College, PA, USA). α was set at 0.05. Due to the exploratory nature of the 
trial  the  analyses  were  not  corrected  for  type  1  errors  due  to  multiple 
comparisons. 
3.3 Results 
A total of 3895 subjects with asthma were invited to participate between August 
2005 and May 2007, of whom 294 gave positive responses. Following telephone 
screening, visits were arranged for 187 subjects and 91 subjects met criteria for 
randomisation (figure 3.2). Sixty eight subjects were randomised to the portion 
of  the  study  that  is  discussed  in  this  chapter.  The  remaining  subjects  were 
randomised to treatment with rosiglitazone and the results for this treatment 
are discussed in the following chapter. Twenty three subjects were allocated to 
the inhaled beclometasone alone and theophylline alone groups and twenty two 
to theophylline and inhaled beclometasone. The baseline demographic, clinical 
(including  previous  inhaled  corticosteroid  and  long acting  β2 agonist  use)  and 
inflammatory  characteristics  of  recruited  subjects  in  each  group  were  well 
matched (tables 3.1 & 3.2). All the endpoints presented from this point are the 
changes  seen  relative  to  the  inhaled  beclometasone  group 
response.Chapter 3    103 
 
Figure 3.2 CONSORT diagram showing flow of participants through the trial.  
SAE; serious adverse event Chapter 3    104 
Table 3.1 Baseline demographics.  
Data  presented  as  median  (IQR)  unless  stated  otherwise.  Abbreviations;  SD;  standard 
deviation, BMI; Body Mass Index, FEV1; Forced expiratory volume in 1 second, pre BD; pre- 
bronchodilator, ACQ; Asthma Control Questionnaire score (range, 0 to 6, with higher scores 
indicating worse asthma control), IgE; immunoglobulin E, LABA; long-acting β2-agonist. 
 
 
  Inhaled 
beclometasone 
Theophylline & 
Inhaled 
beclometasone 
Theophylline 
Number of patients  23  22  23 
Age (years) 
 
42 
(36, 53) 
 
44 
(31, 52) 
46 
(38, 50) 
 
Gender 
Female (% of total) 
 
61  55  65 
 
BMI (kg/m²) 
Mean (range) 
 
25.5 
(18.4, 34.2) 
26.0 
(17.3, 36.1) 
26.6 
(18.6, 37.1) 
 
Pack years 
 
24 
(15, 30) 
25 
(11, 40) 
30 
(15, 35) 
 
Duration of asthma (years) 
 
16 
(8, 31) 
15 
(9, 21) 
16 
(9, 30) 
Inhaled  corticosteroid  use  at 
screening 
 
(% of total) 
 
Dose,  beclometasone  equivalent 
(mcg) 
 
 
65 
 
800 
(400, 800) 
 
 
68 
 
800 
(400, 950) 
 
 
74 
 
400 
(400, 900) 
LABA use at screening (%)  26  36  35 
Specific IgE antibody positive (%)  61  50  52 
 
Total IgE level (IU/ml) 
 
87 
(34, 396) 
91 
(31, 383) 
40 
(9, 346) 
 
Spirometry (pre-BD) 
FEV1 (% predicted) 
 
75 
(72, 89) 
78 
(65, 84) 
73 
(64, 84) 
 
Reversibility 
FEV1 % improvement 
 
16 
(13, 20) 
15 
(14, 18) 
18 
(14, 24) 
 
Asthma Control 
Questionnaire score (0 to 6)  
Mean (SD) 
 
1.8 
(0.9) 
1.8 
(0.7) 
2.1 
(0.5) Chapter 3    105 
Table 3.2 Baseline sputum counts and HDAC activity.  
Data expressed as median (IQR) except where expressed. 95% CI; 95% confidence interval. 
 
3.3.1 Lung function 
3.3.1.1  Theophylline and inhaled beclometasone 
After two weeks of treatment with low dose theophylline and beclometasone 
there was a trend for improvement in pre bronchodilator PEF (24.9 L/min (95% 
CI –1.5 to 51.2), p=0.064) (figure 3.3) and pre bronchodilator FVC (132 ml ( 23 to 
286),  p=0.094).  There  were  no  detectable  differences  in  other  lung  function 
endpoints  (table  3.3).  After  four  weeks,  treatment  with  the  combination  of 
theophylline and inhaled beclometasone demonstrated a borderline significant 
improvement in mean pre bronchodilator FEV1 (mean difference 165 ml ( 13 to 
342), p=0.069) (table 3.3 & figure 3.4) and a significant improvement in pre 
bronchodilator PEF (39.9 L/min (10.9 to 68.8), p=0.008) (table 3.3 & figure 3.3) 
and pre bronchodilator FVC (254 ml (63 to 445), p=0.010) (table 3.3).  
  Inhaled 
beclometasone 
Theophylline & 
Inhaled 
beclometasone 
Theophylline 
Sputum total cell count  
(10
6) 
4.3 
(2.6, 7.3) 
5.1 
(3.1, 9.4) 
6.0 
(2.4, 16.1) 
Eosinophils %  0.9 
(0.3, 1.6) 
0.8 
(0.4, 1.8) 
1.3 
(0.5, 2.3) 
Eosinophils (10
4)  2.1 
(0.8, 5.8) 
3.7 
(1.9, 19.5) 
6.3  
(1.7, 28.4) 
Neutrophils %  25.5 
(9.6, 44.6) 
23.5 
(8.6, 42.3) 
16.6 
(8.4, 40.3) 
Neutrophils (10
4)  122.7  
(25, 188) 
83.0  
(35, 302) 
80.0  
(25, 323) 
Macrophages %  52.8 
(32.0, 64.4) 
45.1 
(38.1, 60.8) 
52.1 
(39.1, 64.3) 
Macrophages (10
4)  184.2  
(96, 437) 
271.8 
(165, 452) 
78.0  
(147, 729) 
Lymphocytes %  1.3 
(0.6, 2.6) 
1.6 
(1.0, 2.7) 
1.0 
(0.5, 2.5) 
Lymphocytes (10
4)  4.9  
(2.3, 11.2) 
12.4  
(3.2, 20.7) 
7.1  
(1.5, 22.6) 
Bronchial epithelial cells %  10.5 
(8.3, 15.4) 
16.4 
(8.0, 28.9) 
12.3 
(6.1, 27.2) 
Bronchial epithelial cells (10
4)  40.7  
(20.5, 99.4) 
119.1  
(63.8, 157.6) 
83.7  
(22.1, 168.2) 
HDAC activity 
AFU/10
6 cells 
mean (95% CI) 
2.25 
(0.54, 3.95) 
3.75 
(0.34, 7.16) 
3.62 
(0.61, 6.64) Chapter 3    106 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Change in PEF (L/min) by 28 days of treatment.  
Paired t-test (error bars represent 95% confidence intervals). p-values were derived from 
comparison of groups to beclometasone dipropionate changes using ANCOVA. Figure key- 
ICS;  inhaled  beclometasone,  Theo;  theophylline,  T+ICS;  theophylline  and  inhaled 
beclometasone combination. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Change in FEV1 (ml) by 28 days of treatment.  
Paired t-test (error bars represent 95% confidence intervals). p-values were derived from 
comparison of groups to beclometasone dipropionate changes using ANCOVA. Figure key- 
ICS;  inhaled  beclometasone,  Theo;  theophylline,  T+ICS;  theophylline  and  inhaled 
beclometasone combination 
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Theophylline & 
inhaled 
beclometasone 
Theophylline 
Day 14  133 
(-27, 293) 
52 
(-109, 214)  ∆ Pre BD FEV1 
ml (95% CI) 
Day 28  165 
(-13, 342) 
128 
(-51, 307) 
Day 14  25 
(-1, 51) 
6 
(-20, 33)  ∆ Pre BD PEF 
L/min  (95% CI) 
Day 28    40 * 
(11, 69) 
22 
(-7, 51) 
Day 14  132 
(-23, 286) 
15 
(-141, 171)  ∆ Pre BD FVC 
ml (95% CI) 
Day 28     254 * 
(63, 445) 
176 
(-16, 368) 
∆ ACQ score 
(95% CI) 
 –0.47 * 
(-0.91, -0.04) 
  –0.55 * 
(-0.99, -0.11) 
∆ Sputum total 
cell count 
Cells x 10
6 
(95% CI) 
-2.0 
(-6.3, 1.7) 
-1.7 
(-6.2, 2.1) 
∆ Sputum 
eosinophil 
% 
(95% CI) 
 
Absolute (10
4) 
(95% CI) 
0.0 
(-1·1, 0·6) 
 
-1.62 
(-9·58, 1·82) 
-0.6 
(-1.7, 0.3) 
 
-5.53 
(-17.87, 1.68) 
∆ Sputum 
neutrophil 
% 
(95% CI) 
 
Absolute (10
4) 
(95% CI) 
0.3 
(-12.3, 17.7) 
 
46.8 
(-65.1, 236.2) 
-2.5 
(-22.5, 12.8) 
 
-16.0 
(-199.5, 116.1) 
∆ Sputum 
macrophage 
% 
(95% CI) 
 
Absolute (10
4) 
(95% CI) 
0.5 
(-11.8, 11.3) 
 
-52.7 
(-251.4, 118.7) 
-2.5 
(-21.0, 15.3) 
 
-0.9 
(-250.0, 186.3) 
∆ Sputum 
lymphocyte 
% 
(95% CI) 
 
Absolute (10
4) 
(95% CI) 
  -0.8 * 
(-1.4, -0.1) 
 
  -10.99 * 
(-18.15, -1.65) 
-0.6 
(-1.3, 0.2) 
 
-3.98 
(-10.30, 1.36) 
∆ Sputum 
bronchial 
epithelial cell 
% 
(95% CI) 
 
Absolute (10
4) 
(95% CI) 
1.2 
(-5.8, 7.4) 
 
-20.9 
(-85.1, 50.5) 
-1.0 
(-11.3, 5.7) 
 
-12.9 
(-100·8, 57·3) 
∆ Sputum IL-8  pg/ml 
(95% CI) 
-562.5 
(-2131.0, 131.4) 
  -1201.3 * 
(-2409.6, -76.6) 
∆ Sputum MPO  ng/ml 
(95% CI) 
-126.6 
(-433.9, 58.1) 
  -215.0 * 
(-556.0, -36.7) 
∆ HDAC activity  AFU/10
6 cells 
(95% CI) 
-3.5 
(-23.7, 5.0) 
-2.2 
(-23.4, 3.5) 
Table 3.3 Change in lung function and biomarkers following treatment (relative to response 
to treatment with inhaled beclometasone alone).    
*; p<0.05 Chapter 3    108 
3.3.1.2  Theophylline 
The group treated with theophylline alone did not demonstrate efficacy for any 
lung function outcome except for post bronchodilator FVC at four weeks (304 ml 
(95% CI 5 to 604), p=0.046). 
3.3.1.3  ACQ score 
After four weeks, the combination of theophylline and inhaled beclometasone 
produced a significant improvement in ACQ score ( 0.47 (95% CI –0.91 to –0.04), 
p=0.033) (figure 3.5 and table 3.3). Theophylline alone also reduced the ACQ 
score ( 0.55 (–0.99 to –0.11), p=0.016). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Change in ACQ score by 28 days of treatment. 
Paired t-test (error bars represent 95% confidence intervals). p-values were derived from 
comparison of groups to beclometasone dipropionate changes using ANCOVA. Figure key- 
ICS;  inhaled  beclometasone,  Theo;  theophylline,  T+ICS;  theophylline  and  inhaled 
beclometasone combination 
 
3.3.2 Sputum samples 
3.3.2.1  Induced sputum cytology 
Ninety seven percent of the subjects who completed the trial produced a sample 
adequate  for  analysis  both  pre  and  post treatment.  Treatment  with  the 
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combination of theophylline and inhaled beclometasone was associated with a 
reduction  in  the  mean  absolute  ( 10.99  (95%  CI   18.15,   1.65),  p=0.018)  and 
percentage sputum lymphocyte count ( 0.8% ( 1.4,  0.1), p=0.028) (table 3.3). 
No other relative treatment differences in sputum proportions were observed. 
Given  the  change  in  sputum  lymphocytes,  sputum  supernatant  RANTES  levels 
were subsequently examined. However no difference was detected in RANTES 
expression following treatment with theophylline and inhaled beclometasone ( 
0.131pg/ml ( 0.849, 0.528), p=0.487). 
3.3.2.2  Inflammatory biomarkers in sputum 
At  four  weeks,  treatment  with  theophylline  alone  was  associated  with  a 
reduction in sputum supernatant IL 8 ( 1201.3 pg/ml (95% CI,  2409.6,  276.6), 
p=0.009) and MPO ( 215.0 ng/ml ( 556.0,  36.7), p=0.026) measured by ELISA 
(table 3.3). No significant changes were detected in sputum IL 8 or MPO in the 
group treated with theophylline and inhaled beclometasone. 
3.3.2.3  HDAC activity 
HDAC  activity  was  measurable  for  a  subgroup  within  each  treatment  group 
[inhaled beclometasone n=4, theophylline alone n=7, theophylline and inhaled 
beclometasone n=7]. The majority of samples had a low level of HDAC activity. 
No difference was obvious between the groups at baseline or after treatment 
(Tables 3.2 & 3.3 and figure 3.6). 
3.3.3 Serum theophylline levels 
Serum concentrations were below the current recommended target range (10 
20 g/ml).  The  mean  serum  concentration  for  the  theophylline  alone  group 
(4.9 g/ml, SD 2.4) was similar to that achieved in the theophylline and inhaled 
beclometasone group (4.3 g/ml, SD 2.0). 
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Figure 3.6 Change in HDAC activity from randomisation to 28 days of treatment.  
Individual  plots  of  HDAC  activity  shown.  Error  bars  represent  95%  confidence  intervals. 
Figure key- ICS; inhaled beclometasone, Theo; theophylline, Theo + ICS; theophylline and 
inhaled beclometasone combination 
 
3.3.4 Compliance 
Eighty seven percent of the subjects who completed the trial achieved greater 
than 80% compliance with therapy. 
3.3.5 Adverse events 
Two  serious  adverse  events  occurred  during  the  trial.  Both  occurred  in  the 
theophylline  alone  arm.  One  subject  was  admitted  with  viral  meningitis  and 
another  with  chest  pain  due  to  gastro oesophageal  reflux  (a  pre existing 
condition).  Neither  subject  withdrew  from  the  study.  There  were  two 
withdrawals  due  to  adverse  events.  One  each  occurred  in  the  inhaled 
beclometasone  alone  (diarrhoea  and  vomiting)  and  theophylline  and  inhaled 
beclometasone (headache) arms. The frequency of headache was equal between 
the groups (six reported for theophylline and inhaled corticosteroids, seven for 
theophylline and five for low dose beclometasone). Gastrointestinal upset was 
common in the theophylline alone group with fourteen episodes being reported.  
Two  subjects  reported  nausea  whilst  on  theophylline  and  low  dose 
beclometasone  but  no  other  gastrointestinal  symptoms  were  reported. Chapter 3    111 
Pharyngitis was reported by three subjects in the low dose beclometasone alone 
group.  
3.4 Discussion 
Previous  research  has  demonstrated  that the  therapeutic  response  to  inhaled 
corticosteroids is impaired in smokers with asthma (7,, 8 10), highlighting the 
need for alternative treatment approaches for this large subgroup of asthma. 
This exploratory clinical trial examined the efficacy of an alternative approach 
to treatment of smokers with mild to moderate asthma with the aim of restoring 
corticosteroid sensitivity. The hypothesis behind the study was based on previous 
research that suggested that the addition of low dose theophylline to an inhaled 
corticosteroid  would  improve  lung  function  to  a  greater  degree  than  inhaled 
corticosteroid alone due to a restoration of HDAC activity. This study shows that 
the  combination  of  theophylline  and  inhaled  corticosteroid  produces 
improvements in several indices of lung function and improves asthma control in 
smokers with asthma. 
Treatment with the combination of oral theophylline and inhaled beclometasone 
was associated with a borderline significant increase in pre bronchodilator FEV1 
after  28  days  of  treatment  and  with  a  large  improvement  in  both  pre 
bronchodilator PEF and FVC. The improvement seen in both PEF and FVC (and 
the associated drop in ACQ score) make it likely that the observed improvement 
in FEV1 is real and not a result of multiple comparisons. Given its exploratory 
nature and hence small numbers of participants it is likely that the study was 
slightly  underpowered  to  conclusively  demonstrate  the  change  in  FEV1  with 
treatment. A post hoc power calculation, based on the between patient standard 
deviation (285 ml) for the theophylline and inhaled corticosteroid group suggests 
that  48  subjects  per  group  are  required  for  80%  power  to  detect  a  FEV1 
difference  of  165ml  between  the  combination  of  theophylline  and  inhaled 
corticosteroid and inhaled corticosteroid alone arms. The power calculation for 
PEF  based  on  the  between  patient  standard  deviation  (46.4  L/min)  for  the 
theophylline and inhaled corticosteroid group, reveals that 23 subjects per group 
would  be  required  to  provide  80%  power  for  the  detection  of  a  40  L/min 
difference in PEF. Chapter 3    112 
The  size  of  the  improvement  seen  following  treatment  with  low  dose 
theophylline  and  inhaled  beclometasone  (40  L/min)  is  likely  to  be  clinically 
significant as it is larger (263, 264) or equivalent (265) to the improvements seen 
when long acting β2 agonists are added to inhaled corticosteroids in non smoking 
asthmatics. Furthermore, this improvement is much larger than that produced 
by montelukast (9) and high dose inhaled corticosteroids in smokers with asthma 
(8).  The  improvements  in  lung  function  following  treatment  with  low  dose 
theophylline and inhaled beclometasone were also associated with a reduction in 
ACQ score that was just below the clinically significant threshold of 0.5 (254). 
Therefore further research, powered on these findings, should be carried out 
using low dose theophylline and inhaled corticosteroid to confirm and extend our 
understanding of the efficacy of this combination in smokers with asthma. 
Theophylline alone did not produce any significant changes in pre bronchodilator 
lung function relative to that produced by inhaled beclometasone. Nevertheless 
low dose theophylline treatment did produce an increase in post bronchodilator 
FVC,  a  clinically  significant  reduction  in  ACQ  score  and  reduction  in  sputum 
supernatant cytokines. Previous research has demonstrated that theophylline has 
this effect in COPD (266). No direct comparison was made between low dose 
theophylline  and  the  combination  of  low  dose  theophylline  and  inhaled 
corticosteroid.  However,  it  would  appear  that  if  this  comparison  was  made, 
there would be no clear difference between the two arms. Therefore low dose 
theophylline alone may provide an alternative therapy in smokers with asthma as 
it resulted in a clear improvement in asthma symptoms (as measured by the 
asthma control questionnaire) and could also produce a clear improvement in 
lung function relative to inhaled corticosteroid in an adequately powered trial 
(albeit smaller than that seen with the combination of low dose theophylline and 
inhaled corticosteroid).  
Theophylline has many modes of action including non specific phosphodiesterase 
activity and adenosine receptor antagonism (100) and both of these mechanisms 
could produce bronchodilation. However the improvement in lung function with 
low dose oral theophylline in combination with inhaled beclometasone is unlikely 
to be due to a bronchodilating effect of theophylline alone, given the absence of 
statistically significant improvements in lung function with low dose theophylline Chapter 3    113 
alone. Therefore there appears to be a synergistic interaction between low dose 
theophylline and beclometasone. 
Given the many suggested mechanisms of theophylline there are several ways by 
which low dose theophylline could synergise with corticosteroids to improve lung 
function  in  smokers  with  asthma.  One  potential  mechanism  that  I  have 
attempted to address is the ability of low dose theophylline to restore HDAC 
activity. Exposure to cigarette smoke in-vitro can reduce HDAC activity and this 
can be restored by low doses of theophylline (92, 102) leading to the hypothesis 
that  reduced  HDAC  activity  is  responsible  for  the  reduced  corticosteroid 
response seen in smokers with asthma. The serum concentration of theophylline 
achieved  in  the  subjects  was  within  the  range  previously  demonstrated  to 
stimulate  HDAC  activity.  Unfortunately  an  increase  in  HDAC  activity  was  not 
observed  in  those  subjects  treated  with  theophylline  and  inhaled 
beclometasone.  The  reason  for  this  may  be  explained  by  the  low  number  of 
sputum macrophages harvested for analysis. The subjects recruited were able to 
produce specimens of sufficient quality for differential counting and supernatant 
analysis, but the number of macrophages harvested for HDAC was low and at the 
detection limit of the technique. Another consideration is that there was no step 
to allow for inspection of the cells selected for the HDAC assay. Therefore there 
is the possibility that contamination with non viable cells and neutrophils may 
have  affected  the  results  and  resulted  in  the  observed  low  levels  of  HDAC 
activity. Future work examining theophylline in smokers with asthma needs to 
address  the  underlying  mechanism/s  responsible.  Bronchoalveolar  lavage 
samples should be obtained to allow sufficient macrophages for HDAC analysis 
and to ensure comparisons can be made with previous research. As previously 
mentioned  theophylline  can  also  act  as  a  non specific  phosphodiesterase 
inhibitor and  an adenosine  receptor  antagonist  and  the contribution  of  these 
(and  other)  mechanisms  to  synergism  between  theophylline  and  inhaled 
beclometasone should be examined in smokers with asthma. 
The present study has also demonstrated that treatment with theophylline and 
inhaled beclometasone is associated with a reduction in sputum lymphocytes. 
How a reduction in the number of airway lymphocytes following the addition of 
low  dose  theophylline  would  lead  to  an  improved  response  to  inhaled 
beclometasone is unclear at present. A possible explanation is that the reduction Chapter 3    114 
observed  is  spurious  due  to  the  group  treated  with  theophylline  and  inhaled 
beclometasone  having  a  slightly  higher  sputum  lymphocyte  count  at  baseline 
(albeit  non significantly  different).  Therefore  a  small  drop  in  the  sputum 
lymphocytes  in  this  group  combined  with  a  small  increase  in  the  inhaled 
beclometasone treated group could produce this apparent drop. Previous work 
addressing the reproducibility of induced sputum counts has also demonstrated 
that  sputum  lymphocyte  counts  display  lower  reproducibility  compared  to 
eosinophils and neutrophils so we may be observing the inherent variability of 
this  aspect  of  induced  sputum  (267).  However  low  dose  theophylline  has 
previously  been  demonstrated  to  reduce  bronchoalveolar  lavage  lymphocyte 
numbers with an associated alteration in the CD4/CD8 ratio and reduction in the 
late  asthmatic  response  to  allergen  challenge  (268).  Therefore  the  observed 
reduction in sputum lymphocytes may reflect a true effect of theophylline in this 
patient group. If this issue is to be addressed, in future studies examination of 
bronchial biopsy samples and bronchoalveolar lavage samples will be required. 
This  approach  would  allow  identification  of  lymphocyte  sub types  and  their 
response  to  low  dose  theophylline  and  inhaled  corticosteroid  therapy.  The 
absence of other changes in sputum inflammatory cell profiles is likely to be due 
to both the short duration of treatment and the absence of sputum eosinophilia 
and neutrophilia in the patients studied. 
3.5 Conclusions 
This pilot study demonstrates improvements in both lung function and asthma 
control from the addition of low dose theophylline to inhaled beclometasone in a 
group  of  smokers  with  mild  to  moderate  asthma.  The  presented  results  are 
encouraging  given  the  documented  poor  response  of  smokers  with  asthma  to 
standard  doses  of  inhaled  corticosteroids  and  the  need  for  more  effective 
therapies in this group. Important questions that need to be addressed in future 
trials include: 
•   the effect of lower doses of theophylline and hence the lowest effective 
dose Chapter 3    115 
•  the relative performance of the combination of low dose theophylline and 
low dose inhaled corticosteroid to  
o  high dose inhaled corticosteroid 
o  combined long acting beta agonist and inhaled corticosteroid 
o  leukotriene receptor antagonists 116 
4  Efficacy  of  a  PPARγ  agonist  in  a  group  of 
smokers with asthma 
4.1 Introduction 
Inhaled corticosteroids are recommended as the first line treatment for chronic 
persistent asthma (1, 2). However a significant proportion of individuals with 
asthma fail to establish complete control with this approach (25). Despite the 
use  of  additional  therapies  (including  oral  corticosteroids)  around  10%  of 
subjects  with  asthma  have  poorly  controlled  symptoms  and  this  group  are 
estimated to consume 50% of the costs associated with the treatment of asthma 
(29,  32).  Few  new  treatments  have  become  available  for  asthma  since  the 
introduction  of  inhaled  corticosteroids  with  the  exception  of  leukotriene 
receptor  antagonists  and  anti IgE  therapy,  both  of  which  offer  some 
improvements  in  control  but  are  generally  regarded  as  inferior  to 
corticosteroids.  A  number  of  targeted  treatment  approaches  are  in 
development, for example p38 MAPK inhibitors, with the hope that these will 
provide  better  control  of  corticosteroid  resistant  disease.  However  the 
beneficial effects of corticosteroids depend on their ability to act simultaneously 
via  a  number  of  mechanisms  and  pathways.  Therefore  the  narrow  focus  of 
targeted  therapies  could  mean  that  they  will  only  be  able  to  provide 
improvements in a small proportion of patients. 
Smokers  with  asthma  exhibit  an  impaired  response  to  both  inhaled  and  oral 
corticosteroids (5 10, 22 24), an accelerated decline in lung function (15, 21), 
increased emergency department visits for asthma (with associated costs) (16, 
17)  and  increased  severity of  symptoms  compared  to  non smoking  asthmatics 
(11,  12).  The  prevalence  of  smoking  in  asthma  reflects  that  of  the  general 
population  and  therefore  smokers  with  asthma  comprise  a  large  group  of 
patients with poorly controlled disease (261). Smoking cessation is an effective 
therapy in this group (49), but as sustained quitting rates are low, additional or 
alternative therapies are needed for individuals with asthma who continue to 
smoke. Chapter 4    117 
The  glucocorticoid  receptor  is  a  member  of  the  nuclear  hormone  receptor 
family,  which  includes  peroxisome  proliferator  activated  receptor γ  (PPARγ). 
PPAR γ agonists exert anti inflammatory effects on multiple inflammatory cell 
subtypes in-vitro and reduce inflammation in animal models of both asthma and 
neutrophilic  airways  disease  (113,  114).  Based  on  this  evidence  and  the 
hypothesis  that  the  PPAR γ  agonist  rosiglitazone  would  have  beneficial  anti 
inflammatory actions in smokers with asthma I undertook an exploratory clinical 
trial to examine the effect of rosiglitazone on lung function and other outcomes 
in a group of smokers with asthma. 
4.2 Methods 
4.2.1 Subjects 
Subject  characteristics,  inclusion/exclusion  criteria  and  recruitment  methods 
were  as  described  in  the  general  methods  chapter.  All  subjects  provided 
informed  consent  and  the  study  was  approved  by  the  West  Glasgow  Ethics 
Committee. 
4.2.2 Study design 
A full description of the study is provided in the general methods chapter. In 
brief  the  study  was  a  randomised,  prospective,  double blind,  double dummy, 
active comparator, parallel group design. Subjects were randomly allocated to 
one  of  four  treatment  groups,  two  of  which  are  discussed  in  this  chapter. 
Subjects were randomised to either 4 mg twice a day oral rosiglitazone maleate 
or 100mcg twice a day inhaled hydrofluoroalkane beclometasone dipropionate 
(figure 4.1). Subjects returned for pre bronchodilator lung function at two weeks 
and repeated the assessments carried out at the baseline visit after four weeks. Chapter 4    118 
 
Figure 4.1 Randomisation schedule 
 
4.2.3 Measurements 
A  full  description  of  the  measurements  is  provided  in  the  general  methods 
chapter.  Lung  function  assessments  conformed  to  consensus  guidelines  (246). 
Sputum induction, differential count and supernatant analysis were performed 
as discussed in the general methods chapter. Continuation of smoking during the 
study  was  confirmed  by  history  and  the  detection  of  urinary  nicotine 
metabolites. Subjects were regarded as current smokers if their category was 
mild  smoker  or  greater  and  their  urine  cotinine  level  was  greater  than 
1.1mg/ml.  Treatment  compliance  was  assessed  by  tablet  count  and  inhaler 
weight. 
4.2.4 Statistical analysis 
The  reduced  response  to  inhaled  corticosteroids  in  smokers  with  asthma 
combined  with  a  lack  of  published  information  on  the  effect  of 
thiazolidinediones  in  asthma  prevented  the  performance  of  standard  power 
calculations. The study was informed by FEV1 changes from a previous clinical 
trial employing oral corticosteroids in smokers with asthma (23). This resulted in 
the  estimate  that  22  subjects  were  required  per  group  to  detect  a  230ml 
difference in FEV1 between the treatment arms and to allow for a 10% dropout 
rate. A slightly higher dropout rate occurred (13%) during the trial resulting in a 
short  extension  to  allow  a  larger  numbers  of  subjects  to  be  randomised  to 
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The  primary  endpoint  was  difference  in  pre bronchodilator  FEV1  between 
rosiglitazone  and  beclometasone  alone  at  28  days.  The  secondary  endpoints 
were change in pre and post bronchodilator PEF, FVC, FEF25 75, FEF75 & ACQ. 
Exploratory  endpoints  were  change  in  sputum  differential  &  supernatant  and 
serum  cytokines.  Lung  function  changes  were  examined  using  ANCOVA 
(incorporating Kenward & Roger’s method (262)) using SAS v8.2 (SAS Institute 
Inc,  NC,  USA).  All  data  obtained  after  day  one  of  treatment  was  used  for 
analysis.  The  remaining  statistical  analysis  was  performed  using  Minitab  15 
(Minitab Inc. State College, PA, USA). α was set at 0.05. Due to the exploratory 
nature of the trial the analyses were not corrected for type 1 errors due to 
multiple comparisons. 
4.3 Results 
A total of 3895 subjects with asthma were invited to participate between August 
2005 and May 2007, of whom 294 gave positive responses. Following telephone 
screening, visits were arranged for 187 subjects and 91 subjects met criteria for 
randomisation (Figure 4.2). Forty five subjects were randomised to theophylline 
and  theophylline  and  inhaled  beclometasone.  The  results  from  the  forty six 
subjects  randomised  to  either  rosiglitazone  or  inhaled  beclometasone  will  be 
discussed from this point. Twenty three subjects were allocated to rosiglitazone 
and twenty three to inhaled beclometasone alone. The baseline demographic, 
clinical (including previous inhaled corticosteroid and long acting β2 agonist use) 
and inflammatory characteristics of recruited subjects in each group were well 
matched (tables 4.1 & 4.2). All the endpoints presented are the changes relative 
to the inhaled corticosteroid group response. 
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Figure 4.2 CONSORT diagram.  
SAE; serious adverse event. 
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Inhaled 
beclometasone  Rosiglitazone 
No of patients  23  23 
Age (years) 
 
42 
(36, 53) 
 
 
41 
(33, 54) 
 
Gender 
Female (% of total)  61  57 
 
BMI (kg/m²) Mean (range) 
 
25.5 
(18.4, 34.2) 
26.1 
(19.5, 38.6) 
 
Pack years 
 
24 
(15, 30) 
21 
(13, 40) 
 
Duration of asthma (years) 
 
16 
(8, 31) 
18 
(6, 29) 
Inhaled corticosteroid use at 
screening 
 
(% of subjects) 
 
Dose, 
beclometasone 
equivalent mcg 
65 
 
 
800 
(400, 800) 
83 
 
 
800 
(400, 800) 
LABA use at screening (%)  26  30 
Specific IgE antibody positive (%)  61  78 
Total IgE level (IU/ml) 
 
87 
(34, 396) 
 
 
239 
(49, 488) 
 
Spirometry  
Pre-BD FEV1 (% predicted) 
 
75 
(72, 89) 
 
 
70 
(60, 89) 
 
Reversibility 
FEV1 % improvement 
 
16 
(13, 20) 
 
 
16 
(13, 26) 
 
Asthma Control 
Questionnaire score 
(0 to 6) Mean (SD) 
1.8 
(0.9) 
1.9 
(0.7) 
Table 4.1 Baseline demographics.  
Data presented as median (interquartile range) unless stated otherwise. Abbreviations; SD; 
standard deviation, BMI; Body Mass Index, FEV1; Forced expiratory volume in 1 second, pre 
BD;  pre  bronchodilator,  ACQ;  Asthma  Control  Questionnaire  score  (range,  0  to  6,  with 
higher scores indicating worse asthma control), IgE; immunoglobulin E, LABA; long-acting 
β2-agonist., mcg; microgram, IU/ml; international units per ml, kg/m
2; kilograms per square 
metre. Chapter 4    122 
 
 
  Inhaled beclometasone  Rosiglitazone 
Sputum total cell count (10
6)  4.3 
(2.6, 7.3) 
4.7 
(2.4, 9.9) 
Eosinophils %  0.9 
(0.3, 1.6) 
1.1 
(0.5, 3.0) 
Eosinophils (10
4)  2.1 
(0.8, 5.8) 
5.1 
 (1.5, 17.9) 
Neutrophils %  25.5 
(9.6, 44.6) 
28.8 
(13.1, 46.2) 
Neutrophils (10
4)  122.7  
(25, 188) 
150.3  
(27, 492) 
Macrophages %  52.8 
(32.0, 64.4) 
48.0 
(26.1, 64.1) 
Macrophages (10
4)  184.2  
(96, 437) 
185.8  
(105, 355) 
Lymphocytes %  1.3 
(0.6, 2.6) 
1.4 
(0.7, 2.0) 
Lymphocytes (10
4)  4.9  
(2.3, 11.2) 
8.0  
(2.1, 13.5) 
Bronchial epithelial cells  %  10.5 
(8.3, 15.4) 
11.0 
(6.7, 18.8) 
Bronchial epithelial cells  (10
4)  40.7  
(20.5, 99.4) 
49.6  
(28.4, 110.6) 
Table 4.2 Baseline sputum counts.  
Data expressed as median (IQR) 
 
4.3.1 Lung function 
At  two  weeks,  rosiglitazone  demonstrated  a  borderline  improvement  in  pre 
bronchodilator  FEV1  (164  ml,  (95%  CI  –1  to  329),  p=0.051),  a  significant 
improvement in pre bronchodilator PEF (32.7 L/min, (5.7 to 59.7), p=0.018) and 
significant improvement in both FEF25 75 (0.36 L/sec, (0.088 to 0.632), p=0.010) 
and FEF75 (0.24 L/sec, (0.094 to 0.386), p=0.002)(table 4.3). After four weeks, 
the group treated with rosiglitazone demonstrated a borderline improvement in 
pre bronchodilator  FEV1  (183ml  (–1  to  367),  p=0.051)  (figure  4.3)  and  a 
significant improvement in FEF25 75 (0.243 L/sec (0.025 to 0.461) p=0.030) (figure 
4.4 and table 4.3). There was no difference between the groups treated with 
rosiglitazone  and  inhaled  beclometasone  for  other  measurements  of  lung 
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4.3.2 ACQ score 
There was no difference between the rosiglitazone and inhaled beclometasone 
groups when changes in ACQ scores were compared (table 4.3). 
  Rosiglitazone 
∆ Pre BD FEV1 
 
ml (95% CI) 
Day 14 
 
 
Day 28 
  164 
† 
(-1, 329) 
 
  183 
† 
(-1, 367) 
∆ Pre BD FVC 
 
ml (95% CI) 
Day 14 
 
 
Day 28 
45 
(-114, 204) 
 
156 
(-42, 354) 
∆ Pre BD PEF 
 
L/min (95% CI) 
Day 14 
 
 
Day 28 
   33 * 
(5, 59) 
 
23 
(-6, 53) 
∆ Pre BD FEF25-75 
 
L/sec (95% CI) 
Day 14 
 
 
Day 28 
    0.360 * 
(0.088, 0.632) 
 
    0.243 * 
(0.025, 0.461) 
∆ Pre BD FEF75 
L/sec (95% CI) 
Day 14 
 
 
Day 28 
   0.240 * 
(0.094, 0.386) 
 
 0.111 
(-0.011, 0.233) 
 
∆ ACQ score 
 
∆ 
(95% CI) 
-0.07 
(-0.52, 0.38) 
Table  4.3  Change  in  lung  function  and  ACQ  following  treatment  (relative  to  response  to 
inhaled beclometasone alone).  
PEF; peak expiratory flow, FVC; forced vital capacity, FEF25-75; forced mid-expiratory flow 
rate, FEF75; forced expiratory flow at 75% of FVC, 95% CI; 95 percent confidence intervals. *; 
p<0.05, †; p=0.05 Chapter 4    124 
 
 
 
 
 
 
Figure 4.3 Mean group FEV1 changes from randomisation to 14 and 28 days of treatment  
Paired t-test (error bars represent 95% confidence intervals)). p-values were derived from 
comparison of rosiglitazone group change to inhaled beclometasone dipropionate change 
using ANCOVA. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Mean group FEF25-75 changes from randomisation to 14 and 28 days of treatment   
Paired t-test (error bars represent 95% confidence intervals). p-values were derived from 
comparison of rosiglitazone group change to inhaled beclometasone dipropionate change 
using ANCOVA. 
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4.3.3 Sputum samples 
4.3.3.1  Induced sputum cytology 
No relative treatment differences in sputum proportions were observed (table 
4.4). 
4.3.3.2  Sputum supernatant 
A borderline relative reduction in sputum IL 8 was observed in the group treated 
with rosiglitazone ( 534.1pg/ml, (95% CI  1844.4, 36.5), p=0.068) (table 4.4). 
4.3.4 Compliance 
Eighty five percent of the subjects who completed the study achieved greater 
than 80% compliance with therapy. 
4.3.5 Adverse events 
No  serious  adverse  events  occurred  in  the  rosiglitazone  and  inhaled 
beclometasone  arms  during  the  trial.  There  were  two  withdrawals  due  to 
adverse events. One each occurred in the rosiglitazone (periorbital oedema) and 
inhaled beclometasone alone (diarrhoea and vomiting) arms. The frequency of 
headache was equal between the groups (five for low dose beclometasone and 
four  for  rosiglitazone).  Three  subjects  in  the  low  dose  beclometasone  alone 
group reported pharyngitis. Chapter 4    126 
 
  Rosiglitazone 
∆ Sputum total cell count  ∆ (10
6) 
(95% CI) 
 
1.3 
(-2.1, 4.7) 
 
∆ Sputum eosinophil 
% 
(95% CI) 
 
Absolute (10
4) 
(95% CI) 
 
0.1 
(-1.0, 1.3) 
 
1.42 
(-4.7, 6.4) 
 
∆ Sputum neutrophil 
% 
(95% CI) 
 
Absolute (10
4) 
(95% CI) 
 
4.5 
(-16.5, 26.5) 
 
32.9 
(-120.4, 201.1) 
 
∆ Sputum macrophage 
% 
(95% CI) 
 
Absolute (10
4) 
(95% CI) 
 
3.4 
(-13.3, 16.8) 
 
110.0 
(-27.2, 326.8) 
 
∆ Sputum lymphocyte 
% 
(95% CI) 
 
Absolute (10
4) 
(95% CI) 
 
-0.5 
(-1.1, 0.4) 
 
-0.19 
(-7.0, 5.2) 
 
∆ Sputum  
bronchial epithelial cell 
% 
(95% CI) 
 
Absolute (10
4) 
(95% CI) 
 
-4.7 
(-11.3, 2.0) 
 
5.9 
(-65.8, 78.4) 
 
∆ Sputum IL-8  pg/ml 
(95% CI) 
 
-534.1 
(-1844.4, 36.5) 
 
∆ Sputum MPO  ng/ml 
(95% CI) 
 
-91.3 
(-335.1, 44.2) 
 
Table 4.4 Change in sputum counts and supernatant cytokines following treatment (relative 
to treatment with inhaled beclometasone alone).  
 ; change in endpoint, IL-8; interleukin-8, MPO; myeloperoxidase, pg/ml; picogrammes per 
millilitre, ng/ml; nanogrammes per millilitre. 
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4.4 Discussion  
There  exists  within  asthma  a  sub population  of  patients  who  fail  to  respond 
adequately  to  current  therapies  (25,  29).  As  a  result  this  group  have  worse 
asthma  control  and  consume  a  disproportionate  share  of  healthcare  budgets. 
Smokers with asthma comprise part of this difficult to control group. Previous 
research  has  demonstrated  that  the  therapeutic  response  to  inhaled 
corticosteroids  is  impaired  in  smokers  with  asthma  (5 10).  A  recent  post  hoc 
analysis  suggests  that  smokers  with  asthma  also  fail  to  gain  the  expected 
response to the combination of inhaled steroids and long acting beta agonists 
(compared  to  non  smokers  with  asthma)(10).  This  randomised,  controlled, 
exploratory clinical trial examined the impact of a novel alternative approach 
using  the  PPARγ  agonist  rosiglitazone,  in  a  group  of  smokers  with  mild  to 
moderate asthma. 
Treatment  with  rosiglitazone  produced  a  trend  to  improvement  in  pre 
bronchodilator  FEV1  over  low  dose  inhaled  beclometasone  at  both  14  and  28 
days. This improvement is much larger than the effect seen in previous trials in 
smokers with asthma examining inhaled corticosteroids (7, 8) and was associated 
with  an  improvement  in  PEF  (albeit  non significant)  and  a  significant 
improvement in the spirometric marker of small airway function FEF25 75. The 
improvements in the pre defined secondary endpoints suggest that the change 
observed  in  FEV1  is  real.  The  failure  to  produce  a  conclusive  improvement 
relative to inhaled beclometasone is likely to be due to underpowering for the 
primary endpoint. A post hoc power calculation based on a standard deviation of 
286ml and power of 80% with α set at 5% suggests that 40 patients per group 
would have been required for sufficient powering for this endpoint. 
The improvement seen in FEF75 at 14 days and FEF25 75 at both 14 and 28 days is 
of  interest  as  there  are  few  therapies  available  for  the  treatment  of  small 
airway obstruction. Small airway obstruction, seen in many pulmonary conditions 
including asthma (269), the smoking related condition COPD (270) and several 
interstitial  lung  diseases  (271),  is  associated  with  dynamic  hyperinflation, 
reduced  exercise  tolerance  and  increased  dyspnoea.  Given  the  observed Chapter 4    128 
improvement  consideration  should  be  given  to  studying  PPARγ  agonists  in 
subjects with evidence of small airways obstruction. 
A  surprising  finding  was  that  the  improvement  in  lung  function  produced  by 
rosiglitazone  was  not  associated  with  a  reduction  in  asthma  symptoms  (as 
detected by the ACQ score) or sputum profile or supernatant at 28 days. What 
can  explain  this  discrepancy?  With  regards  the  lack  of  sputum  change  the 
subjects had relatively mild asthma and did not display sputum eosinophilia or 
neutrophilia at baseline. This would explain the lack of change in the proportion 
of these inflammatory cells and possibly the lack of change in sputum cytokines. 
One explanation for the lack of change in ACQ score is that the lung function 
change is a random chance event given the small number of subjects studied. 
However  the  secondary  lung  function  endpoints  demonstrate  a  similar 
improvement so whilst a random chance event is possible other explanations are 
worth consideration. A possible alternative is that we are observing dissociation 
between  lung  function  improvements  and  change  in  the  asthma  control 
questionnaire score. Previous examples include a study comparing two inhaled 
steroid  preparations  which  examined  improvements  in  lung  function  and 
symptoms (as measured by the asthma quality of life questionnaire) (272). The 
study  found  a  clear  difference  in  asthma  symptom  control  between  the  two 
preparations  despite  equivalence  between  the  treatments  for  lung  function 
changes. When examined, the asthma symptom change was found to correlate 
poorly  with  lung  function  changes  (272).  This  dissociation  between  asthma 
symptoms  measured  by  questionnaire  and  lung  function  change  has  been 
observed in other studies (273, 274). An additional alternative explanation for 
the  lack  of  change  in  ACQ  score  is  a  waning  of  the  beneficial  effect  of 
rosiglitazone on lung function by 28 days and hence a lack of detectable effect 
on asthma symptoms. This could be supported by the reduction in the size of in 
PEF,  FEF25 75  and  FEF75  differences  between  the  rosiglitazone  and  inhaled 
beclometasone arms from 14 to 28 days. This waning of effect, if true, could be 
due to tachyphylaxis. Previous research has demonstrated a down regulation of 
PPARγ expression in asthmatics following treatment (117) and future research 
should  follow  PPARγ  expression  in  endobronchial  specimens  during  and  after 
treatment with PPARγ agonists.  Chapter 4    129 
What  are  the  mechanism(s)  by  which  rosiglitazone  could  be  producing  the 
observed  improvements  in  lung  function?  The  cause  of  the  poor  response  to 
corticosteroids  in  smokers  with  asthma  is  currently  unknown.  However  one 
possible reason is that cigarette smoking induces an oxidative stress mediated 
change in the glucocorticoid receptor, resulting in a change in its behaviour and 
efficacy  (32).  Recent  research has  demonstrated  that  rosiglitazone is  able to 
bind  to  the  glucocorticoid  receptor  ligand  binding  domain  with  properties 
suggestive of a partial agonist effect (177). Therefore the presented results may 
be a demonstration of an alternative mode of glucocorticoid receptor activation 
which has resulted in the detected improvements in lung function. Alternatively, 
PPARγ has been shown to modulate a distinct but partially overlapping set of 
inflammatory  genes  compared  to  corticosteroids  (163).  Further  studies 
examining  the  relative  effects  of  rosiglitazone  on  corticosteroid  and  PPARγ 
specific  functional  outputs  are  indicated  in  smokers  with  asthma  and  other 
conditions with relative corticosteroid insensitivity. 
Only one dose of rosiglitazone was employed in this study. This was due to the 
exploratory nature of the trial and the lack of previous data on the efficacy of 
rosiglitazone in asthma. The dose selected is in common use for the treatment 
of non insulin dependent diabetes and within the dose range used in models of 
asthma. Given the suggestion of a response, future trials should incorporate a 
number of different doses to examine the lung function dose response. Another 
aspect of PPARγ stimulation not examined in this trial is the potential synergistic 
interaction between PPARγ and the glucocorticoid receptor (38, 176). Previous 
research suggests that PPARγ may be able to modulate glucocorticoid receptor 
function and hence in circumstances of glucocorticoid insensitive inflammation 
may  restore  corticosteroid  sensitivity.  Therefore  future  trials  should  also 
examine  combinations  of  PPARγ  agonists  and  corticosteroids  to  determine  if 
there is a useful synergistic effect with this combination.  
Polymorphisms in the PPARγ receptor have recently been examined in a group of 
young subjects with asthma (178). Several single nucleotide polymorphisms were 
examined in this study and one common SNP combination, the ProC phenotype, 
was  associated  with  increased  asthma  exacerbations  and  hospital  admissions. 
Unfortunately PPARγ SNPs were not examined in this study and therefore the Chapter 4    130 
role  of  SNPs  in  treatment  response  cannot  be  examined  here.  Clearly  SNPs 
affecting  the  PPARγ  expression  level  and  behaviour  may  be  of  relevance  to 
treatment  response  and  future  work  should  address  the  relevance  of  PPARγ 
receptor polymorphisms to response to treatment with PPARγ agonists. 
4.5 Conclusion 
This  exploratory  trial,  the  first  to  examine  a  PPARγ  agonist  in  asthma,  has 
demonstrated  improvement  in  some  lung  function  parameters  in  a  group  of 
smokers with mild to moderate asthma. The conclusions that can be drawn from 
the study are tempered by the exploratory nature of this work, reflected in the 
short duration of treatment and small number of subjects involved. However the 
results presented provide sufficient information for an adequately powered trial 
of  this  therapy  in  smokers  with  asthma  and  are  encouraging  given  the 
documented poor response of smokers with asthma to standard doses of inhaled 
corticosteroids and the need for more effective therapies in this group. Further 
trials  should  be  undertaken  to  examine  PPARγ  agonists  in  asthma  and  other 
obstructive airway conditions. PPARγ agonists may represent a new therapeutic 
class for inflammatory diseases. 131 
5  Impact  of  smoking  on  cytokine  profiles  in 
asthma 
5.1 Introduction 
The cytokine family acts as a system of communication and control within and 
between  the  innate  and  adaptive  immune  system.  Over  100  cytokines  are 
recognised and many have important roles in the development and persistence 
of  chronic  inflammatory  diseases.  Multiple  cell  types  from  the  innate  and 
adaptive  immune  system  express  and  respond  to  cytokines  and  there  is 
considerable overlap in cytokine production. For example interleukin (IL) 13 can 
be produced by T lymphocytes, mast cells, eosinophils and basophils and IL 6 
can be produced by macrophages, bronchial epithelial cells, T cells and B cells. 
Several cytokines have been linked to the recruitment and continued activation 
of inflammatory cells within the airway lumen and bronchial walls and are being 
targeted  by  pharmaceutical  companies  as  potential  therapeutic  targets  as  a 
result (275).  
Despite the crossover in expression that exists, cytokine profiles can be useful in 
characterising inflammation based on the expression of certain sets of cytokines 
by  certain  inflammatory  cells.  The  classic  example  is  the  division  of  T 
lymphocyte CD4 helper cells into Th1 and Th2 subsets. Th1 cells develop from 
naive T helper cells in response to IL 12, interferon γ (IFNγ) and transforming 
growth factor β (TGFβ) and produce IFNγ, TGFβ and IL 2. Th2 cells differentiate 
in response to IL 4 and produce IL 4, 5, 6, 9, 10, 13 and 25.  
Asthma,  when  introduced  from  an  immunological  perspective,  is  commonly 
portrayed  as  a  prototypic  Th2  disease.  Whilst  some  evidence  obtained  from 
atopic subjects with asthma is available to support this view, it is an obvious 
oversimplification  as  it  does  not  reflect  the  breadth  of  the  inflammatory 
response in asthma, which is best described as heterogeneous (276, 277). The 
best  current  anti inflammatory  therapy  for  asthma  is  inhaled  corticosteroids. 
Corticosteroids are effective in reducing eosinophilic inflammation, a range of 
inflammatory cytokines and provide a degree of asthma symptom control in the Chapter 5    132 
majority of subjects. However not all subjects with asthma gain the expected 
benefits  from  this  treatment  and  this  probably  reflects  variations  in  the 
inflammatory  response  within  asthma.  Cigarette  smoking  is  recognised  to 
modulate the response to treatment with corticosteroids in asthma (261). This 
clinical observation suggests an altered immune response may be present in this 
sub  group.  Cytokines  can  alter  corticosteroid  responses,  as  demonstrated  by 
previous in-vitro research using IL 2 & 4 to induce corticosteroid resistance in T 
lymphocytes (66 69). Previous research in smokers with asthma has identified 
increased sputum IL 8 (41) and reduced sputum IL 18 (42) (compared to matched 
non  smokers  with  asthma).  However  no  further  information  is  available  on 
differences  in  cytokine  profiles  in  smokers  with  asthma  compared  to  non 
smoking asthmatics.  
Recent developments allow the detection of multiple cytokines simultaneously in 
a small volume of sample. This unbiased approach permits the examination of a 
wide range of cytokines, providing increased levels of discrimination between 
different types of inflammatory diseases and more closely reflects the situation 
in-vivo. Therefore a cross sectional study was undertaken to obtain samples to 
examine the hypothesis that smokers with asthma have a reduced response to 
corticosteroids  due  to  increased  levels  of  IL 2  and  4  and  that  smokers  with 
asthma  display  a  generally  altered  cytokine  profile  in  sputum  and  plasma 
compared to non smokers with asthma. 
5.2 Methods 
5.2.1 Subjects 
Subject  characteristics,  inclusion/exclusion  criteria  and  recruitment  methods 
are as described in the general methods chapter. All subjects provided informed 
consent and the study was approved by the West Glasgow Ethics Committee. Chapter 5    133 
5.2.2 Study design 
A full description of the study is provided in the general methods chapter. In 
brief,  the  study  was  a  cross sectional  design  with  unblinded  use  of  oral 
dexamethasone to determine corticosteroid sensitivity. 
5.2.3 Measurements 
Sputum  induction and  processing  were as  previously  described  in  the  general 
methods  chapter.  Briefly  the  whole  sputum  sample  method  was  used  and 
homogenisation  was  via  mechanical  processing  with  reduced  levels  of 
dithiothreitol. Sputum supernatants were collected post processing for sputum 
differential counts and stored in aliquots at  80°C until processing. Plasma was 
from heparinised blood samples. Subject demographics, baseline spirometry pre 
and post inhaled β2 agonist and pre and post oral corticosteroid trial, asthma 
control  questionnaire  (ACQ)  score  and  exhaled  nitric  oxide  levels  (FENO 
performed at flow rate 50ml/sec) were used for the analyses reported in this 
chapter. Baseline results for all subjects were examined. Compliance with oral 
dexamethasone  was  confirmed  by  suppression  of  plasma  cortisol  below 
50nmol/l. If this criterion was met then the subject’s data post corticosteroid 
data was analysed. 
Initial cytokine analysis was performed using a 25 plex cytokine assay (Invitrogen 
Ltd, 3 Fountain Drive, Inchinnan Business Park, Paisley, UK). Through the use of 
spectrally  encoded  antibody  conjugated  beads,  this  assay  can  simultaneously 
detect  eotaxin,  granulocyte/monocyte colony  stimulating  factor  (GM CSF), 
interferon α (IFN α), interferon γ (IFN γ), interleukin (IL) 1 receptor antagonist 
(IL 1RA), IL 1β, IL 2, IL 2 receptor (IL 2R), IL 4, IL 5, IL 6, IL 7, IL 8 (CXCL8), IL 
10, IL 12 (p40/p70), IL 13, IL 15, IL 17, Interferon inducible Protein of 10 kDa 
(IP 10 aka CXCL10), Monocyte Chemotactic Protein 1 (MCP 1), Monokine Induced 
by IFN γ (MIG aka CXC9), Monocyte Inflammatory Protein 1α (MIP 1α aka CCL3), 
Monocyte  Inflammatory  Protein  1β  (MIP 1β  aka  CCL4),  Regulated  upon 
Activation,  Normal  T  cell  Expressed  and  Secreted  (RANTES  aka  CCL5),  and 
Tumour Necrosis Factor α (TNF α). The assay allows for the detection of each 
individual cytokine in a single sample due to the unique fluorescent properties of Chapter 5    134 
the individual bead with reference to a standard curve for each cytokine. The 
signal output and hence cytokine concentration was determined on a Luminex 
100
TM  analyser  (Luminex  Corporation,  12212  Technology  Blvd,  Austin,  Texas, 
USA)  by  interpolation  into  a  standard  curve  made  up  of  standards  of  known 
concentration. The determined concentration of some cytokines, when below 
the lowest standard concentration but greater than zero, was accepted if the 
regression obtained from the standards was linear in that working range and was 
of  sufficient  gradient  to  allow  for  confident  extrapolation.  Otherwise  the 
concentrations were accepted to be half of the lowest standard rather than zero 
in order that these values could be included. Sputum cytokines were performed 
in all groups and plasma cytokine measurements in smokers and non smokers 
with  asthma  only.  No  reproducibility  testing  was  performed  for  the  Luminex 
assay. 
A high sensitivity ELISA for IL 6 (Abcam plc, Cambridge, UK) was employed to 
examine and corroborate the Luminex findings for this cytokine. Briefly, samples 
were  diluted  based  on  the  Luminex  result  to  ensure  they  were  within  the 
working range of the assay (0.8 to 50 pg/ml). One hundred microliters of sample 
was added to an equal volume of diluent in the pre coated wells of the EILSA 
plate followed by fifty microliters of biotinylated anti IL 6. The samples were 
then gently shaken for three hours at room temperature. The plate was then 
washed and horse radish peroxidase solution was added to each well followed by 
gentle shaking for thirty minutes. The plate was then washed followed by the 
addition  of  tetramethylbenzidine  solution.  The  plate  was  covered  for  five 
minutes and then read on a plate reader with 450nm as the primary wavelength 
and 620nm as the reference immediately after the application of stop solution 
(sulphuric acid). No reproducibility testing was performed. 
5.2.4 Statistical analysis 
Parametric data was assessed using t testing and non parametric using Mann 
Whitney  testing.  All  comparisons  are  between  smokers  and  non  smokers.  Ex 
smokers were not included in the formal comparison analyses due to the small 
number  of  subjects  but  some  basic  significance  tests  were  performed. 
Correlations  were  performed  using  Spearman  rank  correlation  testing  (result Chapter 5    135 
derived by this method designated by ρ) and Pearson correlation (result derived 
by this method designated by r). Adjustment for multiple comparisons was not 
performed routinely as all data was treated as exploratory. Correction where 
performed  was  by  the  Bonferonni  method.  α  was  set  at  0.05.  Analysis  was 
performed on SAS v 9.1 (TS1M3) for Windows (SAS Institute Inc., NC, USA) and 
MINITAB 15 (Minitab Inc. State College, PA, USA). 
5.3 Results 
75  volunteers  were  screened  for  suitability.  22  smokers  with  asthma,  21  non 
smokers  with  asthma  and  10  ex smokers  with  asthma  were  recruited  to  the 
study. 20 smokers, 21 non smokers and 10 ex smokers were able to provide a 
suitable  sputum  sample  for  analysis.  18  smokers,  9  ex smokers  and  16  non 
smokers with asthma completed the corticosteroid trial and were able to provide 
a sputum sample. 19 smokers and 20 non smokers with asthma provided plasma 
samples at baseline and 18 smokers and 17 non smokers with asthma provided a 
plasma sample at completion of the corticosteroid trial. 
5.3.1 Baseline demographics 
The recruited subjects were well matched for relevant clinical characteristics 
(tables  5.1,  5.2  &  5.3).  Smokers  with  asthma  had  significantly  higher  daily 
inhaled  corticosteroid  dose  and  asthma  control  questionnaire  scores.  The 
bronchodilator response of smokers with asthma was lower than that observed in 
non smokers  with  asthma.  No  significant  difference  was  evident  for  baseline 
sputum  eosinophil  or  sputum  neutrophil  percentage  when  smokers  and  non 
smokers with asthma were compared (table 5.3). 
5.3.2 Lung function response to oral corticosteroid trial 
Non smokers with asthma made a significant improvement in lung function in 
response to the oral corticosteroid trial (figure 5.1 & table 5.4). This was in 
contrast  to  smokers  and  ex smokers  with  asthma  who  both  failed  to  make  a 
significant  improvement  in  lung  function  in  response  to  oral  corticosteroids. Chapter 5    136 
There was no significant difference present when change in lung function was 
compared between the groups. 
  Smokers 
(n=22) 
Ex-Smokers 
(n=10) 
Non-Smokers 
(n=21) 
Age  
(yrs) 
46.6 
(6.7) 
49.8 
(9.0) 
42.5 
(10.0) 
Sex (F:M)  12:10  5:5  11:10 
BMI  
(kg/m
2) 
26.6 
(6.0) 
31.2 
(5.3) 
28.9 
(5.1) 
Asthma Duration 
(yrs) 
22.1 
(15.9) 
24.6 
(15.9) 
28.6 
(15.0) 
Pack yrs  27.6 
(15.7) 
28.5 
(15.9)   
Ex-smokers (no of yrs)    7.7 
(4.5)   
Inhaled steroid 
(mcg/day) 
   1046 * 
(611) 
1280 
(551) 
679 
(419) 
ACQ Score 
(0 to 6)   
   2.2 * 
(0.9) 
2.3 
(0.7) 
1.5 
(0.8) 
Oral daily 
dexamethasone dose 
(mg) 
6.6 
(0.9) 
7.3 
(0.9) 
7.1 
(0.8) 
Equivalent daily 
prednisolone dose (mg) 
44.1 
(6.1) 
48.3 
(6.1) 
47.1 
(5.0) 
Table 5.1 Baseline demographics.  
Data presented as mean (SD). *; p≤0.05.  
 
 
 
Smokers 
(n=22) 
Ex-Smokers 
(n=10) 
Non-Smokers 
(n=21) 
Pre BD FEV1  
(litres) 
2.24 
(0.58) 
2.47 
(0.79) 
2.43 
(0.69) 
Pre BD FEV1 
(% predicted) 
73.6 
(18.5) 
79.7 
(24.1) 
73.3 
(15.3) 
Pre BD PEF  
(l/min) 
360.5 
(77.8) 
388.0 
(124.8) 
399.1 
(98.6) 
Pre BD PEF  
(% predicted) 
81.7 
(20.8) 
85.4 
(24.7) 
85.8 
(19.1) 
Pre BD FVC 
(litres) 
3.33 
(0.8) 
3.63 
(0.9) 
3.68 
(0.9) 
Pre BD FVC 
(% predicted) 
89.6 
(12.8) 
96.4 
(19.8) 
92.9 
(12.2) 
Pre BD FEV1/FVC  68.1 
(12.1) 
67.5 
(8.3) 
65.9 
(9.9) 
Pre BD FEF25-75 
(% pred) 
44.8 
(19.7) 
49.2 
(24.1) 
42.7 
(16.1) 
FEV1 BD response    15.1 * 
(8.5) 
19.5 
(17.7) 
23.3 
(15.9) 
Table 5.2 Pre steroid lung function.  
Data presented as mean (SD). *; p≤0.05. Chapter 5    137 
 
  Smokers 
(n=20) 
Ex-Smokers 
(n=10) 
Non-Smokers 
(n=21) 
Total cell count (10
6)  
mean (SD) 
6.1 
(6.5) 
8.3 
(9.8) 
7.1 
(14.8) 
Eosinophils %  0.4 
(0.0, 1.0) 
1.0 
(0.1, 5.0) 
0.3 
(0.0, 2.0) 
Eosinophils (10
4)  2.0 
(0.0, 4.0) 
5.0 
(1.0, 23.0) 
1.0 
(0.0, 7.0) 
Neutrophils %  34 
(24, 56) 
37 
(22, 63) 
24 
(11, 41) 
Neutrophils (10
4)  125.0 
(77, 240) 
151.0 
(99, 304) 
106.5 
(39, 178) 
Macrophages %  37 
(25, 61) 
31 
(27, 60) 
45 
(32, 61) 
Macrophages (10
4)  168.0 
(106, 243) 
132.0 
(82, 199) 
121.0 
(78, 254) 
Lymphocytes %  0.1 
(0, 0.6) 
0.0 
(0, 0) 
0.0 
(0, 0.5) 
Lymphocytes (10
4)  1.0 
(0.0, 3.0) 
0.0 
(0.0, 0.0) 
0.0 
(0.0, 2.0) 
Bronchial epithelial cells %  16 
(9, 26) 
23 
(12, 31) 
23 
(12, 31) 
Bronchial  epithelial  cells 
(10
4) 
59.0 
(25, 98) 
57.0 
(24, 60) 
55.0 
(40, 109) 
Table 5.3 Baseline sputum profiles.  
Data presented as median (IQR) except where indicated 
 
 
 
Lung function response  
(FEV1 (ml)) 
(95% CI) 
 
Non-smokers with asthma    173 * 
(10, 336) 
Ex-smokers with asthma  257 
(-154, 667) 
Smokers with asthma  32 
(-115, 178) 
Table 5.4 Within group lung function response to oral steroid.  
Data presented as mean change (95% CI). *; p<0.05 
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Figure 5.1 Within group change in FEV1 in response to oral steroid trial.  
Data  presented  as  mean  (95%  CI).  Interval  bars  represent  95%  confidence  intervals  and 
mean. *; p<0.05. 
 
5.3.3 Change  in  sputum  cell  profile  in  response  to  oral 
corticosteroid trial 
All groups demonstrated significant within group eosinophil changes in response 
to oral corticosteroids. The eosinophil response of smokers with asthma to the 
corticosteroid trial was equivalent to that observed in non smokers with asthma 
(smokers  change   0.4%  (95%  CI   0.8,  0.0),  non smokers   0.2%  ( 2.0,  0.0), 
p=0.430).  Smokers  with  asthma  also  demonstrated  a  trend  to  a  reduction  in 
sputum  neutrophil  percentage  following  oral  corticosteroids  (change   12.0%  ( 
25.01, 1.99), p=0.081). However no difference was evident when compared to the 
neutrophil change observed in non smokers. No significant changes were evident 
within or between the groups for the other sputum cell subtypes in response to 
the oral corticosteroid trial. 
*  Change  
in FEV1  
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5.3.4 Change in asthma control questionnaire score 
No  improvement  was  detected  in  asthma  symptoms  as  measured  by  asthma 
control questionnaire score (ACQ) in smokers with asthma in response to oral 
corticosteroids  (change   0.1  (95%  CI   0.7,  0.6),  p=0.804).  Non smokers  with 
asthma did demonstrate a reduction in ACQ score but this was less than the 
minimal  clinically  significant  reduction  of 0.5  (254)  (change   0.4  ( 0.7,   0.0), 
p=0.031).  Ex smokers  demonstrated  a  large  and  significant  reduction  in  ACQ 
score (change  1.0 ( 1.8,  0.1), p=0.029). No significant difference was present 
when  change  in  ACQ  score  in  non smokers  and  smokers  with  asthma  was 
compared.  
Change in ACQ score demonstrated a significant negative correlation with lung 
function  improvement  for  non smokers  and  ex smokers  with  asthma.  The 
correlation between ACQ score and lung function change in smokers with asthma 
demonstrated a trend to improvement: 
•  Non smokers; r =  0.63, p=0.007 
•  Ex smokers; r =  0.69, p=0.039 
•  Smokers; r =  0.42, p=0.062 
5.3.5 Sputum supernatant cytokines 
The majority of the sputum cytokines detectable by  the Luminex assay were 
measurable in the majority of subjects (table 5.5). Expression levels were close 
to the limit of detectability for IL 4 in all groups, IFN γ in non smokers and ex 
smokers with asthma & IL 15 in non smokers with asthma. 
Smokers with asthma tended to a higher median concentration for all cytokines 
and had significantly higher levels (relative to non smokers with asthma) for: 
•  IFN γ (smokers with asthma 2.6 pg/ml (IQR 0.7, 7.7), non smokers 0.3 
pg/ml (IQR 0.3, 0.3), p=0.025) (figure 5.2),  
•  IL 2 (4.4 pg/ml (3.7, 6.5), 3.6 pg/ml (3.3, 4.5), p=0.041) (figure 5.3),  Chapter 5    140 
•  IL 4 (0.1 pg/ml (0.1, 4.9), 0.1 pg/ml (0.1, 0.1), p=0.038) (figure 5.4),  
•  IL 6 (34.4 pg/ml (14.1, 72.4), 8.1 pg/ml (4.4, 11.1), p<0.001) (figure 5.5),  
•  IL 7  (28.5  pg/ml  (14.0,  65.6),  16.3  pg/ml  (6.6,  18.8),  p=0.044)  (figure 
5.6),  
Sputum IL 12 and IL 17 levels demonstrated a trend  to a difference between 
smokers and non smokers with asthma (IL 12; smokers 30.6 pg/ml (12.6, 49.6), 
non smokers 15.5 pg/ml (8.7, 22.2), p=0.050, IL 17; smokers 44.9 pg/ml (4.0, 
146.1), non smokers 4.0 pg/ml (4.0, 16.3), p=0.080). Performing corrections for 
multiple  comparisons  resulted  in  all  sputum  cytokine  differences  losing 
statistical significance save sputum IL 6 (p=0.023).  
Adjusting for inhaled corticosteroid dose did not remove any of the differences 
and strengthened several. For example sputum IL 12 and IL17 were significantly 
higher in smokers with asthma as a result of this change (IL 12; adjusted mean 
difference  37.2  pg/ml  (95%  CI  7.4,  67.1),  p=0.016,  IL 17;  102.4  pg/ml  (14.9, 
190.0), p=0.023). 
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Figure 5.2 Baseline sputum supernatant IFNγ.  
Data presented as individual points with median. 
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  Smokers  Ex-Smokers  Non-Smokers 
Eotaxin  2.6 
(0.7, 7.7) 
4.6 
(0.7, 5.5) 
1.1 
(0.3, 2.1) 
GM-CSF  21.5 
(8.4, 76.1) 
20.1 
(6.6, 96.9) 
17.0 
(6.6, 26.1) 
IFN-α  24.5 
(20.8, 55.5) 
24.5 
(20.8, 85.5) 
20.8 
(16.8, 27.9) 
IFN-γ     2.6 * 
(0.3, 13.2) 
0.3 
(0.3, 25.0) 
0.3 
(0.3, 0.3) 
IL-1RA  12480 
(3475, 18561) 
5205 
(3808, 7943) 
3448 
(2173, 8428) 
IL-1β  19.4 
(14.1, 34.4) 
16.7 
(15.4, 42.1) 
16.7 
(12.7, 20.7) 
IL-2     4.4 * 
(3.7, 6.5) 
3.8 
(3.3, 5.1) 
3.6 
(3.3, 4.5) 
IL-2R  105.8 
(11.9, 287.8) 
163.7 
(113.0, 568.1) 
40.2 
(11.9, 132.3) 
IL-4     0.1 * 
(0.1, 4.9) 
0.1 
(0.1, 2.0) 
0.1 
(0.1, 0.1) 
IL-5  4.7 
(2.8, 10.6) 
3.5 
(3.1, 6.6) 
3.1 
(2.4, 4.2) 
IL-6     34.4 * 
(14.1, 72.4) 
34.9 
(13.6, 148.9) 
8.1 
(4.4, 11.1) 
IL-7     28.5 * 
(14.0, 65.6) 
36.2 
(14.5, 59.0) 
16.3 
(6.6, 18.8) 
IL-8  1096 
(398, 3059) 
1715 
(476, 5862) 
650 
(332, 1030) 
IL-10  3.2 
(1.8, 9.4) 
3.2 
(1.8, 6.4) 
1.8 
(1.5, 2.4) 
IL-12    30.6 
† 
(12.6, 49.6) 
23.6 
(12.6, 56.8) 
15.5 
(8.7, 22.2) 
IL-13  29.4 
(20.5, 47.6) 
29.9 
(22.5, 57.7) 
24.4 
(20.5, 28.1) 
IL-15  13.5 
(0.6, 45.8) 
14.5 
(0.6, 79.8) 
0.6 
(0.6, 7.0) 
IL-17  44.9 
(4.0, 146.1) 
36.3 
(4.0, 164.0) 
4.0 
(4.0, 16.3) 
IP-10  52.6 
(31.6, 104.5) 
192.6 
(54.0, 327.1) 
59.8 
(26.3, 90.2) 
MCP-1  298.4 
(162.5, 396.2) 
317.2 
(189.6, 452.6) 
192.8 
(140.6, 214.8) 
MIG  127.9 
(50.8, 239.3) 
191.1 
(94.4, 229.0) 
124.8 
(47.8, 146.5) 
MIP-1α  26.9 
(16.5, 62.9) 
45.4 
(29.0, 71.2) 
20.8 
(17.4, 29.0) 
MIP-1β  30.1 
(19.3, 86.7) 
128.1 
(43.0, 352.1) 
27.8 
(17.6, 38.8) 
RANTES  42.8 
(32.0, 64.1) 
58.4 
(38.1, 107.5) 
37.3 
(23.0, 44.9) 
TNF-α  3.7 
(1.7, 7.6) 
4.0 
(2.5, 6.5) 
2.2 
(1.9, 2.8) 
Table 5.4 Sputum cytokine results-Baseline comparisons.  
Data presented as median (IQR). All pg/ml. *; p≤0.05, 
†; p=0.05 Chapter 5    142 
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Figure 5.3 Baseline sputum supernatant IL-2.  
Data presented as individual points with median.  
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Figure 5.4 Baseline sputum supernatant IL-4.  
Data presented as individual points with median.  
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Figure 5.5 Baseline sputum supernatant IL-6.  
Data presented as individual points with median.  
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Figure 5.6 Baseline sputum supernatant IL-7.  
Data presented as individual points with median.  
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5.3.5.1  Baseline sputum cytokine correlations 
Smokers with asthma demonstrated a number of significant correlations between 
sputum cytokine concentrations and clinical endpoints: 
•  Sputum  IL 6  and  IL 8  demonstrated  negative  correlations  with  baseline 
pre bronchodilator FEV1: 
o  IL 6; ρ=  0.47 (95% CI  0.75,  0.03), p=0.032 (Figure 5.7) 
o  IL 8; ρ=  0.46 ( 0.75,  0.03), p=0.034  
•  Sputum IL 6 and 8 also demonstrated positive correlations with subject 
age: 
o  IL 6; ρ= 0.45 (0.01, 0.75), p=0.039 
o  IL 8; ρ= 0.59 (0.21, 0.82), p=0.004  
•  Sputum IL 6 correlated negatively with exhaled nitric oxide (FENO) levels 
(ρ=  0.54 ( 0.81,  0.08), p=0.020) 
•  Sputum IL 8 levels correlated positively with baseline ACQ score (ρ= 0.45 
(0.01, 0.75), p=0.040) 
•  Sputum IL 8 correlated positively with pack years (ρ= 0.62 (0.25, 0.84), 
p=0.002) 
•  Sputum IL 1RA demonstrated a positive correlation with asthma duration 
(ρ= 0.44 ( 0.01, 0.74), p=0.048) 
•  Sputum MIP1α and MIP1β levels both correlated positively with subject 
age (MIP1α; ρ= 0.47 (0.03, 0.75) p=0.032, MIP1β; ρ= 0.50 (0.07, 0.77), 
p=0.020) 
No correlation was evident between sputum IL 6 and pack years in smokers with 
asthma (ρ=0.35 ( 0.11, 0.69), p=0.124). Chapter 5    145 
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Figure 5.7 Scatter plot of smokers with asthma pre-steroid sputum Log IL-6 against pre-
bronchodilator pre-corticosteroid trial FEV1.   
 
Sputum cytokines from non smokers with asthma also demonstrated correlations 
with some clinical endpoints: 
•  Sputum IFNγ correlated positively with baseline pre bronchodilator FEV1 
(ρ= 0.44 (0.01, 0.73), p=0.041), and negatively with percentage change in 
FEV1 in response to corticosteroids (ρ=  0.53 ( 0.80,  0.09), p=0.018) 
Multiple negative correlations were evident between sputum cytokines from non 
smokers with asthma and asthma duration: 
•  IL 1β; ρ=  0.48 ( 0.75,  0.05), p=0.025  
•  IL 2; ρ=  0.52 ( 0.78,  0.12), p=0.012 
•  IL 5; ρ=  0.66 ( 0.85,  0.33), p<0.001 
•  IL 10; ρ=  0.62 ( 0.83,  0.26), p=0.002 
•  IL 13; ρ=  0.42 ( 0.72, 0.01), p=0.049 
•  GM CSF; ρ=  0.47 ( 0.75,  0.04), p=0.029 
ρ= -0.47 (95% CI -0.75, -0.03), p=0.032 
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•  IFNα; ρ=  0.59 ( 0.81,  0.21), p=0.003 
•  MIP1α; ρ=  0.56 ( 0.80,  0.16), p=0.007 
•  MIP1β; ρ=  0.46 ( 0.75,  0.04), p=0.029  
Sputum cytokines from ex smokers with asthma also demonstrated a number of 
correlations. Negative correlations were present between sputum IL 8 and MCP 1 
and FENO: 
•  IL 8 and FENO; ρ=  0.71 ( 0.93,  0.09), p=0.022 
•  MCP 1 and FENO; ρ= 0.69 ( 0.93,  0.06), p=0.027 
Positive correlations were present between IL 6, MIP1α, MIP1β and baseline ACQ 
score in ex smokers with asthma: 
•  IL 6 and ACQ; ρ= 0.68 (0.09, 0.92), p=0.021 
•  MIP1α and ACQ; ρ= 0.63 ( 0.01, 0.90), p=0.042 
•  MIP1β and ACQ; ρ= 0.67 (0.08, 0.92) p=0.023 
IL 6  and  asthma  duration  also  positively  correlated  (ρ=  0.67  (0.07,  0.91), 
p=0.024) and a strong correlation was present between sputum IL 6 and pack 
years (ρ= 0.68 (0.09, 0.92), p=0.022) in ex smokers with asthma. 
5.3.6 Baseline plasma cytokines 
Several  differences  in  median  plasma  cytokine  concentrations  were  evident 
when smokers and non smokers with asthma were compared (table 5.6). Smokers 
demonstrated significantly reduced median plasma levels of IL 1RA, 10 & 13 and 
GM CSF: 
•  IL 1RA; smokers 209 pg/ml (IQR 160, 252) non smokers 247 pg/ml (IQR 
224, 279), p=0.024 (Figure 5.8) 
•  IL 10; smokers 1.5 pg/ml (1.4, 1.7), non smokers 1.7 pg/ml (1.5, 2.6), 
p=0.027 (Figure 5.9) Chapter 5    147 
•  IL 13; smokers 19.5 pg/ml (17.4, 21.5), non smokers 21.5 pg/ml (20.0, 
23.4), p=0.004 (Figure 5.10) 
•  GM CSF; smokers 6.6 pg/ml (5.1, 13.0), non smokers 10.3 pg/ml (10.3, 
26.1), p= 0.028 (Figure 5.11) 
A  borderline  significant  difference  in plasma  IL 12  was  also  present  (smokers 
69.1  pg/ml  (46.0,  76.1),  non smokers  70.9  pg/ml  (64.3,  85.7),  p=0.053). 
Correcting for multiple comparisons resulted in all plasma cytokine differences 
losing statistical significance. 
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Figure 5.8 Baseline plasma IL-1RA levels in non-smokers with asthma and smokers with 
asthma. 
Data presented as individual points with median.  
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  Smokers  Non 
Smokers 
Eotaxin  88.8 
(50.7, 129.5) 
75.4 
(42.7, 86.0) 
GM-CSF     6.6 * 
(5.1, 13.0) 
10.3 
(10.3, 26.1) 
IFN-α  31.2 
(24.5, 34.3) 
32.7 
(28.7, 38.6) 
IFN-γ  2.0 
(0.3, 4.2) 
2.6 
(0.6, 4.2) 
IL-1RA     209 * 
(160, 252) 
247 
(224, 279) 
IL-1β  13.4 
(10.7, 20.1) 
15.4 
(12.7, 18.7) 
IL-2  4.4 
(3.7, 5.6) 
5.0 
(4.6, 6.6) 
IL-2R  294 
(165, 354) 
251 
(214, 306) 
IL-4  9.7 
(6.3, 11.3) 
10.5 
(8.7, 12.7) 
IL-5  2.5 
(2.2, 2.7) 
2.5 
(2.5, 2.9) 
IL-6  1.5 
(1.2, 2.4) 
1.7 
(1.3, 3.2) 
IL-7  16.3 
(7.7, 18.0) 
19.7 
(14.9, 25.0) 
IL-8  5.1 
(3.6, 6.8) 
6.1 
(3.6, 8.0) 
IL-10    1.5 * 
(1.4, 1.7) 
1.7 
(1.5, 2.6) 
IL-12    69.1 
† 
(46.0, 76.1) 
70.9 
(64.3, 85.7) 
IL-13    19.5 * 
(17.4, 21.5) 
21.5 
(20.0, 23.4) 
IL-15  4.1 
(0.6, 8.0) 
7.5 
(1.4, 9.9) 
IL-17  22.6 
(8.6, 47.7) 
33.4 
(16.3, 56.2) 
IP-10  10.0 
(8.1, 17.0) 
14.5 
(10.8, 17.9) 
MCP-1  175 
(116, 259) 
165 
(148, 234) 
MIG  12.0 
(12.0, 12.0) 
12.0 
(12.0, 13.7) 
MIP-1α  24.1 
(19.1, 25.7) 
24.1 
(24.1, 27.3) 
MIP-1β  27.8 
(24.4, 31.3) 
31.3 
(27.2, 35.3) 
RANTES  4639 
(3654, 6269) 
6387 
(4300, 9426) 
TNF-α  2.7 
(2.1, 2.9) 
2.9 
(2.5, 3.2) 
Table 5.6 Baseline plasma cytokines.  
All pg/ml. Expressed as median (IQR). *; p≤0.05, 
†; p=0,05 
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Figure  5.9  Baseline  plasma  IL-10  levels  in  non-smokers  with  asthma  and  smokers  with 
asthma.  
Data presented as individual points with median.  
 
Smokers Non smokers
35
30
25
20
15
10
I
L
 
1
3
 
(
p
g
/
m
l
)
 
Figure  5.10  Baseline  plasma  IL-13  levels  in  non-smokers  with  asthma  and  smokers  with 
asthma.  
Data presented as individual points with median.  
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Figure 5.11 Baseline plasma GM-CSF levels in non-smokers with asthma and smokers with 
asthma. 
Data presented as individual points with median.  
 
5.3.6.1  Baseline plasma cytokine correlations  
A number of correlations were present between baseline plasma cytokines and 
clinical characteristics.  
IL2 and IL2R correlated with pre corticosteroid pre BD FEV1 in smokers with 
asthma: 
•  IL 2; ρ=  0.46 (95% CI  0.76,  0.01), p=0.040 
•  IL 2R; ρ=  0.62 ( 0.84,  0.24), p=0.003 
A  trend  to  statistical  significance  was  evident  for  the  correlation  between 
plasma IL 6 and IL 12 and pre corticosteroid pre BD FEV1 in the smokers with 
asthma: 
•  IL 6; ρ=  0.42 ( 0.73, 0.05), p=0.068 
p=0.028 Chapter 5    151 
•  IL 12; ρ=  0.39 ( 0.72, 0.07), p=0.087 
Multiple correlations were also evident between baseline plasma cytokines from 
smokers with asthma and FEV1 response to oral corticosteroid: 
•  IFN α; ρ= 0.45 ( 0.01, 0.75), p=0.049 
•  IL 1RA; ρ= 0.68 (0.33, 0.87), p<0.001 
•  IL 1β; ρ= 0.62 (0.23, 0.84), p=0.003 
•  IL 2; ρ= 0.58 (0.17, 0.82), p=0.007 
•  IL 5; ρ= 0.60 (0.20, 0.83), p=0.004 
•  MIP 1α; ρ= 0.48 (0.03, 0.77), p=0.033 
•  IL 12; ρ= 0.55 (0.13, 0.80), p=0.011 
•  IL 15; ρ= 0.63 (0.25, 0.84), p=0.002 
Further  correlations  were  observed  between  FENO  and  smokers  with  asthma 
plasma cytokines: 
•  IL 17; ρ= 0.60 (0.17, 0.84), p=0.008 
•  RANTES; ρ=  0.59 ( 0.83,  0.15), p=0.009 
No correlation was evident between plasma IL 6 and pack years in the smokers 
with asthma (ρ=  0.31 ( 0.67, 0.17), p=0.194).  
Non smokers also demonstrated correlations for plasma cytokines but these were 
with different clinical parameters. Correlations existed between ACQ score at 
baseline and non smokers with asthma plasma cytokines for: 
•  IL 8; ρ= 0.44 (0.00, 0.74), p=0.043 
•  MCP 1; ρ= 0.57 (0.16, 0.81), p=0.007 
A borderline significant correlation was also present between IFNγ and baseline 
ACQ  score  (ρ=  0.43  ( 0.02,  0.73),  p=0.055).  Non  smokers  with  asthma Chapter 5    152 
demonstrated a significant correlation between plasma IFNγ and subject age (ρ= 
 0.48 ( 0.76,  0.05), p=0.027) and several correlations between plasma cytokines 
and asthma duration: 
•  IL 2; ρ=  0.52 ( 0.78,  0.10), p=0.015 
•  MCP 1; ρ=  0.45 ( 0.74,  0.01), p=0.041 
•  MIP 1β; ρ=  0.44 ( 0.74, 0.00), p=0.047 
A borderline correlation was also evident between IL 1β and asthma duration (ρ= 
 0.42 ( 0.73, 0.02), p=0.056). 
5.3.7 Correlation between sputum cytokines 
When  sputum  cytokine  relationships  were  examined,  using  the  data  from  all 
groups combined, a number of strongly significant relationships were evident. 
Sputum IL 2 & 4 demonstrated a strong correlation (ρ=0.73, p<0.001) and IFNγ 
correlated strongly with IL 2 (ρ=0.74, p<0.001), IL 4 (ρ=0.95, p<0.001) and IL 12 
(ρ=0.79, p<0.001). Sputum IL 6 correlated weakly with IL 17 (ρ= 0.29, p=0.039) 
and strongly with IL 8 (ρ= 0.70, p<0.001) and MCP 1 (ρ= 0.74, p<0.001). 
5.3.8 Correlation between plasma and sputum cytokines 
When the correlations between plasma and sputum cytokines from all subjects 
were  examined  only  two  statistically  significant  correlations  were  present. 
Plasma and sputum eotaxin demonstrated a positive correlation (ρ= 0.66 (95% CI 
0.43,  0.81),  p<0.001).  Plasma  and  sputum  RANTES  demonstrated  a  negative 
correlation  (ρ=   0.33  ( 0.59,   0.01),  p=0.041).  A  number  of  cytokines 
demonstrated borderline significant associations: 
•  IL 1RA; ρ=  0.28 ( 0.55, 0.05), p=0.090 
•  IL 2; ρ= 0.29 ( 0.04, 0.56), p=0.079 
•  IL 7; ρ=  0.30 ( 0.57, 0.02), p=0.065 
•  MIG; ρ= 0.31 ( 0.02, 0.57), p=0.061 Chapter 5    153 
•  MIP1α; ρ= 0.29 ( 0.04, 0.56), p=0.080 
Non smokers with asthma demonstrated a significant correlation between plasma 
and sputum eotaxin (ρ= 0.54 (0.12, 0.79), p=0.011) and borderline significant 
correlations between plasma and sputum: 
•  GM CSF; ρ= 0.38 ( 0.08, 0.70), p=0.094 
•  IL 2; ρ= 0.39 ( 0.06, 0.71), p=0.078 
•  IL 15; ρ= 0.40 ( 0.05, 0.72), p=0.072 
•  MIG; ρ= 0.43 ( 0.02, 0.73), p=0.055 
•  MIP1α; ρ= 0.40 ( 0.05, 0.72), p=0.074 
•  MIP1β; ρ= 0.38 ( 0.08, 0.70), p=0.092 
Smokers  with  asthma  also  demonstrated  a  significant  correlation  between 
plasma  and  sputum  eotaxin  (ρ=  0.63  (0.22,  0.85),  p=0.004)  and  further 
significant correlations for IL 1RA (ρ=  0.56 ( 0.82,  0.11), p=0.015) and IL 2 (ρ= 
0.51  (0.04,  0.80),  p=0.029).  No  borderline  significant  correlations  between 
plasma and sputum cytokines were evident for smokers with asthma. 
5.3.9 Cytokine response to oral corticosteroid trial 
5.3.9.1  Sputum cytokine responses 
When  examined  post  corticosteroid  trial  sputum  median  cytokine  levels 
demonstrated  significant  differences  between  smokers  and  non  smokers  with 
asthma for IL 1RA and eotaxin and a failure of sputum IL 6 levels to normalise 
(table 5.7 and figure 5.12): 
•  IL1RA; smokers 16140 pg/ml (IQR 4208, 23359), non smokers 4838 pg/ml 
(IQR 2626, 7892), p=0.033 
•  Eotaxin;  smokers  4.2  pg/ml  (1.5,  9.9),  non smokers  0.8  (0.2,  1.7), 
p=0.012 
•  IL 6;  smokers  24.3  pg/ml  (17.5,  74.2),  non smokers  7.3  (2.2,  21.1), 
p=0.027 Chapter 5    154 
A borderline difference was still present for sputum IL 12 (smokers 41.5 (20.3, 
114.0), non smokers 18.4 (7.7, 52.7), p=0.080).  
Smokers post steroid Smokers pre steroid
600
500
400
300
200
100
0
I
L
-
6
 
(
p
g
/
m
l
)
 
Figure 5.12 Comparison of pre steroid and post steroid sputum IL-6 in smokers with asthma 
Data presented as individual points with median.  
 
Few statistically significant within group changes were evident in response to 
oral corticosteroids. Smokers with asthma demonstrated an increase in sputum 
IFNα (53.5 pg/ml (95% CI 12.1, 94.8), p=0.014) and IL 17 (119.6 pg/ml (30.7, 
208.5),  p=0.011).  A  smaller  but  non significant  increase  was  also  evident  for 
these cytokines in the non smokers in response to the corticosteroid trial (IFNα; 
24.5 pg/ml ( 4.2, 53.3), p=0.089, IL 17; 67.4 pg/ml ( 8.5, 143.3), p=0.078). An 
increase in MIP1β was detected in the non smokers with asthma (31.6 pg/ml 
(4.6,  58.5),  p=0.025).  No  significant  differences  were  evident  for  change  in 
sputum  cytokines  in  smokers  with  asthma  compared  to  non  smokers  with 
asthma. 
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  Smokers  Ex 
Smokers 
Non 
Smokers 
Eotaxin     4.2 * 
(1.5, 9.9) 
1.9 
(1.1, 6.1) 
0.8 
(0.2, 1.7) 
GM-CSF  56.4 
(10.3, 144.9) 
38.6 
(23.1, 180.2) 
31.7 
(8.4, 102.8) 
IFN-α  58.5 
(20.8, 137.2) 
48.1 
(27.9, 122.9) 
31.2 
(18.8, 74.2) 
IFN-γ  6.2 
(0.3, 47.4) 
0.3 
(0.3, 68.5) 
0.3 
(0.3, 26.9) 
IL-1RA     16140 * 
(4208, 23359) 
12168 
(7528, 14239) 
4838 
(2626, 7892) 
IL-1β  28.9 
(14.7, 82.4) 
62.4 
(20.7, 83.0) 
18.1 
(12.4, 40.9) 
IL-2  5.2 
(3.6, 10.6) 
4.5 
(3.6, 11.8) 
4.2 
(3.3, 5.4) 
IL-2R  132.1 
(5.0, 834.3) 
113.0 
(40.2, 976.8) 
60.3 
(5.0, 529.9) 
IL-4  3.5 
(0.1, 22.0) 
0.1 
(0.1, 25.2) 
0.1 
(0.1, 7.6) 
IL-5  6.5 
(2.9, 26.2) 
3.8 
(3.5, 24.0) 
3.8 
(2.4, 10.2) 
IL-6     24.3 * 
(17.5, 74.2) 
16.0 
(4.4, 52.4) 
7.3 
(2.2, 21.1) 
IL-7  22.6 
(9.7, 66.6) 
29.3 
(8.7, 63.5) 
12.6 
(5.8, 38.1) 
IL-8  1389 
(329, 3325) 
681 
(409, 1867) 
400 
(209, 1280) 
IL-10  5.6 
(1.5, 11.8) 
4.8 
(1.6, 10.9) 
2.1 
(1.5, 7.1) 
IL-12  41.5 
(20.3, 114.0) 
33.3 
(18.4, 113.2) 
18.4 
(7.7, 52.7) 
IL-13  45.5 
(20.5, 97.3) 
35.3 
(28.1, 103.1) 
25.8 
(21.5, 68.7) 
IL-15  16.5 
(0.6, 112.9) 
19.0 
(0.6, 152.1) 
3.1 
(0.6, 67.9) 
IL-17  116.4 
(4.0, 303.6) 
86.3 
(4.0, 312.0) 
16.2 
(4.0, 201.2) 
IP-10  15.2 
(7.2, 29.9) 
16.4 
(9.9, 23.6) 
16.4 
(6.4, 63.9) 
MCP-1  345 
(185, 492) 
269 
(168, 383) 
184 
(124, 305) 
MIG  73.6 
(12.0, 231.6) 
157.3 
(47.8, 239.3) 
60.1 
(24.9, 164.8) 
MIP-1α  41.9 
(17.4, 96.6) 
82.6 
(22.4, 146.7) 
26.1 
(17.4, 57.0) 
MIP-1β  47.1 
(21.0, 109.0) 
59.1 
(38.3, 113.4) 
36.5 
(14.9, 85.0) 
RANTES  29.3 
(19.5, 54.8) 
31.1 
(20.0, 59.2) 
32.5 
(12.4, 47.8) 
TNF-α  5.0 
(1.9, 11.3) 
11.8 
(2.6, 15.5) 
2.6 
(1.9, 7.1) 
Table 5.7 Post steroid trial sputum cytokines.  
Data presented as median pg/ml (IQR). *; p<0.05  
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5.3.9.2   Plasma cytokine responses to oral corticosteroids 
The difference between smokers and non smokers for plasma IL 1RA and IL 13 
was still present post oral corticosteroids. The difference between smokers and 
no smokers  for  plasma  GM CSF  and  IL 10  was  narrowed  as  a  result  of  oral 
corticosteroids and lost statistical significance. However other plasma cytokines 
changed  in  response  to  the  oral  corticosteroid  trial  resulting  in  significant 
differences becoming evident when smokers and non smokers with asthma were 
compared (table 5.8): 
•  IFNα; smokers 29.5 pg/ml (IQR 24.5, 34.3), non smokers 34.3 pg/ml (IQR 
31.2, 37.2), p=0.035 
•  IL 5;  smokers  2.2  pg/ml  (1.9,  2.2),  non  smokers  2.5  pg/ml  (2.2,  2.5), 
p=0.006 
•  IL 7; smokers 7.6 pg/ml (6.8, 14.5), non smokers 15.4 pg/ml (13.5, 17.1), 
p=0.019 
•  MIP 1α; smokers 20.8 pg/ml (20.8, 22.4), non smokers 24.1 pg/ml (22.4, 
27.3), p=0.016 
•  MIP 1β; smokers 24.4 pg/ml (21.5, 30.1), non smokers 30.1 pg/ml (27.8, 
32.4), p=0.011 
•  TNFα;  smoker  2.1  pg/ml  (1.9,  2.5),  non  smokers  2.7  pg/ml  (2.4,  2.9), 
p=0.007 
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  Smokers  Non 
Smokers 
Eotaxin  149.2 
(97.9, 208.3) 
101.1 
(82.5, 123.5) 
GM-CSF  10.3 
(5.1, 11.6) 
10.3 
(6.6, 18.6) 
IFN-α     29.5 * 
(24.5, 34.3) 
34.3 
(31.2, 37.2) 
IFN-γ  1.0 
(0.3, 2.0) 
0.5 
(0.3, 3.1) 
IL-1RA     142.1 * 
(116.6, 178.5) 
178.5 
(160.3, 214.9) 
IL-1β  12.0 
(9.3, 16.1) 
13.4 
(12.7, 19.4) 
IL-2    4.4 
† 
(3.8, 5.3) 
5.0 
(4.4, 7.2) 
IL-2R  176.6 
(132.2, 220.3) 
195.4 
(170.3, 232.6) 
IL-4  6.3 
(4.8, 9.3) 
7.3 
(5.3, 11.3) 
IL-5     2.2 * 
(1.9, 2.2) 
2.5 
(2.2, 2.5) 
IL-6  1.4 
(1.1, 1.8) 
1.6 
(1.2, 4.5) 
IL-7      7.6 * 
(6.8, 14.5) 
15.4 
(13.5, 17.1) 
IL-8  4.3 
(3.1, 4.8) 
4.0 
(2.9, 6.1) 
IL-10  1.4 
(1.4, 1.7) 
1.5 
(1.5, 2.4) 
IL-12  58.1 
(39.8, 63.8) 
53.2 
(47.8, 59.4) 
IL-13    19.5 * 
(17.4, 21.5) 
21.5 
(19.5, 25.3) 
IL-15  1.3 
(0.6, 4.0) 
2.2 
(0.6, 11.9) 
IL-17  6.1 
(4.0, 39.6) 
28.3 
(4.0, 38.5) 
IP-10     3.9 * 
(3.2, 5.4) 
6.4 
(4.3, 9.7) 
MCP-1  116.8 
(92.1, 181.5) 
122.3 
(103.7, 192.3) 
MIG  12.0 
(12, 12) 
12.0 
(12, 12) 
MIP-1α     20.8 * 
(20.8, 22.4) 
24.1 
(22.4, 27.3) 
MIP-1β     24.4 * 
(21.5, 30.1) 
30.1 
(27.8, 32.4) 
RANTES  3273 
(2888, 4134) 
4773 
(3390, 5449) 
TNF-α     2.1 * 
(1.9, 2.5) 
2.7 
(2.4, 2.9) 
Table 5.8 Post steroid trial plasma cytokines.  
Data presented as median pg/ml (IQR). *; p<0.05  Chapter 5    158 
Examination  of  within  group  changes  demonstrated  that  a  number  of  plasma 
cytokines changed in response to oral corticosteroid trial. Smokers with asthma 
demonstrated an increase in plasma eotaxin (48.5 pg/ml (95% CI 23.6, 73.4), 
p=0.001) and reduction in: 
•  IFNγ;  1.5 pg/ml (95%CI  2.7, 0.2), p=0.022 
•  IL 2R;  88.8 pg/ml ( 137.4,  40.1), p=0.001 
•  IL 4;  3.2 pg/ml ( 5.2,  1.3), p=0.003 
•  IL 5;  0.5 pg/ml ( 0.8,  0.2), p=0.003 
•  IL 7;  5.1 pg/ml ( 10.2,  0.0), p=0.049 
•  IL 8;  1.9 pg/ml ( 2.8,  0.9), p=0.001 
•  IL 12;  7.7 pg/ml ( 12.0,  3.4), p=0.002 
•  IP 10;  7.6 pg/ml ( 10.0,  5.2), p<0.001 
•  MCP 1;  59.2 pg/ml ( 109.3,  9.0), p=0.024 
•  MIP1β;  3.7 pg/ml ( 6.5,  0.9), p=0.014 
•  RANTES;  2207 pg/ml ( 3706,  707), p=0.007 
Non  smokers  with  asthma  also  made  a  number  of  significant  within  group 
changes in response to oral corticosteroid. Plasma eotaxin increased (36.8 pg/ml 
(95% CI 21.0, 52.6), p<0.001) and reductions were evident in: 
•  IL 1RA;  71.7 pg/ml (95% CI  123.9,  19.5), p= 0.010 
•  IL 2R;  54.7 pg/ml ( 95.4,  13.9), p=0.012 
•  IL 4;  2.4 pg/ml ( 4.6,  0.3), p=0.027 
•  IL 8;  1.2 pg/ml ( 2.3,  0.1), p=0.033 
•  IL 12;  20.8 pg/ml ( 31.3,  10.4), p=0.001 
•  IP 10;  5.9 pg/ml ( 10.3,  1.6), p=0.011 Chapter 5    159 
•  RANTES;  2106 pg/ml ( 3961,  252), p=0.029 
Comparison of the within group changes in plasma cytokines demonstrated that 
plasma  IL 12  was  reduced  to  a  greater  degree  in  non smokers  with  asthma 
compared to smokers with asthma in response to the oral corticosteroid trial 
(non smokers change  19.0 pg/ml ( 26.5,  6.6), smokers  8.9 pg/ml ( 11.5,  1.1), 
p=0.025). 
5.3.10  IL-6 high sensitivity ELISA 
5.3.10.1  ELISA results 
A high sensitivity ELISA was performed to examine the IL 6 sputum supernatant 
result obtained by Luminex. By this method smokers with asthma again had a 
higher  median  concentration  of  sputum  IL 6  compared  to  non smokers  with 
asthma at baseline (smokers 14.5 pg/ml (IQR 9.1, 59.9), non smokers 3.1 pg/ml 
(IQR 0.4, 6.6), p<0.001) and post oral corticosteroids (smokers 10.0 pg/ml (2.7, 
33.5), non smokers 3.1 pg/ml (0.0, 8.9), p=0.041) (table 5.9 & figure 5.13). Ex 
smokers levels of sputum IL 6 appeared to be equivalent to smokers with asthma 
at baseline. Post oral corticosteroid trial the ex smokers appeared to have a 
sputum IL 6 level closer to non smokers with asthma. 
High  dose  oral  corticosteroids  did  not  reduce  sputum  IL 6  levels  in  smokers 
(Change  17.4 pg/ml (95% CI  58.0, 23.1), p=0.376) and non smokers with asthma 
(Change 7.1 pg/ml ( 9.7, 23.1), p=0.383). 
 
Smokers  Ex-smokers  Non-Smokers 
Pre-steroid IL-6 
(pg/ml) 
  14.5 
‡
 
(9.1, 59.9) 
11.6 
(4.3, 50.3) 
3.1 
(0.4, 6.6) 
Post steroid IL-6 
(pg/ml) 
  10.0 * 
(2.7, 33.5) 
2.9 
(0.4, 23.9) 
3.1 
(0.0, 8.9) 
Table 5.9 Pre and post sputum IL-6 levels measured by high sensitivity ELISA.  
Data presented as median (IQR). *; p<0.05, ‡; p<0.001 Chapter 5    160 
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Figure 5.13 Individual plot of IL-6 levels obtained by high sensitivity ELISA in non-smokers 
with asthma and smokers with asthma. 
Data presented as individual points with median.  
 
5.3.10.2  Comparison of Luminex and ELISA results 
When  the  two  methods  were  compared  there  was  evidence  of  a  strong 
correlation  between  the  sputum  IL 6  results  obtained  by  Luminex  and  high 
sensitivity ELISA: 
•  Smokers; r = 0.84, p<0.001 (figure 5.14) 
•  Ex smokers; r = 0.89, p=0.001 
•  Non smokers; r = 0.84, p<0.001 
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Figure 5.14 Correlation between Log Luminex IL-6 and Log ELISA IL-6 results for smokers 
with asthma. 
 
5.4 Discussion 
Smokers with asthma fail to gain the expected benefits from both inhaled and 
oral corticosteroids (5 10, 22 24). This reduced response is associated with an 
accelerated decline in lung function (15, 21), increased emergency department 
visits  (16,  17)  and  increased  severity  of  asthma  symptoms  compared  to  non 
smoking subjects with asthma (11, 12). The route by which smoking alters the 
corticosteroid responsiveness of smokers with asthma is currently unclear with 
several mechanisms proposed (32, 40). However corticosteroids are recognised 
to reduce pro inflammatory cytokine levels with associated beneficial effects in 
asthma,  and  an  altered  cytokine  environment  can  induce  corticosteroid 
insensitivity in T lymphocytes in-vitro (66 69). An altered cytokine environment 
has also been observed in non smoking corticosteroid resistant asthmatics (64, 
65). Therefore altered cytokine profiles may be relevant to the development of 
reduced corticosteroid sensitivity in smokers with asthma. 
An important issue to consider is that multiple significance tests were performed 
to generate the results presented in this chapter. At a significance level of 5% Chapter 5    162 
the odds of a false positive result is as high as one test in twenty. Therefore a 
number  of  false  positive  differences  are  possibly  contained  in  the  presented 
data. Correction through the use of the Bonferonni adjustment resulted in all 
baseline sputum (save IL 6) and plasma cytokines losing statistical significance. 
However the application of such methods can be viewed as a dubious way to 
deal  with  data  gathered  from  a  small  exploratory  study  as  strong  and 
mechanistically significant observations will be dismissed as a result. Examining 
multiple  cytokines  in  an  unbiased  fashion  is  also  more  likely  to  provide 
significant insights into the causes of corticosteroid resistance as cytokines do 
not work in isolation and determining patterns of alteration are important. The 
large number of significantly altered cytokines discovered using the multiplex 
approach suggests that smokers with asthma do have a significantly different 
cytokine  profile  compared  to  non  smokers  with  asthma.  Future  adequately 
powered studies should examine these findings.  
In  this  cross  sectional  study,  smokers  with  asthma  failed  to  gain  significant 
improvements in lung function during an oral corticosteroid trial. This reduced 
response reflects and confirms previous research in smokers with asthma (23, 
24).  Smokers  and  non smokers  with  asthma  displayed  equivalent  sputum 
differential counts at baseline. The finding of a lack of corticosteroid response in 
this group of smokers with asthma despite the absence of sputum neutrophilia is 
interesting and suggests that the resistance in the recruited subjects is not due 
neutrophilic inflammation. The contrast in lung function response between the 
smokers  and  non  smokers  with  asthma  was  associated  with  a  number  of 
differences in sputum and plasma cytokine levels. Sputum supernatants obtained 
from smokers with asthma demonstrated increased levels of IL 2, 4, 6, 7 & IFNγ 
and a borderline increased level of IL 12 and 17.  
Significant differences were present at baseline for inhaled corticosteroid dose 
and  ACQ  score  between the  smokers  and non  smokers  with asthma. Previous 
research has demonstrated that smokers with asthma have higher ACQ scores 
despite matched lung function measures (12) and the increased symptoms in this 
group are likely to have led to the prescription of increased doses of inhaled 
corticosteroids. To examine the effect of this difference an adjustment of the 
sputum cytokine results for differences in baseline inhaled corticosteroid dose 
was performed. The expectation was that this adjustment would remove any Chapter 5    163 
false associations. The adjustment did not reduce the significant differences in 
IL 2, 4, 6, 7 and IFNγ between smokers and non smokers with asthma, resulted 
in multiple additional cytokine differences becoming evident and strengthened 
the difference present in sputum IL 12 and 17. The presence of increased levels 
of several cytokines in induced sputum supernatant from smokers with asthma 
suggests  that  this  group  display  an  altered  and  increased  level  of  airway 
inflammation compared to non smokers with asthma with similar lung function. 
Are the increases in sputum cytokines demonstrated in this study responsible for 
the corticosteroid resistance seen in smokers with asthma?  
The largest difference in sputum cytokines between smokers and non smokers 
was for IL 6 and this is the only cytokine difference that would survive p value 
adjustment. The presence of a significant difference between smokers and non 
smokers was also subsequently confirmed by high sensitivity ELISA. This increase 
in sputum IL 6 was resistant to oral corticosteroids and is a novel observation in 
smokers with asthma. IL 6 is a pleiotropic pro inflammatory cytokine which sits 
at the junction between the innate and adaptive immune response and has an 
important  role  in  Th 17  differentiation  (278).  Previous  research  has 
demonstrated an  inverse  correlation between  IL 6  and  lung  function in  COPD 
(279). IL 6 is also upregulated in subjects with COPD (280) and in both COPD and 
asthma during exacerbations (281, 282). Bronchoalveolar lavage samples from 
corticosteroid  resistant  non smokers  with  asthma  have  been  demonstrated  to 
contain  increased  levels  of  IL 6  (65).  The  finding  in  this  study  that  IL 6  is 
increased  in  smokers  with  asthma  and  is  unresponsive  to  high  dose  oral 
corticosteroids  suggests  that  sputum  IL 6  may  play  an  important  role  in  the 
development of corticosteroid insensitivity in smokers with asthma. IL 6 signals 
via  signal  transducer  and  activator  of  transcription 3  (STAT3)  resulting  in 
increased gene transcription and activation of NF κB (283 285). Therefore IL 6 
acting  via  STAT3  and  other  gp130  coupled  pathways  may  induce  persistent 
corticosteroid  insensitive  inflammation  in  smokers  with  asthma  akin  to  a 
persistent viral infection. This finding is of interest in the light of the recent 
development  of  IL 6  receptor  blockers  for  the  treatment  of  inflammatory 
conditions. IL 6 receptor blockade may therefore represent a useful approach in 
smokers with poorly controlled asthma. Chapter 5    164 
Previous research has demonstrated increased expression in IL 2 and 4 in cells 
obtained  by  bronchoalveolar  lavage  from  corticosteroid  resistant  non smokers 
with  asthma  (64).  This  finding  was  confirmed  and  extended  by  the 
demonstration that the combination of IL 2 and 4 can induce a corticosteroid 
resistant state in peripheral blood T lymphocytes in-vitro (66 69). The effects of 
the  combination  of  IL 2  and  IL 4  can  be  overcome  by  the  simultaneous  co 
administration  of  IFNγ  in-vitro  (69)  and  corticosteroid  responsive  asthmatics 
demonstrate an increase in IFNγ expressing cells following treatment with oral 
prednisolone (64). This alteration in IFNγ expression mirrors the narrowing of the 
difference in IFNγ concentration following corticosteroids observed in this study. 
The  finding  that  detectable  levels  of  IL 2  and  4  are  present  in  the  sputum 
supernatant of corticosteroid resistant smokers with asthma is intriguing and the 
finding of increased IFNγ at baseline may be an indication of an intrinsic attempt 
to  overcome  the  effects  of  raised  IL 2  &  4.  However  previous  attempts  at 
measurement of IL 4 in ex-vivo samples have been fraught with difficulty. Given 
the low levels of IL 2 and 4 detected in the samples in this study any conclusions 
for  these  cytokines  must  be  cautious.  Further  work  examining  BAL  cytokine 
levels of IL 2, 4 and IFNγ tied to clinical characterisation and examination of 
corticosteroid responses of ex-vivo samples is required before firm conclusions 
can be drawn. 
IFNγ is regarded as a characteristic Th1 cytokine with a role for the induction of 
various  cytokines.  Sputum  IL 6  can  also  be  regarded  in  this  light.  Can  the 
alteration in sputum cytokines in smokers with asthma be a result of smoking 
producing a skewing of asthma from a Th2 to a Th1 phenotype? This could be 
possible. COPD is associated with increased pulmonary and systemic expression 
of IL 6 (286 288) and cells expressing IFNγ in bronchial biopsies (289, 290). IL 12, 
which  was on  the threshold  of  statistical  significance,  was also  raised  in  the 
smokers with asthma and is important for the induction of IFNγ expression (291). 
Non smoking subjects with severe asthma who fail to gain the expected benefits 
from  corticosteroids  express  increased  levels  of  IFNγ  (275,  292)  and  IFNγ  is 
known  to  both  promote  the  expression  of  Th1  cytokines  and  suppress  those 
associated  with  Th2  environments  (293).  Given  the  presence  of  the  common 
environmental factor of smoking it is tempting to extrapolate that smokers with 
asthma have an alteration in their inflammatory response from the Th2 response Chapter 5    165 
characteristic  of  allergic  asthma  to  the  Th1  inflammation  present  in  COPD. 
Smokers  with  asthma  and  subjects  with  COPD  both  display  reduced 
corticosteroid responsiveness and accelerated lung function decline and if the 
inflammation present in subjects with COPD and smokers with asthma shares a 
common cytokine profile then therapies designed for COPD may also prove to be 
effective in smokers with asthma. 
IL 7 is essential for the development of T and B lymphocytes and may play a role 
in dendritic cell survival (294). The finding of increased sputum supernatant IL 7 
in smokers with asthma is novel and may reflect previous work which identified 
a  reduction  in  bronchial  biopsy  B lymphocyte  and  dendritic  cell  numbers  in 
smokers with asthma (62). Raised sputum cytokine IL 7 levels may reflect an 
attempt at restoration of airway B lymphocyte numbers. No differences were 
evident in sputum lymphocyte proportions between smokers and non smokers 
with asthma. However sputum lymphocyte numbers are usually very low so it 
will be difficult to detect a difference in airway T lymphocyte numbers even if 
this is present. Further investigation of the role of IL 7 and IL 7 homologues such 
as Thymic Stromal Lymphopoetin in the control of airway T and B lymphocytes 
and airway dendritic cells in smokers with asthma should be considered. 
The lack of a difference for sputum IL 8 when smokers and non smokers with 
asthma  were compared  contrasts  with  previous  work  in  smokers  with  asthma 
(41).  However  direct  comparison  with  the  previous  study  is  difficult  as  the 
smokers  with  asthma  in  the  prior  study  were  not  prescribed  inhaled 
corticosteroids.  The  mean  pack  year  history  of  the  smokers  with  asthma 
recruited  to  this  trial  were  higher  than  the  previous  study  and  the  standard 
deviations were equivalent. Therefore the narrowing of the difference between 
the two groups is not due to lower pack year histories in the recruited group and 
appears to be due to the existence of a group with lower levels of IL 8 reflected 
in the lower quartile which overlaps with the non smokers with asthma. This 
could reflect alteration in smoking habits, with the current group of smokers 
with asthma smoking less per day. An alternative explanation is that the lack of 
a difference may reflect technical differences as the assay employed for the 
detection of IL 8 was different. The previous study employed an ELISA method 
and the current study used Luminex and this may be partially responsible for to 
the  lack  of  difference  in  this  study.  However  correlations  were  still  present Chapter 5    166 
between sputum IL 8 and a number of clinical characteristics corroborating the 
previous study and the importance of this cytokine in smoking related pulmonary 
responses. 
Overall  the  data  presented  in  this  chapter,  allied  to  previous  work 
demonstrating increased sputum IL 8 (41) and reduced IL 18 (42) in smokers with 
asthma, suggests that the inflammation present in this group is different from 
non smokers  with  asthma  and  represents  a  unique  inflammatory  phenotype. 
Unfortunately  it  is  not  possible  to  be  certain  as  to  the  cellular  sources 
responsible for the altered sputum cytokines detected in smokers with asthma as 
samples were not processed for immunocytochemistry. A number of cells could 
be  responsible  for  the  increased  cytokines  and  several  cell  types  may  be 
contributing. For example, macrophages (65, 70), bronchial epithelial cells (295) 
and T lymphocytes can all produce IL 6. It is difficult to conclude which of these 
or indeed if all cell types are responsible for the differences detected between 
smokers and non smokers with asthma. Future work needs to address this issue. 
The inclusion of a small group of ex smokers with asthma allowed for a limited 
examination  of  the persistent  effect of  smoking  on  asthma.  A  previous  study 
which examined oral corticosteroid responses in smokers with asthma suggested 
that ex smokers with asthma have a heterogeneous response to corticosteroids 
(23). A similar response was evident in the group of ex smokers recruited for this 
study despite the average duration of smoking cessation being over seven years. 
The ex smokers with asthma had similarities in their cytokine profile to both 
smokers and non smokers with asthma. Given the heterogeneous response of the 
ex smokers with asthma to oral corticosteroids consideration should be given to 
an adequately powered study to determine the alterations in cytokine profiles 
following  smoking  cessation  that  predict  the  restoration  of  corticosteroid 
response. 
Examination of systemic cytokine profiles using peripheral blood samples also 
revealed differences between smokers and non smokers with asthma at baseline. 
However  a  different  cytokine  profile  emerged  with  smokers  with  asthma 
generally  expressing  lower  levels  of  plasma  cytokines  than  non  smokers  with 
asthma. Smokers with asthma had significantly lower levels of plasma IL 1RA, 
10, 13 and GM CSF and a borderline reduced level of IL 12 compared to non Chapter 5    167 
smokers with asthma. No difference was evident in plasma IL 2, 4, 6, 7 or IFNγ. 
This  reduction  in  plasma  cytokines  suggests  that  smokers  with  asthma,  in 
contrast to COPD, do not suffer from a generalised systemic inflammation due to 
an  ‘overspill’  of  pulmonary  inflammation.  The  presence  of  increased  sputum 
supernatant IL 6 but similar peripheral IL 6 levels in smokers with asthma also 
suggests  that  smokers  with  asthma  display  a  different  phenotype  to  both 
subjects with COPD and non smokers with asthma. However high sensitivity CRP 
concentrations were not determined in this study and need to be performed to 
allow  true  comparison  with  the  previous  work  in  subjects  with  COPD.  The 
disparity between the sputum and systemic cytokine levels means that future 
studies should concentrate on measurement of cytokines from airway samples in 
preference to peripheral blood. Future research should compare smokers with 
asthma to non smokers with asthma and subjects with COPD to determine the 
similarities and differences in inflammatory system activity between the groups. 
The cytokine profiles post corticosteroid trial revealed a number of interesting 
findings. Smokers with asthma, despite failing to respond clinically, did reduce a 
number of sputum supernatant cytokines. Non smokers with asthma also reduced 
a  number  of  sputum  cytokines  in  association  with  an  improvement  in  lung 
function.  Which  cytokines  responded  differently  when  the  two  groups  were 
compared?  Post  corticosteroid  sputum  levels  of  IL 1RA,  6  and  Eotaxin  were 
significantly higher in the smokers with asthma.  Sputum IL 2, 4 and IFNγ did not 
significantly change in either smokers or non smoker with asthma in response to 
oral  corticosteroids  but  statistical  significance  was  lost.  This  may  reflect  an 
increase  in  IL 2,  4  &  IFNγ  in  non  smokers  with  asthma,  a  reduction  in  the 
cytokines in smokers with asthma or reflect variability in the assay. However 
comparison of within group changes did not reveal any cytokines that behaved 
differently  in  the  non  smokers  with  asthma  and  therefore  the  baseline 
comparisons are likely to provide the greatest insights. The failure of sputum IL 
6 to reduce in response to high dose oral corticosteroids again suggests that this 
cytokine is associated with the mechanism(s) responsible for the reduced lung 
function  response  in  smokers  with  asthma.  Further  studies  are  required  to 
examine this cytokine in characterised smokers and non smokers with asthma.  Chapter 5    168 
5.5 Conclusion 
Smokers  with  asthma  display  alterations  of  both  sputum  supernatant  and 
peripheral cytokine profiles that are associated with reduced response to oral 
corticosteroids. The increase in sputum IL 6 displayed by smokers with asthma 
which is resistant to oral corticosteroids may reflect increased NF κB activation 
via  increased  STAT3  leading  to  corticosteroid  resistant  inflammation.  The 
dissociation between peripheral and sputum cytokine profiles demonstrates that 
direct sampling in smokers with asthma may be crucial to the determination of 
the causes of the altered corticosteroid response in this group. Future studies 
should  endeavour  to  examine  cytokine  profiles  in  smokers  with  asthma  with 
comparison  to  subjects  with  COPD  using  bronchoscopic  sampling  as  this  will 
allow  reference  to  the  responsible  airway  cell  populations  and  allow  further 
dissection of the inflammatory processes in this group. 169 
6  Relevance  of  HDAC  activity  to  corticosteroid 
response in smokers with asthma 
6.1 Introduction 
Smokers  with  asthma  exhibit  an  impaired  response  to  both  inhaled  and  oral 
corticosteroids (5 10, 22 24). Previous research has demonstrated that smokers 
with asthma also suffer increased symptoms (11, 12), an accelerated decline in 
lung function (15, 21) and increased emergency department visits for asthma 
(16, 17) compared to matched non smoking asthmatics. 
The prevalence of smoking in asthma reflects that of the general population and 
therefore smokers with asthma represent a large group of patients with poorly 
controlled disease (13). Smoking cessation is the obvious target for both health 
practitioners and smokers with asthma and this approach has been demonstrated 
to be an effective therapy in this group (49). However as sustained quitting rates 
are low either improvements on current treatments or alternative therapies are 
required for individuals with asthma who continue to smoke. Development of 
new treatments requires understanding of the alteration in the phenotype of 
asthma induced by smoking and its relationship to treatment response. 
The discipline of epigenetics has revealed a mechanism that may be of relevance 
to the reduced response to corticosteroids observed in smokers with asthma. 
Epigenetics examines the effect of post translational covalent modifications of 
chromatin on the control of gene expression. An in-vitro model of inflammation 
has demonstrated that approximately half of the immunosuppressant activity of 
corticosteroids is produced via the removal of acetyl groups from DNA associated 
histone  proteins  (98).  The  removal  of  acetyl  groups  from  histone  proteins  at 
areas of active transcription results in a conformational change in chromatin in 
the  targeted  area  leading  to  cessation  of  active  transcription  (81).  Cigarette 
smoke  has  been  demonstrated  to  reduce  HDAC  activity  in-vitro  (92)  and  a 
reduction in HDAC activity in smokers with asthma could explain their relative 
corticosteroid insensitivity. Chapter 6    170 
Therefore this cross sectional study was designed to test the hypothesis that 
smokers with asthma have a reduced level of HDAC activity compared to non 
smokers  with  asthma  and  that  this  is  associated  with  reduced  corticosteroid 
responsiveness. 
6.2 Methods 
6.2.1 Subjects 
Subject  characteristics,  inclusion/exclusion  criteria  and  recruitment  methods 
were  as  described  in  the  general  methods  chapter.  All  subjects  provided 
informed  consent  and  the  study  was  approved  by  the  West  Glasgow  Ethics 
Committee. 
6.2.2 Study design 
A full description of the study is provided in the general methods chapter. In 
brief, the subjects were recruited to a cross sectional study with unblinded use 
of oral dexamethasone to determine corticosteroid sensitivity. The baseline visit 
consisted  of  a  number  of  assessments  including  sputum  and  blood  for 
macrophage/monocyte  HDAC  activity  assessment  and  lung  function 
measurement  by  spirometry.  At  the  completion  of  the  corticosteroid  trial 
subjects  were  re assessed  within  24  hours  of  their  last  dose  and  repeated 
spirometry, venesection and sputum induction for HDAC activity assessment.  
6.2.3 Measurements 
A  full  description  of  the  measurements  is  provided  in  the  general  methods 
chapter.  Lung  function  assessments  conformed  to  consensus  guidelines  (246). 
Sputum induction and processing and blood processing for HDAC measurement 
was performed as discussed in the general methods chapter. Assay variability 
testing was not performed for the HDAC test utilised in this thesis. Chapter 6    171 
6.2.4 Statistical analysis 
Parametric data was examined using paired t testing or 2 sided t testing and 
non parametric  data  with  Wilcoxon Mann Whitney  testing.  Comparisons  were 
between smokers and non smokers with asthma. Ex smokers were not included 
in formal comparison analyses due to the small number of subjects in this group. 
Correlations  were  performed  predominately  with  Spearman  Ranks  and 
supplementary calculations with Pearson’s (indicated by ρ for Spearman and r 
for Pearson when presented). Statistical analysis was performed using Minitab 15 
(Minitab Inc. State College, PA, USA) and SAS v 9.1 (TS1M3) for Windows (SAS 
Institute Inc., NC, USA). α was set at 0.05. No adjustments were performed for 
multiple comparisons. 
6.3 Results 
Sputum samples suitable for measurement of HDAC activity were obtained from 
18 non smokers, 9 ex smokers and 18 smokers with asthma at baseline and from 
14 non smokers, 9 ex smokers and 14 smokers with asthma at completion of the 
corticosteroid trial. Suitable baseline blood samples were obtained from 20 non 
smokers, 9 ex smokers and 22 smokers with asthma and from 17 non smokers, 9 
ex smokers  and  18  smokers  with  asthma  at  completion  of  the  corticosteroid 
trial. 
6.3.1 Baseline comparisons 
The baseline characteristics are discussed in detail in chapter 5 sections 5.3.1 to 
5.3.4. A brief review of the relevant findings will be presented here. 
6.3.1.1  Clinical characteristics 
Subjects  were  well  matched  for  clinical  variables  at  baseline.  Smokers  with 
asthma were taking higher levels of inhaled corticosteroids and had higher ACQ 
scores compared to non smokers with asthma. Chapter 6    172 
6.3.1.2  Lung function measurements 
Smokers  and  non smokers  with  asthma  were  well  matched  for  lung  function 
measures  at  baseline,  although  non smokers  with  asthma  demonstrated  a 
greater degree of bronchodilator response compared to smokers with asthma. 
6.3.1.3  Baseline sputum characteristics 
No differences were present between smokers and non smokers when baseline 
sputum profiles were compared. There was an absence of eosinophilia in both 
smokers and non smokers with asthma.  
6.3.2 Corticosteroid response 
Non smokers  with  asthma  made  a  significant  lung  function  response  to  oral 
corticosteroids. This was in contrast to smokers and ex smokers with asthma who 
failed to make a significant within group response to oral corticosteroids. No 
difference was evident when between groups responses were compared. 
6.3.3 Change in clinical characteristics and sputum profile 
Non smokers with asthma demonstrated a reduction in ACQ score in response to 
the oral corticosteroid trial in contrast to smokers with asthma. No significant 
differences in the response of ACQ score and sputum to dexamethasone were 
detectable between the smokers and non smokers with asthma. 
6.3.4 Baseline HDAC activity 
6.3.4.1  Baseline sputum macrophage HDAC activity 
No differences were detectable between smokers and non smokers with asthma 
in baseline sputum HDAC activity levels (smokers 92.8 µmol/l/10
 6 cells (IQR 7.2, 
277.8), non smokers 82.7 µmol/l/10
 6 cells (34.3, 150.5) p=0.960) (table 6.1 and 
figure  6.1).  Ex smokers  had  a  similar  sputum  HDAC  activity  level  (55.4 
µmol/l/10
 6 cells) to smokers and non smokers with asthma. Chapter 6    173 
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Figure 6.1 Baseline sputum HDAC activity in non-smokers, ex-smokers and smokers with 
asthma. 
 
6.3.4.2  Baseline blood monocyte HDAC activity 
Baseline blood HDAC activity was equivalent in both smokers and non smokers 
with asthma (smokers 1.63 µmol/l/10
 6 cells (IQR 1.19, 3.10) non smokers 1.99 
µmol/l/10
 6 cells (1.52, 3.84), p=0.180) (table 6.1 and figure 6.2). Ex smokers 
with  asthma  blood  HDAC  activity  levels  were  equivalent  to  smokers  and  non 
smokers with asthma. 
 
Smokers  Ex-smokers  Non smokers 
Baseline  sputum  HDAC 
activity µmol/10*6  
92.8 
(7.1, 299.2) 
55.4 
(20.7, 247.7) 
82.7 
(30.2, 153.1) 
Baseline  blood  HDAC 
activity µmol/10*6 
1.63 
(1.19, 3.10) 
2.51 
(1.81, 3.65) 
1.99 
(1.52, 3.84) 
Table 6.1 Comparison of HDAC activity across groups for sputum and blood.  
Data presented as median (IQR). 
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Figure  6.2  Baseline  blood  HDAC  activity  in  non-smokers,  ex-smokers  and  smokers  with 
asthma. 
 
6.3.4.3  Relationship of sputum HDAC activity to lung function response to 
dexamethasone 
The baseline sputum HDAC activity of smokers with asthma did not predict FEV1 
response to dexamethasone. When examined using a 15% improvement in FEV1 as 
the discriminator of corticosteroid responsiveness, the average HDAC activity of 
the two corticosteroid responsive smokers was 24.1 µmol/l/10
 6 cells. Sputum 
HDAC activity of the unresponsive group was 135.3 µmol/l/10
 6 cells (IQR 7.2, 
342.1). When the same comparison was made in the non smokers with asthma no 
difference  was  obvious  between  the  subjects  who  responded  and  those  that 
failed  to  improve  (responders  103.2  µmol/l/10
 6  cells  (2.3,  150.5),  non 
responders 82.7 µmol/l/10
 6 cells (30.2, 172.3) p=0.753).  
No  correlation  was  evident  between  baseline  sputum  HDAC  activity  and  FEV1 
response to oral corticosteroids (ρ= 0.10 (95% CI  0.41, 0.22), p=0.519) (figure 
6.3). When examined as separate groups no correlations were evident between 
baseline sputum HDAC activity and FEV1 response to corticosteroids: 
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•  Smokers with asthma; ρ= 0.14 ( 0.59, 0.38), p=0.601 
•  Non smokers with asthma; ρ=  0.08 ( 0.59, 0.47), p=0.764 
•  Ex smokers with asthma; ρ= 0.00 ( 0.70, 0.70), p=1.000 
 
 
Figure  6.3  Relationship  between  FEV1  response  to  dexamethasone  and  baseline  sputum 
macrophage HDAC activity.  
 
6.3.4.4  Relationship  of  blood  HDAC  activity  to  lung  function  response  to 
dexamethasone 
Baseline blood HDAC activity similarly failed to predict lung function response in 
smokers with asthma (>15% response mean activity 1.6 µmol/l/10
 6 cells, <15% 
response  1.7  µmol/l/10
 6  cells  (IQR  0.9,  3.2))  and  non smokers  with  asthma 
(<15% response 1.9 µmol/l/10
 6 (1.3, 3.8), >15% response 1.5 µmol/l/10
 6 (1.4, 
4.0)).  
To  allow  a  further  examination  of  the  available  data,  correlations  were 
performed between the lung function changes for all subjects and HDAC activity. 
No relationship was evident between the FEV1 response across all groups and 
baseline blood HDAC activity (ρ=  0.08 (95% CI  0.36, 0.21) p=0.611) (figure 6.4). 
When  examined  according  to  smoking  history  no  positive  correlations  were 
evident between lung function response and blood HDAC activity: 
Baseline 
HDAC 
activity 
( mol/l/10
6 
cells) 
FEV1 percentage improvement to dexamethasone 
ρ=-0.10 (95% CI -0.41, 0.22), p=0.519 Chapter 6    176 
•  Smokers with asthma; ρ=  0.37 (95% CI  0.70, 0.08), p=0.097 
•  Non smokers with asthma; ρ=  0.05 ( 0.54, 0.45), p=0.824 
•  Ex smokers with asthma; ρ= 0.38 ( 0.38, 0.83), p=0.299 
 
Figure  6.4  Relationship  between  FEV1  response  to  dexamethasone  and  baseline  blood 
monocyte HDAC activity. 
 
6.3.4.5  Correlation between sputum HDAC and blood HDAC activity 
No relationship was evident between blood and sputum HDAC activity at baseline 
(Pearson correlation; r=  0.22, p = 0.163) (figure 6.5) 
Baseline 
HDAC 
activity 
( mol/l/10
6 
cells) 
FEV1 percentage improvement to dexamethasone 
ρ= -0.08 (95% CI -0.36, 0.21) p=0.611 Chapter 6    177 
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Figure 6.5 Scatterplot of baseline blood and sputum HDAC activity (with regression). 
 
6.3.5 Change in HDAC activity in response to dexamethasone 
6.3.5.1  Change in sputum HDAC activity 
No  change  was  detectable  in  sputum  HDAC  activity  within  the  smoker,  ex 
smoker  or  non  smoker  groups.  Post  dexamethasone  sputum  HDAC  activity  in 
smokers with asthma was equivalent to non smokers with asthma (smokers HDAC 
activity 98.3 µmol/l/10
 6 (IQR 23.9, 558.5), non smokers 33.8 µmol/l/10
 6 (12.9, 
128.6),  p=0.220).  The  change  in  sputum  HDAC  activity  in  response  to 
dexamethasone  was  also  equal  (smokers  change  53.2  µmol/l/10
 6(6.2,  594.4), 
non smokers   72.2  µmol/l/10
 6  ( 137.2,  23.7),  p=0.120).  Ex smokers 
demonstrated an increase in HDAC activity of a similar magnitude to smokers 
with asthma (60.1 µmol/l/10
 6 ( 162.5,  424.6)). 
6.3.5.2  Change in blood HDAC activity 
No change was detectable in blood HDAC activity in response to dexamethasone 
in non smokers (HDAC within group change 0.82 µmol/l/10
 6 (95% CI  0.98, 2.61), 
p=0.347) and ex smokers with asthma ( 1.83 µmol/l/10
 6 ( 7.03, 3.37), p=0.440). 
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Smokers with asthma demonstrated a trend to an increase in blood HDAC activity 
in response to dexamethasone when within group response was examined (7.02 
µmol/l/10
 6 ( 0.38, 14.41), p=0.061). 
Post  corticosteroid  blood  HDAC  activity  levels  were  significantly  higher  in 
smokers  with  asthma  compared  to  non  smokers  with  asthma  (smokers  3.36 
µmol/l/10
 6  (2.0,  10.7),  non smokers  1.86  µmol/l/10
 6  (1.1,  3.2),  p=0.022).  A 
trend  to  significance  was  evident  when  changes  in  blood  HDAC  activity  in 
response  to  dexamethasone  in  smokers  and  non  smokers  with  asthma  were 
compared (smokers 2.46 µmol/l/10
 6 ( 0.1, 7.2), non smokers 0.52 µmol/l/10
 6 ( 
0.5, 1.4), p=0.074). Ex smokers with asthma displayed similar levels of blood 
HDAC  activity  to  smokers  post  oral  corticosteroid  trial  (ex smokers  2.50 
µmol/l/10
 6 (2.0, 5.2)). 
No relationship was evident between change in blood HDAC activity and lung 
function response when all subjects were included (ρ=  0.18 (95% CI  0.5, 0.1) 
p=0.246).  When  examined  as  individual  groups  no  correlations  were  evident 
between the change in blood HDAC activity and FEV1 response in smokers (ρ= 
0.24  ( 0.3,  0.6),  p=0.329)  or  non  smokers  with  asthma  (ρ=   0.01  ( 0.5,  0.5), 
p=0.958). However a strong and highly significant correlation was found between 
change in blood HDAC activity and lung function response in ex smokers with 
asthma (ρ=  0.94 ( 1.0,  0.7), p<0.001) (figure 6.6). 
 
 
Figure 6.6. Relationship between change in blood HDAC activity and change in FEV1 in ex-
smokers with asthma 
 
FEV1 percentage improvement to dexamethasone 
 
Change in 
blood HDAC 
activity 
( mol/l/10
6 
cells) 
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6.4 Discussion 
Smokers with asthma display a reduced response to corticosteroids (5 10, 22 24). 
The  cause  (or  causes)  of  this  reduced  response  is  currently  unknown.  The 
purpose of this exploratory study was to determine HDAC activity levels in this 
sub  group  of  asthma  in  comparison  to  non smokers  with  asthma  and  its 
relationship  to  corticosteroid  response.  Previous  research  carried  out  in-vitro 
(103), in subjects with COPD (86, 87) and non smoking subjects with asthma (84) 
suggests  that  reduced  HDAC  activity  is  of  relevance  to  corticosteroid 
responsiveness. Smoking has been demonstrated to reduce HDAC activity in-vitro 
(92) and therefore reduced HDAC activity was expected in smokers with asthma. 
However  this  study  has  provided  no  evidence  to  support  the  hypothesis  that 
HDAC  activity  is  suppressed  in  either  sputum  macrophages  or  blood  borne 
monocytes in smokers with asthma. This was combined with a lack of correlation 
between lung function response to corticosteroids and HDAC activity.  
What can explain this discrepancy? An obvious conclusion is that smokers with 
asthma do not have a reduced level of HDAC activity and therefore altered HDAC 
activity does not explain the differences in response to corticosteroid displayed 
by  smokers  with  asthma.  However  there  are  a  number  of  technical  issues  to 
consider.  The  previous  research examining  the  relevance  of  HDAC  activity  to 
corticosteroid response has been carried out in cell lines or cells obtained by 
bronchoalveolar lavage. Induced sputum has previously been demonstrated to 
provide different information compared to samples obtained by bronchoalveolar 
lavage  (182)  and  induced  sputum  samples  the  central  airways  in  contrast  to 
bronchoalveolar  lavage  which  obtains  samples  from  smaller  airways  (183). 
Therefore  a  possible  explanation  that  needs  to  be  considered  is  that  the 
macrophages  obtained  are of a  different phenotype  and  hence  HDAC  activity 
compared  to  those  that  exist  in  the  periphery  of  the  lungs.  Another 
consideration  is  that  there  was  no  step  to  allow  for  inspection  of  the  cells 
selected  for  the  HDAC  assay.  Therefore  there  is  the  possibility  that 
contamination  with  non viable  cells  and  neutrophils  may  have  affected  the 
results and led to low levels of HDAC activity and lack of a difference between 
smokers and non smokers with asthma. Chapter 6    180 
The samples obtained for this study were processed at a research centre with an 
interest  in  the  examination  of  HDAC  activity  in  airways  disease.  Based  on 
previous  research  using  induced  sputum, a  new  technique  (in cell  assay)  was 
developed  for  assessment  of  HDAC  activity  to  allow  for  its  determination  in 
samples of lower cell numbers. Therefore as this study is the first to use this 
technique  in  the  comparison  of  subjects  with  asthma  with  differing  smoking 
histories we may be observing a flaw in the technique. Despite best efforts in 
validation the technique may be too insensitive to detect differences that are 
present  between  smokers  and  non  smokers  with  asthma.  An  additional 
consideration  is  that  the  absence  of  a  difference  in  HDAC  activity  between 
smokers  and  non  smokers  with  asthma,  if  correct,  may  mask  important 
differences in HDAC containing enzyme isoforms and  subsequent alteration in 
substrate target levels of acetylation. The simple approach taken in this study to 
address differences in overall level of HDAC activity did not address these issues. 
Future  studies  should  consider  examination  of  HDAC  isoforms  and  targets  of 
HDAC containing complexes to determine which are important in determining a 
subject’s response to corticosteroids.  
An  additional  weakness  of  this  study  is  that  no  attempt  was  made  to  assess 
histone  acetyl  transferase  (HAT)  activity.  The  epigenetic  response  to 
corticosteroids  can  be  viewed  as  an  alteration  in  the  balance  in  HDAC/HAT 
activity. Previous research has identified HAT activity to be elevated in alveolar 
macrophages  obtained  from  non smoking  corticosteroid  naive  subjects  with 
asthma (84). Smokers with asthma may display large increases in HAT activity 
and this increased HAT activity may be insensitive to corticosteroid treatment. 
The balance between HDAC and HAT activity that exists in smokers with asthma 
needs to be addressed in future studies comparing smokers with asthma to non 
smokers with asthma and normal subjects. 
The absence of correlation between sputum macrophage HDAC activity and lung 
function change in response to corticosteroid is surprising. However the within 
group response of the non smokers with asthma subjects to treatment with oral 
corticosteroids was slightly smaller than expected. This may reflect that most of 
the  non smoking  subjects  with  asthma  were  already  treated  with  moderate 
doses  of  inhaled  corticosteroids  and  therefore  may  not  have  been  able  to 
demonstrate large increases in lung function. Future studies in this area may Chapter 6    181 
need  to  consider  examining  groups  divided  by  treatment  level  and  symptom 
intensity using a system such as the GINA categorisation.  
A previous trial has demonstrated that non smokers with asthma do not have 
altered levels of HDAC activity in peripheral blood compared to normal subjects 
and that peripheral blood HDAC activity increases in non smokers with asthma in 
response to an oral corticosteroid trial (84). The presented data demonstrates 
that smokers with asthma also make a significant increase in peripheral blood 
monocyte HDAC activity in response to corticosteroids. Ex smokers with asthma, 
a  proportion  of  whom  were  able  to  demonstrate  a  good  response  to  oral 
corticosteroids,  demonstrated  a  highly  correlated  and  significant  relationship 
between  lung  function  improvement  and  change  in  blood  HDAC  activity. 
However  this  relationship  was  reciprocal  and  currently  defies  explanation. 
Previous work in COPD has found that ex smokers with COPD display differing 
HDAC responses to treatment compared to smokers with COPD (296) and this 
finding  in  ex smokers  with  asthma  may  be  a  manifestation  of  an  altered 
inflammatory phenotype that exists in ex smokers. However there is also the 
possibility  that  this  result  is  a  type  1  error  due  to  multiple  comparisons  so 
further examination of this relationship should be considered before any firm 
conclusions are drawn. 
6.5 Conclusions 
This  exploratory  cross  sectional  study  has  demonstrated  that  smokers  with 
asthma  have  levels  of  sputum  macrophage  HDAC  activity  comparable  to  non 
smokers with asthma. This study has not confirmed a role for reduced HDAC 
activity  in  smokers  with  asthma  but  should  be  regarded  as  inconclusive  at 
present.  This  finding  is  surprising  but  requires  further  examination  and 
confirmation using techniques comparable to previous publications. Therefore to 
address these issues HDAC and HAT activity, HDAC isoform expression and the 
substrates  of  HDAC  and  HAT  containing  complexes  should  be  examined  in 
samples obtained by bronchoscopy from smokers and non smokers with asthma 
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7  Non-invasive  assessment  of  inflammation  in 
smokers with asthma 
7.1 Introduction 
7.1.1 Extended flow nitric oxide analysis 
Non invasive assessment of airway inflammation, through the measurement of  
exhaled nitric oxide at a flow rate of 50ml/sec, has developed into a useful 
exploratory endpoint in clinical trials since its discovery in the exhaled breath of 
subjects  with  asthma  (47,  210).  A  raised  exhaled  nitric  oxide  concentration 
displays  a  degree  of  correlation  with  airway  eosinophilia  and  therefore  is 
thought to provide a quick method of assessment for this established indication 
for corticosteroid treatment (47). As a result it is likely that exhaled nitric oxide 
measurement will go on to become part of the routine assessment of subjects 
with asthma referred to secondary care. 
Unfortunately current cigarette smoking markedly reduces exhaled nitric oxide 
levels at the standard flow rate of 50ml/sec (50) rendering the test less useful, 
both for the assessment of airway inflammation in smokers with asthma and as 
an exploratory endpoint in clinical trials. A recent publication suggests that a 
percentage change in exhaled nitric oxide correlates with asthma control and 
may therefore provide an alternative approach in smokers with asthma (221). 
However further work is required to corroborate this evidence and its place in 
the investigation of smokers with asthma.  
An  alternative  approach  involving  examination  of  exhaled  nitric  oxide  using 
multiple exhalation flow rates provides additional information beyond exhaled 
nitric  oxide  concentration.  Mathematical  modelling  using  the  results  from 
multiple flow rates, based on the assumption that the lungs can be divided into 
two compartments (composed of the conducting airways and the alveoli), has 
led to the development of a technique termed extended flow analysis. Extended 
flow  analysis  enables  estimates  to  be  derived  for  alveolar  nitric  oxide 
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(airway wall nitric oxide flux (the rate of radial transport of nitric oxide across 
the airway into the exhaled air), airway wall concentration and diffusion rate) 
(222, 227, 255, 297). This approach has demonstrated elevated levels of alveolar 
nitric  oxide  in  subjects  with  severe  asthma  (compared  to  subjects  with  mild 
asthma)  (256,  257)  and  subjects  with  COPD  (225,  258)  (although  this  is  not 
consistent (52)). Active smoking does not reduce alveolar nitric oxide levels in 
normal  subjects  (226,  259)  and  alveolar  nitric  oxide  levels  are  equivalent  in 
smokers and ex smokers with COPD (52, 225). Therefore extended flow analysis 
may  provide  useful  exploratory  endpoints  in  the  assessment  of  smokers  with 
asthma. 
However the calculation of alveolar nitric oxide and associated measurements is 
complicated  by  the  existence  of  multiple  methods  of  derivation  (227).  The 
original  paper  examining  nitric  oxide  exchange  mechanics  used  three  high 
exhalation flow rates with plots of the elimination rate of nitric oxide against 
flow rate and subsequent linear regression through  the plotted data (222). A 
similar method, performed using two low flow rates and prolonged exhalation 
allows for estimates to be derived for airway wall nitric oxide concentration, 
nitric oxide diffusion across the airway and airway nitric oxide flux levels (227, 
255). An alternative method using non linear regression enables the derivation of 
alveolar  nitric  oxide,  airway  wall  nitric  oxide  concentration,  nitric  oxide 
diffusion and flux (255). Each of these models provides slightly different values 
for the derived parameters although normal values and values in subjects with 
asthma are available (table 7.1)(227). No research has been published to date 
examining  extended  flow  nitric  oxide  analysis  using  these  models  in  smokers 
with asthma. 
Therefore to test the hypothesis that smokers with asthma have elevated levels 
of alveolar nitric oxide compared to non smokers with asthma, reflecting their 
increased symptoms from asthma and alterations in other exhaled nitric oxide 
parameters  (compared  to  non smokers  with  asthma)  the  following  study  was 
undertaken.  The  use  of  an  oral  corticosteroid  trial  also  allowed  for  the 
examination of the supplementary hypothesis that smokers with asthma display a 
restoration  of  alveolar  nitric  oxide  levels  towards  the  range  present  in  non 
smokers with asthma in response to corticosteroid therapy. Chapter 7    184 
7.1.2 Exhaled breath condensate pH 
Exhaled breath condensate (EBC) assessment, which involves the collection of 
expiratory gas vapours in a cooled tube, has been suggested to show promise as 
an  exploratory  endpoint  in  studies  of  asthma.  Previous  research  has 
demonstrated that the pH of EBC is reduced during periods of exacerbation in 
asthma, returning to normal in parallel with clinical resolution (57). EBC pH also 
correlates negatively with induced sputum neutrophilia in subjects with COPD 
and  sputum  eosinophilia  in  non smoking  subjects  with  asthma  (238).  Smokers 
with asthma have previously been demonstrated to have lower EBC pH values 
than non smokers with asthma (58). EBC can be collected outside of the research 
laboratory for subsequent pH analysis and potentially represents a simple and 
useful non invasive marker. 
Therefore to examine the hypothesis that smokers with asthma display lower 
levels  of  exhaled  breath  condensate  pH  compared  to  non smokers,  and  the 
additional  hypothesis  that  following  oral  corticosteroids  exhaled  breath 
condensate  pH  is  equivalent  in  smokers  and  non smokers  with  asthma,  the 
following study was undertaken. 
7.2 Methods 
7.2.1 Subjects 
Subject  characteristics,  inclusion/exclusion  criteria  and  recruitment  methods 
were  as  described  in  the  general  methods  chapter.  All  subjects  provided 
informed  consent  and  the  study  was  approved  by  the  West  Glasgow  Ethics 
Committee. 
7.2.2 Study design 
A full description of the study is provided in the general methods chapter. In 
brief, the subjects were recruited to a cross sectional study with unblinded use 
of  oral  dexamethasone  to  determine  corticosteroid  sensitivity.  Subjects 
performed  extended  flow  nitric  oxide  analysis  and  EBC  collection  for  pH Chapter 7    185 
measurement before and at the completion of the corticosteroid trial. A small 
sub set of patients attended one month after completion of the corticosteroid 
trial to investigate the duration of corticosteroid effects on extended flow nitric 
oxide parameters. 
7.2.3 Measurements 
A  full  description  of  the  measurements  is  provided  in  the  general  methods 
chapter.  Briefly,  subjects  were  asked  to  refrain  from  eating  and  to  avoid 
caffeine containing drinks within three hours of performing the tests. Smokers 
with asthma were also asked to refrain from smoking for three hours. Exhaled 
carbon  monoxide  measurements  were  performed  to  confirm  abstinence  from 
smoking. Inhaled medications were withheld consistent with available guidelines 
(246) to facilitate spirometry testing later in the study visit. 
Nitric oxide measurements were performed at multiple flow rates (30, 50, 100, 
150, 200, 250 & 300ml/sec) using a Niox Flex analyser within built in Flex Flow 
programme and automatic flow regulator (Aerocrine AB, Sundbybergsvägen 9, 
SE 171 73 Solna, Sweden). The Niox Flex meets joint ATS/ERS criteria for the 
measurement of on line FENO (47) and the Flex Flow programme automatically 
assesses the NO measurements against pre set accuracy criteria. At flow rates 
above 30ml/sec the permitted deviation was +/  10% and below 30ml/sec +/  
3ml/sec. Readings out with these boundaries were automatically rejected. The 
exhalation time for each flow rate was; 10 seconds for 30 ml/sec, 10 s for
 50 
ml/sec,  6  seconds  for  100, 150,  200,  250  and
  300 ml/sec.  Three  acceptable 
readings were obtained for each flow rate. A built in delay prevented subjects 
performing the measurements at less than 30 second intervals. A system check 
was  carried  out  after  six  attempts  to  ensure  drift  had  not  occurred  in  the 
measurement.  Calibration  was  performed  fortnightly  using  a  certified  nitric 
oxide  gas  cylinder.  The  results  collected  and  displayed  by  the  Flex Flow 
programme were exhaled nitric oxide concentration (FENO) and elimination rate 
of nitric oxide (VNO). No reproducibility testing was performed. 
Exhaled nitric oxide linear and non linear modelling was performed according to 
previously published methodology (222, 227, 255). This previous work utilises a 
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airway and an expansible alveolar compartment combined with the assumption 
that NO is produced at a constant rate per unit volume in both compartments. 
This division is hoped to detected differences that are masked by the standard 
flow rate i.e. a subject with small airway inflammation may have an equivalent 
exhaled nitric oxide level to a subject with well controlled asthma (using the 
standard flow rate) but a significantly higher alveolar nitric oxide. The currently 
available models have been demonstrated to provide good estimates of alveolar 
nitric  oxide,  with  levels  in  the  range  of  that  observed  during  endobronchial 
sampling  and  are  also  able  to  replicate  the  observed  linear  relationship  of 
exhaled NO with flow rate. To calculate estimates for the desired parameters 
subjects exhale at several flow rates and the exhaled nitric oxide concentration, 
elimination rate of nitric oxide (amount of NO absorbed from the airway wall 
into the airstream) and exhalation flow rate are plotted followed by linear or 
non linear fitting to the data (examples provided in figures 7.1 and 7.2). 
 
Figure 7.1 Plot of elimination rate of exhaled nitric oxide against exhalation flow rate.  
Line represents linear regression through the data points. The slope of the line reflects the 
alveolar nitric oxide concentration and the y-intercept the airway wall flux. 
VNO; elimination rate of exhaled nitric oxide, pl/sec; picolitres per second, ml/sec; millilitres 
per second Chapter 7    187 
 
Figure  7.2  Plot  of  exhaled  nitric  oxide  concentration  against  exhalation  flow  rate.  Line 
represents non-linear regression through the data points.  
FENO; exhaled nitric oxide concentration, ppb; parts per billion, ml/sec; millilitres per second 
 
Linear  modelling  was  performed  initially  according  to  (222)  using  VNO  results 
from 100, 200 and 300 ml/sec flow rates with subsequent comparison against 
results derived using data from 100, 150, 200 & 250 ml/sec and 100, 150, 200, 
250 & 300 ml/sec flow rates. Plotting VNO results against exhalation flow rates 
and linear regression allows derivation of alveolar nitric oxide and airway flux 
according to the following equation (see figure 7.1): 
VNO = Calv.VE + J’awNO 
Where VNO= elimination rate of exhaled nitric oxide (ml/s), VE = exhalation flow rate (ml/s), 
Calv= alveolar NO concentration (ppb), J’awNO=maximum NO flux (pl/sec). 
 
Where alveolar nitric oxide corresponded to the gradient of the line and flux was 
obtained from the y intercept of the line. If a subject’s data provided a negative 
value for alveolar nitric oxide following regression their data was not included in 
the final analysis as this was felt to represent a test error. 
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Airway  wall  nitric  oxide  diffusion  and  concentration  was  obtained  by  linear 
regression using the VNO and FENO results from the 30 and 50ml/sec flow rates. 
VNO was plotted against FENO followed by linear regression. Nitric oxide flux was 
obtained from the y intercept and nitric oxide diffusion from the reciprocal of 
the  gradient  of  the  slope.  Airway  wall  concentration  was  obtained  from  the 
relationship (255): 
 
J’awNO = CawNODawNO 
Where  J’awNO=maximum  NO  flux  (pl/sec),  CawNO=airway  wall  concentration  (ppb), 
DawNO=diffusion from airway wall to airway (pl/sec/ppb) 
 
Nonlinear regression was performed using the FENO data from all flow rates with 
the restriction of positive boundaries for all parameters. Plotting FENO against VE 
(see figure 7.2) and solving for the following equation enabled the derivation of 
estimates  for  alveolar  nitric  oxide,  airway  nitric  oxide  concentration,  airway 
wall nitric oxide diffusion and flux parameters. (255): 
 
FENO = CawNO + (Calv   CawNO)e
( DawNO/VE) 
Where  FENO=exhaled  NO  concentration  (ppb),  CawNO=airway  wall  concentration  (ppb), 
DawNO=diffusion  from  airway  wall  to  airway  (pl/sec/ppb),  Calv  =alveolar  NO  level  (ppb), 
VE=flow rate of exhalation (ml/sec) 
 
An estimate of airway flux was subsequently derived for this model from the 
relationship (227): 
J’awNO = CawNODawNO 
 
Previously published results using the presented models are presented in table 
7.1. This data will provide reference ranges for the data presented in the results 
section. Chapter 7    189 
 
 
  Normal adults 
Non-smokers 
with asthma 
(No ICS) 
Non-smokers 
with asthma 
(ICS) 
Linear modelling       
Calv (ppb)  1.0-1.9  1.1-1.5  1.2-1.9 
Jaw (pl/s)  600-1200  2500-6512  700-2416 
Caw (ppb)  75-98  255  108-144 
Daw (pl/s/ppb)  7.7-11.0  25.5  11.8-22.3 
Non-linear 
modelling 
 
Calv (ppb)  3.2-5.0 
 
Jaw (pl/s)  1020  6512  2416 
Caw (ppb)  149  255.3  108.3 
Daw (pl/s/ppb)  5.7-7.4  25.5  22.3 
Table  7.1  Ranges  for  normal  adults,  non-smoking  subjects  with  asthma  not  treated  and 
treated with inhaled corticosteroid.  
Based on previous published results (52, 227, 255, 257, 298, 299). Mean values for groups 
presented. ICS; inhaled corticosteroid treated, Calv; alveolar nitric oxide, Jaw; airway nitric 
oxide flux, Caw; nitric oxide concentration in airway wall, Daw; airway wall diffusion rate of 
nitric oxide, ppb; parts per billion, pl/s; picolitres per second, pl/s/ppb; picolitres per second 
per parts per billion. 
 
Exhaled  breath  condensate  was  collected  using  a  Jaeger  EcoScreen®.  The 
subjects performed tidal breathing for ten minutes whilst wearing a nose clip. 
De aeration of the sample was performed for ten minutes using argon as per 
recommended guidelines and previous published methodology (56, 57). Sample 
pH was measured immediately on completion of de aeration following a twenty 
second  period  to  allow  stabilisation  of  the  probe  reading  in  the  sample.  No 
reproducibility testing was performed. 
7.2.4 Statistical analysis 
Parametric data was assessed using t testing and non parametric using Mann 
Whitney testing. All extended flow analysis are presented as median (IQR) and 
all  comparisons  are between  smokers  and non  smokers. Ex smokers  were  not 
included in formal comparison analyses due to the small number of subjects in Chapter 7    190 
this group. All data was treated as exploratory. α was set at 0.05. Analysis and 
linear  and  non linear  modelling  was  performed  using  SAS  v  9.1  (TS1M3)  for 
Windows  (SAS  Institute  Inc.,  NC,  USA).  Results  are  presented  as  median 
(interquartile range) unless stated otherwise. 
7.3 Results 
7.3.1 Baseline comparisons 
The baseline characteristics are discussed in detail in chapter 5 sections 5.3.1 to 
5.3.4. A brief review of the relevant findings will be presented here. 
The subjects were well matched at baseline but mean ACQ score and inhaled 
corticosteroid dose were higher in smokers with asthma. Smokers with asthma 
had a smaller bronchodilator response compared to non smokers with asthma. 22 
smokers,  10  ex smokers  and  21  non smokers  were  recruited  to  the  study.  20 
smokers, 9 ex smokers and 17 non smokers completed  the oral corticosteroid 
trial. Non smokers with asthma made a significant lung function response to oral 
corticosteroids in contrast to smokers and ex smokers with asthma. 
19 smokers, 9 ex smokers and 20 non smokers with asthma were able to perform 
acceptable nitric oxide measurements at baseline and 19 smokers, 7 ex smokers 
and  17  non smokers  with  asthma  performed  acceptable  measurements  post 
corticosteroid trial. 16 smokers, 9 ex smokers and 15 non smokers with asthma 
performed acceptable exhaled nitric oxide measurements after a period of one 
month had elapsed from the oral corticosteroid trial. 
7.3.2 Exhaled nitric oxide-FENO50 
Clear differences were evident between smokers and non smokers with asthma 
at baseline (table 7.2 and figure 7.3), on completion of the corticosteroid trial 
and  one  month  after  oral  corticosteroids.  There  appeared  to  be  a  small 
reduction in FENO50 in smokers with asthma in response to oral corticosteroids. Chapter 7    191 
 
  Smokers  Ex-smokers  Non-smokers 
FENO50 pre steroid 
(ppb) 
  11.1 
‡ 
(3.6, 13.5) 
19.8 
(15.8, 43.5) 
32.8 
(17.7, 73.2) 
FENO50 post steroid 
(ppb) 
  6.1 
† 
(3.3, 8.1) 
11.4 
(7.0, 22.0) 
12.4 
(10.1, 22.0) 
FENO50  1  month  post 
steroid (ppb) 
  8.4 * 
(4.6, 13.9) 
20.6 
(8.9, 23.5) 
13.5 
(6.5, 23.7) 
Table 7.2 Exhaled nitric oxide measured at standard flow rate of 50ml/sec.  
FENO50; exhaled nitric oxide concentration at 50ml/sec, ppb; parts per billion. Data presented 
as median (IQR). p values refer to comparison of smokers and non smokers. *; p<0.05, †; 
p<0.01, ‡, p<0.001.  
 
 
 
Figure 7.3 Baseline exhaled nitric oxide (FENO50) levels.  
ppb; parts per billion. 
 
7.3.3 Exhaled breath condensate pH 
No  significant  differences  in  EBC  pH  were  evident  between  smokers  and  non 
smokers  with  asthma  at  baseline,  post  oral  corticosteroid  trial  or  one  month 
later (table 7.3). When within group responses to oral corticosteroid trial were 
compared there was no significant difference (smokers; median change 0.05 (IQR 
 0.08, 0.17) non smokers; 0.03 ( 0.09, 0.15), p=0.770). EBC pH one month post 
corticosteroid was equivalent to EBC pH at baseline and post corticosteroid trial.  
Exhaled 
Nitric 
Oxide  
50ml/sec 
(ppb) 
Non smokers 
with asthma 
Ex smokers 
with asthma 
Smokers 
with asthma 
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Smokers  Ex smokers  Non-smokers 
EBC pH Pre steroid  7.22 
(7.16, 7.27) 
7.29 
(7.24, 7.33) 
7.26 
(7.16, 7.36) 
EBC pH Post steroid  7.29 
(7.13, 7.36) 
7.36 
(7.20, 7.38) 
7.34 
(7.21, 7.36) 
EBC pH 1 month post 
steroid 
7.21 
(7.15, 7.27) 
7.25 
(7.25, 7.30) 
7.25 
(7.18, 7.31) 
Table  7.3  EBC  pH  at  baseline,  post  corticosteroid  trial  and  one  month  after  oral 
corticosteroid trial.  
Data presented as median (IQR). EBC; exhaled breath condensate. 
 
7.3.4 Extended flow nitric oxide 
7.3.4.1  Alveolar Nitric Oxide and Airway Wall Flux 
 
Smokers  with  asthma  displayed  a  lower  median  level  of  alveolar  nitric  oxide 
compared to non smokers with asthma at baseline although this difference was 
lost after the oral corticosteroid trial (table 7.5). Smokers with asthma also had 
significantly lower levels for median nitric oxide flux pre and post steroid. The 
median alveolar nitric oxide concentration and flux in ex smokers with asthma 
was  intermediate  to  the  non smokers  and  smokers  with  asthma  at  baseline. 
However alveolar nitric oxide post corticosteroid appeared to be lower than that 
observed in smokers and the level of nitric oxide flux was equivalent to that 
observed in non smokers with asthma. 
 
Smokers  Ex smokers  Non-smokers 
Calv pre steroid 
(ppb) 
   1.42 * 
(0.43, 2.01) 
1.71 
(0.59, 2.79) 
2.45 
(1.11, 3.52) 
Jaw pre steroid 
(pl/s) 
   572.8 
† 
(216.7, 734.4) 
987.6 
(695.2, 3308.3) 
1535.0 
(784.6, 3495.6) 
Calv  post steroid 
 (ppb) 
1.79 
(0.68, 2.38) 
0.58 
(0.40, 0.76) 
1.89 
(1.37, 2.93) 
Jaw post steroid  
(pl/s) 
   147.6 
† 
(65.0, 458.0) 
570.0 
(413.9, 932.6) 
577.0 
(456.9, 1361.7) 
Table 7.5 Linear regression analysis results for 100, 200, 300 ml/sec.  
Calv;  alveolar nitric oxide, Jaw; nitric oxide flux. ppb; parts per billion, pl/s; picolitres per 
second. p values refer to comparison of smokers and non smokers. *; p<0.05, †; p<0.01, ‡, 
p<0.001. 
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Performance of linear regression with data from multiple additional flows (100, 
150, 200 & 250 and subsequently with the addition of data from 300 ml/sec) 
altered  the  concentrations  derived  for  alveolar  nitric  oxide.  For  example, 
median alveolar nitric oxide values for smokers with asthma at baseline derived 
using four flows was 1.53 ppb (IQR 0.09, 2.50) and five flows was 1.03 ppb ( 
0.03, 2.02). However the use of data from extra flow rates did not remove the 
significant difference between the groups at baseline or affect the narrowing of 
the difference following the oral corticosteroid trial. Values derived for nitric 
oxide flux were not obviously affected by the use of data from additional flow 
rates. 
Linear regression using the low flow rates of 30 and 50ml/sec produced different 
values for nitric oxide flux compared to higher flows. However in keeping with 
the previous models, smokers with asthma had significantly lower nitric oxide 
flux levels at baseline (smokers 396.8 pl/s (IQR 68.8, 834.7), non smokers 1984.6 
pl/s (1257.9, 5580.5), p<0.001) and post oral corticosteroid (smokers 207.4 pl/s 
( 8.4,  635.2),  non smokers  587.2  pl/s  (383.2,  1342.4),  p=0.004)  using  this 
approach.  When  response  to  oral  corticosteroids  was  compared  smokers  with 
asthma  made  a  significantly  smaller  reduction  in  nitric  oxide  flux  (smokers 
change  77.2 pl/s ( 284.3, 139.2), non smokers change  1363.8 pl/s ( 4094.8,  
678.0), p=0.003). Ex smokers with asthma displayed airway wall concentrations 
and flux levels similar to those observed in non smokers with asthma. 
 
Non linear  regression  produced  equivalent  median  alveolar  nitric  oxide 
concentrations in smokers and non smokers with asthma at baseline (smokers 
1.39 ppb (IQR 0.00, 1.95), non smokers 0.78 ppb (0.00, 1.69), p=0.760) and post 
oral corticosteroid trial (smokers 0.97 ppb (0.00, 2.04), non smokers 1.25 ppb 
(0.43,  2.14),  p=0.360)  (table  7.6  &  figure  7.4).  No  significant difference  was 
evident between smokers and non smokers with asthma when change in alveolar 
nitric oxide in response to oral corticosteroid was compared (smokers median 
change 0.00 ppb (IQR  0.61, 0.64), non smokers median change 0.43 ppb (0.00, 
1.27), p=0.240). Ex smokers with asthma had alveolar nitric oxide levels slightly 
lower than those observed in smokers with asthma. 
7.3.4.1.2  Non-linear regression analysis Chapter 7    194 
 
 
 
 
Figure 7.4 Baseline alveolar nitric oxide (Calv)-non-linear modelling.  
ppb; parts per billion. 
 
 
Smokers  Ex smokers  Non-smokers 
Calv pre steroid 
(ppb) 
1.39 
(0.00, 1.95) 
0.32 
(0.00, 0.97) 
0.78 
(0.00, 1.69) 
Jaw pre steroid 
(pl/s) 
   697.4 
† 
(322.5, 1204.8) 
1278.3 
(715.6, 4221.8) 
2087.8 
(1093.4, 5033.6) 
Calv  post steroid 
 (ppb) 
0.97 
(0.00, 2.04) 
0.61 
(0.00, 0.78) 
1.25 
(0.43, 2.14) 
Jaw post steroid  
(pl/s) 
   335.7 
† 
(278.7, 732.0) 
947.4 
(438.3, 1302.5) 
676.9 
(608.2, 1132.4) 
Table 7.6 Non linear regression analysis.  
Results presented as median (IQR). Calv; alveolar nitric oxide,  Jaw; nitric  oxide flux. ppb; 
parts per billion, pl/s; picolitres per second. p values refer to comparison of smokers and 
non smokers.  *; p<0.05, †; p<0.01, ‡, p<0.001. 
 
Nitric  oxide  flux  values  were  significantly  lower  in  smokers  with  asthma  at 
baseline  (smokers  697.4  pl/s  (IQR  322.5,  1204.8),  non smokers  2087.8  pl/s 
(1093.4,  5033.6),  p=0.002)  and  post  oral  corticosteroids  (smokers  335.7  pl/s 
(278.7, 732.0), non smokers 676.9 pl/s (608.2, 1132.4), p=0.004) (table 7.6 and 
figure 7.5). Smokers with asthma also demonstrated a trend to a reduction in 
nitric oxide flux in response to oral corticosteroids (smokers within group median 
change  260.1 pl/s (IQR  492.1, 33.1), p=0.064). This was in contrast to non 
Non smokers 
with asthma 
Ex smokers 
with asthma 
Smokers 
with asthma 
Alveolar 
nitric 
oxide 
(ppb) 
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smokers  where  a  large  and  strongly  significant  reduction  was  observed  (non 
smokers  1363.0 pl/s ( 3831.0,  725.0), p<0.001). Baseline levels for nitric oxide 
flux in ex smokers with asthma were higher than those observed in smokers with 
asthma and suggested a trend towards the levels observed in non smokers with 
asthma. 
 
Figure 7.5 Baseline nitric oxide flux (Jaw)-non-linear modelling.  
pl/s; picolitres per second. 
 
7.3.4.2  Airway wall Nitric Oxide concentration and Nitric Oxide diffusion 
 
The airway wall nitric oxide concentration was significantly lower in smokers 
with asthma at baseline (smokers 8.6 ppb (IQR  4.4, 53.3), non smokers 147.6 
ppb (59.7, 243.3), p=0.002) (table 7.7). However post oral corticosteroids this 
difference  was  narrowed  and  became  non significant,  although  a  trend  to  a 
difference  was  evident  (smokers  15.0  ppb  (0.2,  37.0),  non smokers  45.0  ppb 
(20.8,  89.4),  p=0.08).  Smokers  with  asthma  made  a  significantly  smaller 
reduction  in  airway  wall  nitric  oxide  concentration  in  response  to  oral 
corticosteroids when assessed by linear modelling (smokers median change  1.47 
ppb (IQR  24.4, 19.9), non smokers  111.6 ppb ( 188.3, 2.4), p=0.030). Levels 
obtained for ex smokers at baseline were higher than smokers and were similar 
to the levels observed in non smokers (ex smokers; baseline 166.9 ppb (43.6, 
253.1), post corticosteroid 86.0 ppb (57.4, 118.9)). 
7.3.4.2.1  Linear regression 
Non smokers 
with asthma 
Ex smokers 
with asthma 
Smokers 
with asthma 
Airway 
wall 
flux 
(pl/s) 
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Smokers  with  asthma  had  a  trend  to  lower  rates  of  airway  wall  nitric  oxide 
diffusion compared to non smokers at baseline (smokers 11.7 pl/s/ppb (IQR  
19.2, 17.7), non smokers 18.0 pl/s/ppb (7.3, 26.0), p=0.070), but no difference 
was evident post oral corticosteroid trial (smokers 0.8 pl/s/ppb ( 43.3, 30.4), 
non smokers  12.2  pl/s/ppb  (4.5,  20.0),  p=0.240)  (table  7.7).  No  significant 
difference in airway wall nitric oxide diffusion response to oral corticosteroids 
was evident when the two groups were compared. Ex smokers diffusion levels 
were  equivalent  to  smokers  and  did  not  appear  to  significantly  change  in 
response to oral corticosteroids. 
  
Smokers  Ex smokers  Non-smokers 
Caw pre steroid 
(ppb) 
   8.6 
† 
(-4.4, 53.3) 
166.9 
(43.6, 253.1) 
147.6 
(59.7, 243.3) 
Daw pre steroid 
(pl/s/ppb) 
11.7 
(-19.2, 17.7) 
6.0 
(0.8, 16.6) 
18.0 
(7.3, 26.0) 
Caw post steroid 
(ppb) 
15.0 
(0.2, 37.0) 
86.0 
(57.4, 118.9) 
45.0 
(20.8, 89.4) 
Daw post steroid 
(pl/s/ppb) 
0.8 
(-43.3, 30.4) 
6.7 
(3.1, 11.3) 
12.2 
(4.5, 20.0) 
Table  7.7  Airway  wall  concentration  and  diffusion  of  nitric  oxide  produced  by  linear 
regression using 30 and 50ml/sec flow rates.  
Caw; airway wall concentration of nitric oxide, Daw; airway wall nitric oxide diffusion, ppb; 
parts  per  billion,  pl/s/ppb;  picolitres  per  second  per  parts  per  billion.  p  values  refer  to 
comparison of smokers and non smokers. †; p<0.01. 
 
 
Smokers  with  asthma  had  significantly  lower  airway  wall  nitric  oxide 
concentrations at both baseline (smokers 25.9 ppb (IQR 7.1, 32.2), non smokers 
117.8 ppb (62.0, 173.5), p<0.001) (table 7.8) and post oral corticosteroid trial 
(smokers  10.8  ppb  (7.0,  25.5),  non smokers  38.7  ppb  (27.2,  81.6),  p=0.021). 
When responses to the corticosteroid trial were compared it was evident that 
non smokers with asthma made a significantly greater reduction in airway wall 
nitric oxide concentration (smokers median change  5.5 ppb (IQR  18.9, 0.9), 
non smokers   54.1  ppb  ( 116.2,   24.8),  p=0.020).  Ex smokers  demonstrated  a 
trend towards the levels observed in non smokers with asthma at baseline. No 
change in airway wall nitric oxide concentrations were observed in response to 
oral corticosteroids in the ex smokers with asthma. 
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Nitric oxide diffusion was equivalent in both groups at baseline and post oral 
corticosteroid  trial.  The  changes  in  nitric  oxide  diffusion  in  response  to  the 
corticosteroid trial were equivalent and small in nature (smokers median change 
 8.9 pl/s/ppb ( 28.0, 43.3), non smokers  6.3 pl/s/ppb ( 21.1, 0.0), p=0.700). 
Ex smokers demonstrated parity for nitric oxide diffusion at baseline with an 
apparent reduction in response to oral corticosteroids. 
 
Smokers  Ex smokers  Non-smokers 
Caw pre steroid 
(ppb) 
  25.9 
‡ 
(7.1, 32.2) 
62.9 
(35.9, 269.3) 
111.8 
(62.0, 173.5) 
Daw pre steroid 
(pl/s/ppb) 
25.7 
(6.0, 46.5) 
24.8 
(1.0, 33.4) 
27.8 
(15.7, 36.5) 
Caw post steroid 
(ppb) 
  10.8 * 
(7.0, 25.5) 
64.3 
(17.0, 177.7) 
38.7 
(27.2, 81.6) 
Daw post steroid 
(pl/s/ppb) 
29.8 
(1.0, 55.4) 
6.3 
(1.0, 20.1) 
16.2 
(7.5, 28.9) 
Table 7.8  Airway wall concentration and diffusion of nitric oxide produced by non-linear 
regression.  
Caw; airway wall concentration of nitric oxide, Daw; airway wall nitric oxide diffusion, ppb; 
parts  per  billion,  pl/s/ppb;  picolitres  per  second  per  parts  per  billion.  p  values  refer  to 
comparison of smokers and non smokers. *; p<0.05, ‡; p<0.001. 
 
7.3.4.3  Comparison of linear and non-linear models 
Comparison  between  the  linear  and  non linear  methods  was  possible  for  the 
baseline  results.  A  Bland Altman  plot  for  alveolar  nitric  oxide  (figure  7.6), 
reveals that the models provided very different results for alveolar nitric oxide 
levels with disagreements of up to 8 ppb and a more routine difference of about 
4 ppb present.  
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Figure  7.6  Bland-Altman  plot  of  Alveolar  nitric  oxide  (Calv)  difference  (linear-non-linear) 
against alveolar nitric oxide (Calv) average for linear and non-linear models 
 
7.3.4.4  Impact  of  corticosteroids  on  extended  flow  measurements  at  one 
month 
Performance of extended flow nitric oxide measurements one month post oral 
corticosteroid trial allowed a simple examination of the duration of effect of the 
corticosteroid trial on these markers of inflammation.  
When alveolar nitric oxide derived by linear modelling (using three flow rates) 
was examined it was evident that corticosteroids continued to have an effect at 
one  month.  Alveolar  nitric  oxide  was  equivalent  in  smokers  and  non smokers 
with  asthma  in  contrast  to  baseline  (table  7.9).  Comparing  the  change  in 
alveolar  nitric  oxide  from  pre  corticosteroid  visit  to  one  month  post 
corticosteroids demonstrated that alveolar nitric oxide significantly increased in 
the smokers with asthma (smokers median change 1.34 ppb (IQR 0.21, 2.31), 
non smokers  0.52 ppb ( 1.21, 0.18), p=0.007). Airway nitric oxide flux at one 
month  post  oral  corticosteroid  trial  continued  to  be  significantly  lower  in 
smokers with asthma (table 7.9). However nitric oxide flux showed a reduction 
in both groups with a trend to a larger reduction in non smokers with asthma 
(smokers median change  136.9 pl/s (IQR  429.7, 209.6), non smokers change  
281.7  pl/s  ( 875.0,   18.7),  p=0.060).  Ex smokers  with  asthma  demonstrated 
continued suppression of their alveolar nitric oxide level at one month whilst 
their flux had recovered towards baseline levels and showed parity with non 
smokers with asthma. 
Average Calv (linear and non linear mean) 
Calv 
difference 
(linear–
nonlinear) Chapter 7    199 
 
 
Smokers  Ex smokers  Non-smokers 
Calv pre steroid 
(ppb) 
    0.69 * 
(0.19, 1.93) 
0.87 
(0.07, 2.56) 
2.19 
(1.10, 3.34) 
Jaw pre steroid 
(pl/s) 
    572.8 
‡ 
(216.7, 734.4) 
987.6 
(695.2, 3047.5) 
1563.7 
(797.4, 3659.0) 
Calv 1 month post 
steroid (ppb) 
1.82 
(1.08, 2.65) 
0.00 
(-0.63, 0.69) 
1.37 
(0.13, 3.00) 
Jaw 1 month post 
steroid (pl/s) 
   462.2 
† 
(215.1, 671.7) 
1129.6 
(433.2, 1235.7) 
1213.7 
(591.3, 2637.4) 
Table 7.9 Variation in alveolar nitric oxide and airway nitric oxide for linear modelling using 
100, 200 & 300ml/sec flow rates.  
Results presented as median (IQR). Calv; alveolar nitric oxide,  Jaw; nitric  oxide flux. ppb; 
parts per billion, pl/s; picolitres per second. *; p<0.05, †; p<0.01, ‡, p<0.001. 
 
Alveolar nitric oxide estimates generated by non linear modelling demonstrated 
a trend to higher alveolar nitric oxide levels at one month in the smokers with 
asthma  (smokers  1.61  ppb  (IQR  0.0,  2.5),  non smokers  0.23  ppb  (0.0,  0.6), 
p=0.059) (table 7.10). When alveolar nitric oxide change from baseline to one 
month post corticosteroid was compared there appeared to be a slight rise in the 
smokers with asthma (smokers median change 0.63 ppb (IQR  0.01, 1.20), non 
smokers 0.00 ppb ( 1.67, 0.23), p=0.060). 
Non linear  modelling  revealed  that  smokers  with  asthma  continued  to  have 
significantly lower nitric oxide flux levels after one month (smokers 378.7 pl/s 
(IQR  130.2,  902.0),  non smokers  1379.8  pl/s  (591.9,  3324.2),  p=0.006)  (table 
7.10).  No  difference  was  evident  when  change  in  flux  from  baseline  to  one 
month post oral corticosteroid trial was compared (smokers median change  92.3 
pl/s  (IQR   607.7,  78.9),  non smokers   358.7  pl/s  ( 1161.9,  33.5),  p=0.380). 
Reflecting the linear modelling result, non linear modelling also suggested that 
ex smokers with asthma displayed suppressed levels of alveolar nitric oxide at 
one month. Nitric oxide flux levels had also returned to the range observed at 
baseline in ex smokers with asthma at one month. Chapter 7    200 
 
 
Smokers  Ex smokers  Non-smokers 
Calv pre steroid 
(ppb) 
1.39 
(0.00, 1.95) 
0.32 
(0.00, 0.97) 
0.78 
(0.00, 1.69) 
Jaw pre steroid 
(pl/s) 
   697.4 
† 
(322.5, 1204.8) 
1278.3 
(715.6, 4221.8) 
2087.8 
(1093.4, 5033.6) 
Caw pre steroid 
(ppb) 
   25.9 
‡ 
(7.1, 32.2) 
62.9 
(35.9, 269.3) 
111.8 
(62.0, 173.5) 
Daw pre steroid 
(pl/s/ppb) 
25.7 
(6.0, 46.5) 
24.8 
(1.0, 33.4) 
27.8 
(15.7, 36.5) 
Calv  1  month  post 
steroid (ppb) 
1.61 
(0.00, 2.51) 
0.00 
(0.00, 0.18) 
0.23 
(0.00, 0.58) 
Jaw  1  month  post 
steroid (pl/s) 
   378.7 
† 
(130.2, 902.0) 
1290.8 
(280.1, 1611.3) 
1379.8 
(591.9, 3324.2) 
Caw  1  month  post 
steroid (ppb) 
39.5 
(8.5, 113.9) 
91.8 
(44.5, 194.3) 
60.6 
(36.8, 152.2) 
Daw  1  month  post 
steroid(pl/s/ppb) 
1.5 
(1.0, 25.4) 
5.8 
(1.0, 22.4) 
14.9 
(1.0, 29.8) 
Table  7.10  Variation  in  alveolar  nitric  oxide,  airway  nitric  oxide  flux,  concentration  and 
diffusion for non-linear modelling.  
Results  presented  as  median  (IQR).  Calv;  alveolar  nitric  oxide,  Jaw;  nitric  oxide  flux,  Caw; 
airway wall concentration of nitric oxide, Daw; airway wall nitric oxide diffusion. ppb; parts 
per billion, pl/s; picolitres per second pl/s/ppb; picolitres per second per parts per billion. †; 
p<0.01, ‡, p<0.001. 
 
In contrast to baseline, airway wall nitric oxide (derived by non linear modelling) 
was  equivalent  in  smokers  and  non smokers  with  asthma  at  one  month.  This 
narrowing of the difference appeared to be partly due to an increase in this 
marker in smokers with asthma and a sustained suppression in non smokers (one 
month post levels; smokers 39.5 ppb (8.5, 113.9), non smokers 60.6 ppb (36.8, 
152.2), p=0.370) (table 7.10). No obvious difference was evident in nitric oxide 
diffusion one month post oral corticosteroid trial when smokers and non smokers 
were compared. However levels appeared to be lower in smokers with asthma 
compared  to  baseline  (smokers  1.5  pl/s/ppb  (1.0,  25.4),  non smokers  14.9 
pl/s/ppb (1.0, 29.8), p=0.110). Airway wall nitric oxide concentrations in ex 
smokers with asthma appeared to be higher than non smokers with asthma at 
one month post oral corticosteroid trial. 
Airway wall concentrations at one month, derived using low flows and linear 
modelling, were equivalent (smokers 16.7 ppb ( 4.7, 109.6), non smokers 69.7 
ppb  (24.2,  145.7),  p=0.170).  Comparison  of  the  change  in  airway  wall Chapter 7    201 
concentrations demonstrated a trend to a larger reduction in non smokers with 
asthma (smokers  5.1 ppb ( 19.9, 64.1), non smokers  37.9 ppb ( 195.5, 61.8), 
p=0.055). Nitric oxide diffusion was significantly lower in smokers with asthma 
(smokers  2.6  pl/s/ppb  ( 15.4,  9.2),  non smokers  12.9  pl/s/ppb  (4.6,  20.5), 
p=0.026).  However  when  median  change  from  baseline  was  examined  no 
difference in response was evident (smokers 7.3 pl/s/ppb (IQR  11.4, 17.9), non 
smokers  1.6 pl/s/ppb ( 13.3, 10.4), p=0.400). In contrast to the result derived 
by non linear modelling, ex smokers with asthma airway wall concentration at 
one month post oral corticosteroid was close to the level observed in smokers 
with asthma (ex smokers one month post corticosteroid 15.9 ppb ( 19.3, 112.0)). 
7.4 Discussion  
Smokers  with  asthma  display  a  reduced  response  to  inhaled  and  oral 
corticosteroids  (5 10,  22 24).  This  altered  response  is  associated  with  worse 
asthma control reflected in the higher ACQ scores of smokers with asthma (12). 
New  treatments  are  currently  being  developed  for  corticosteroid  resistant 
airway obstruction and may be useful in the management of this group. However 
to justify the cost and effort involved in performing definitive trials for these 
medications supportive evidence will initially be required from small exploratory 
trials in smokers with asthma. Therefore an exploratory endpoint that detects 
subtle  anti inflammatory  effects  which  do  not  rapidly  translate  into  lung 
function changes in smokers with asthma would be a useful additional test for 
the standard short exploratory trial. I chose to examine both exhaled breath 
condensate pH and extended flow nitric oxide analysis based on the hypothesis 
that both could provide a non invasive test that reflects the poorly controlled 
inflammation present in smokers with asthma.  
Extended  flow  analysis  provides  additional  insights  into  airway  nitric  oxide 
metabolism, compared to the standard measurement of exhaled nitric oxide at a 
flow rate of 50ml/sec. Active smoking does not appear to reduce the alveolar 
nitric oxide concentration (226, 259) and elevated alveolar nitric oxide has been 
detected in subjects with COPD (225, 258). Based on this work and the potential 
ability of extended flow analysis to provide further additional insights in smokers 
with asthma and that it may correlate with the increased symptoms present in Chapter 7    202 
smokers with asthma I felt that it was worthy of study. The data produced by 
linear modelling demonstrates that smokers with asthma have reduced alveolar 
nitric oxide, nitric oxide flux and airway wall diffusion levels compared to non 
smokers with asthma and, when compared to previous research, perhaps lower 
alveolar nitric oxide levels than healthy non smokers (table 7.1). The difference 
in alveolar nitric oxide levels in smokers and non smokers with asthma is novel 
and contrasts  with  previous  research  in  normal  smokers  (226)  and  COPD  (52, 
225). The oral corticosteroid trial demonstrates that the difference in alveolar 
nitric  oxide  levels  between  smokers  and  non smokers  with  asthma  (as 
determined by linear modelling) can be reduced by oral corticosteroids and this 
effect persists for at least one month. 
In  contrast, non linear  modelling demonstrates equivalency  for alveolar nitric 
oxide in smokers and non smokers with asthma. This result is consistent with 
previous work in normal smokers (226) and smokers and ex smokers with COPD 
(52).  Again  alveolar  nitric  oxide  levels  were  not  raised  in  reflection  of  the 
increased  symptoms  in  smokers  with  asthma  and  no  clear  change  in  alveolar 
nitric oxide was evident in either group in response to high dose corticosteroids 
leading one to question the usefulness of this endpoint. When the results from 
the linear and non linear models were compared by Bland Altman plot it was 
evident that the models could not be regarded as interchangeable.  
Airway  nitric  oxide  flux  derived  by  both  linear  and  non linear  modelling 
demonstrates  a  clear  difference  for  this  endpoint  between  smokers  and  non 
smokers with asthma. Smokers with asthma display nitric oxide flux levels close 
to  those  previously  observed  in  normal  non smokers.  Nitric  oxide  flux  also 
demonstrates sensitivity to oral corticosteroids in both smokers and non smokers 
with asthma. The evidence of clear change in smokers with asthma nitric oxide 
flux following oral corticosteroids when derived by linear modelling and a trend 
to a reduction when derived by non linear modelling is intriguing and suggests 
that nitric oxide flux is worthy of further study. Non linear and linear modelling 
also revealed the novel finding that airway wall nitric oxide concentrations are 
significantly lower in smokers with asthma at baseline, post oral corticosteroid 
trial and at one month post oral corticosteroid in contrast to linear modelling. 
Airway  wall  nitric  oxide,  derived  by  both  linear  and  non linear  modelling, 
appears  to  be  sensitive  to  oral  corticosteroids  with  non smokers  making Chapter 7    203 
significantly greater reductions in response to oral corticosteroids. Smoking did 
not  affect  airway  wall  diffusion  for  nitric  oxide  and  this  is  consistent  with 
previously published work in normal smokers (226, 259) and ex smoking subjects 
with COPD (52, 225). 
The  finding  of  reduced  airway  nitric  oxide  flux,  nitric  oxide  airway  wall 
concentrations and alveolar nitric oxide (when derived by linear modelling) in 
smokers with asthma is intriguing and it is tempting to speculate on possible 
causes. This study is not able to demonstrate the mechanism(s) by which this 
occurs but possible causes include cigarette smoke induced consumption of nitric 
oxide  (51,  52),  competition  for  required  substrates  by  other  inflammatory 
pathways activated by cigarette smoke (53) and reduced inducible nitric oxide 
synthase (iNOS) concentrations in airway epithelial cells in response to smoking 
(55). Future studies examining nitric oxide synthesis and reaction products in the 
bronchial epithelium and submucosa in smokers and non smokers with asthma 
should, in parallel, determine extended flow nitric oxide parameters. 
A  final  significant  issue  that  needs  to  be  resolved  is  the  determination  of  a 
significant  change  in  any  of  the  flow  independent  nitric  oxide  parameters  in 
response to treatment (similar to that which exhaled nitric oxide (measured at 
50ml/sec) has been undergoing). This study can be viewed as one of the first 
steps in addressing this issue. However the recent demonstration that significant 
changes can be detected in exhaled nitric oxide levels in smokers with asthma 
with an alternative simple approach (221) may hamper the development of this 
technique as a replacement method for assessing smokers with asthma. 
The inclusion of a group of ex smokers with asthma in the study has allowed 
some simple observations to be made. Ex smokers with asthma have previously 
demonstrated evidence suggestive of a restoration of corticosteroid sensitivity 
after many years of smoking cessation (23). The ex smoking subjects recruited to 
this study failed to show clear improvements in lung function in response to oral 
corticosteroids  despite  a  mean  duration  of  quitting  of  seven  years.  When 
compared  to  smokers  and  non smokers  with  asthma,  ex smokers  appeared  to 
represent  a  separate  phenotype  with  the  result  for  some  parameters  being 
equivalent  to  those  observed  in  smokers  and  others  to  the  results  for  non 
smokers with asthma. These findings coupled to the observation suggestive of a Chapter 7    204 
restoration of corticosteroid sensitivity in a sub group of ex smokers with asthma 
should prompt further research into this group. The proportion of ex smokers 
with asthma in the population will substantially increase in coming years due to 
recent changes in legislation and public perception of smoking and too little is 
known about the characteristics and behaviour of this group. 
Exhaled breath condensate pH has been examined in asthma exacerbations and 
demonstrates correlation with clinical improvement (57), sputum neutrophilia in 
COPD and sputum eosinophilia in asthma (238). EBC can be collected outside of 
the research lab allowing the collection of samples by non specialised personnel 
at, for example, the subject’s general practice. This facet of EBC may be useful 
as attendance at hospital based research units may be responsible for some of 
the  reluctance  observed  in  some  subjects  with  regards  clinical  trial 
participation. EBC pH has previously been examined by one group in smokers 
with asthma (58). The authors demonstrated that smokers with asthma had a 
lower EBC pH than non smokers with asthma. If this finding was corroborated 
then the restoration of EBC pH towards the level present in non smokers with 
asthma would have provided a suitable exploratory endpoint. In this exploratory 
study EBC pH measurements were performed at baseline, immediately post oral 
corticosteroid  trial  and  one  month  after  oral  corticosteroids  in  smokers,  ex 
smokers  and  non smokers  with  asthma.  Surprisingly  EBC  pH  was  found  to  be 
equivalent in the three groups at all timepoints and therefore unresponsive to 
high dose oral corticosteroids. The reason for this discordant result is not clear. 
EBC was collected in this study using a commercially available apparatus and 
processed in accordance with previously published research. The authors of the 
previous trial used an unusual method (the subjects breathed through a frozen 
syringe)  for  EBC  collection  and  this  may  have  had  an  effect  on  the 
measurements. How this would have a greater effect on the pH of EBC collected 
from smokers with asthma is not immediately obvious. Another explanation is 
that  both  this  and  the  previous  trial  are  small  and  sampling  error  may  have 
produced this disparity. Possible additional explanations are that the smokers 
with asthma recruited to the previous trial may have been experiencing subtle 
subclinical  exacerbations  or  were  not  fully  recovered  from  a  previous 
exacerbation and hence would have had a spurious reduction in their EBC pH. 
The  results  obtained  for  this  trial  leads  one  to  conclude  that  EBC  pH  is Chapter 7    205 
insufficiently  sensitive  and  discriminatory  to  be  employed  as  an  exploratory 
endpoint. 
7.5 Conclusion 
In conclusion, in the first trial to examine extended flow nitric oxide analysis in 
a group of smokers with asthma, linear modelling demonstrated that smokers 
display  lower  levels  of  alveolar  nitric  oxide  compared  to  non smokers  with 
asthma whilst non linear modelling demonstrated that alveolar nitric oxide in 
smokers  and  non smokers  with  asthma  was  equivalent.  Nitric  oxide  flux  and 
airway wall concentration of nitric oxide are lower in smokers with asthma using 
both linear and non linear modelling. Significant differences exist between the 
result derived for alveolar nitric oxide using linear and non linear models. The 
use of extended flow analysis and non linear modelling may eventually provide a 
useful  exploratory  endpoint  for  the  assessment  of  smokers  with  asthma  but 
consensus is required with regards the best form of modelling given the lack of 
agreement between linear and non linear modelling. Research also needs to be 
performed to identify the minimal clinically significant change in the parameters 
derived  by  extended  flow  nitric  oxide  analysis.  Finally  exhaled  breath 
condensate pH is equivalent in smokers and non smokers with asthma and does 
not change in response to a two week oral corticosteroid trial. In light of this 
finding the utilisation of EBC pH as an exploratory endpoint in clinical trials in 
smokers with asthma cannot be justified. 206 
8  Conclusions and future directions 
8.1 Summary of findings 
Smokers with asthma consistently display reduced responses to corticosteroids 
compared to non smokers with asthma (5 10, 22 24). This response is associated 
with worse control of asthma (11, 12), accelerated decline in lung function (15, 
21) and increased use of emergency services (16, 17). Smoking is common in 
asthma with rates reflecting the prevalence in the general population (261) and 
therefore  it  represents  a  significant  problem  for  patients  and  respiratory 
physicians. 
The results presented in this thesis show that smokers with asthma demonstrate 
improvements in lung function following treatment with the combination of low 
dose  theophylline  and  inhaled  corticosteroid  and  treatment  with  the  PPARγ 
agonist rosiglitazone. Low dose theophylline appears to be acting in synergy with 
inhaled  corticosteroids  suggesting  the  possibility  of  a  re sensitisation  to 
corticosteroids in smokers with asthma. Low dose theophylline when given alone 
also improves symptoms in smokers with asthma and should be investigated as a 
potential  alternative treatment  for those  smokers  with  asthma not  willing  to 
take inhaled corticosteroid. The response to the PPARγ agonist rosiglitazone is 
the first demonstration of an anti inflammatory effect through stimulation of 
this nuclear hormone receptor in humans and may herald a new class of anti 
inflammatory agents. 
The  study  attempting  to  identify  mechanisms  responsible  for  the  reduced 
response displayed by smokers with asthma to corticosteroids demonstrated that 
smokers with asthma display alterations in the pulmonary and systemic cytokine 
environment  suggestive  of  a  deviation  from  a  Th2  to  a  Th1  inflammatory 
response.  The  identification  of  increased  sputum  supernatant  levels  of  IL 6 
which  are  resistant  to  high  dose  oral  corticosteroids  is  significant  given  the 
important role that this cytokine has at the interface between acute and chronic 
inflammation and the innate and adaptive immune response. Chapter 8    207 
Previous research has suggested that a reduced response to corticosteroids is 
partially due to an oxidative stress mediated reduction in total HDAC activity 
through post translational modification in HDAC enzyme isoforms. The results 
presented  here  suggest  that  total  HDAC  activity  in  smokers  with  asthma  is 
equivalent to non smokers with asthma. However as this is the first attempt to 
measure this marker in induced sputum technical issues may be preventing the 
demonstration of a difference and therefore the study should be regarded as 
non conclusive. 
Smokers with asthma display worse symptoms from asthma when assessed using 
symptom questionnaires. However their exhaled nitric oxide level measured at 
the conventional flow rate of 50ml/sec is markedly reduced. Extended flow rate 
nitric oxide parameters were calculated in smokers with asthma based on the 
hypothesis  that  this  would  reveal  increased  levels  of  alveolar  nitric  oxide 
correlating with the increased asthma symptoms observe in this group. However 
smokers with asthma demonstrated lower or equivalent levels of alveolar nitric 
oxide. This observation combined with the cytokine findings from the same study 
and  the  observation  that  smokers  with  asthma  display  reduced  response  to 
corticosteroids is consistent with the possibility that inflammation in smokers 
with asthma is deviated from the eosinophilic/Th2 inflammation displayed by 
some non smokers with asthma. 
8.2 Limitations of presented research 
Conducting a period of original independent clinical research with the aim of 
obtaining  a  higher  degree  requires  several  compromises.  The  first  and 
overarching concern is undertaking a study that is feasible within the available 
time  limits.  The  study  examining  theophylline  and  the  PPARγ  agonist 
rosiglitazone presented here is short and recruited a small number of subjects 
and therefore cannot be viewed as the definitive study of these approaches to 
the treatment of smokers with asthma. However large, multi centre definitive 
management trials examining these approaches in smokers with asthma can now 
be conducted as a result of the findings presented here. The study examining 
potential mechanisms for the reduced response to corticosteroids observed in Chapter 8    208 
smokers with asthma also included a small number of patients and therefore the 
findings will also require corroboration in larger trials. 
Closely allied to the constraints of limited time and finance is the desire to fully 
interrogate the available data. However to adopt a data mining approach raises 
the possibility of false positive results due to multiple comparisons. To reduce 
this possibility each study was conducted according to a prearranged analysis 
plan and in the case of the trial examining theophylline and rosiglitazone the 
plan  included  predefined  primary  and  secondary  endpoints.  Despite  this 
approach  both  trials  could  contain  false  positive  results.  Therefore  I  have 
presented  and  discussed  the  available  results  with  this  in  mind.  All  work 
presented in this thesis should be viewed as exploratory and therefore requiring 
corroboration. 
Another issue of great importance is the characterisation of patients and the 
differentiation of smokers and ex smokers with asthma from subjects with COPD. 
COPD occurs as a direct result of prolonged exposure to inhaled noxious stimuli. 
In the developed world the agent predominantly responsible is cigarette smoke. 
Given the common link of smoking and the substantial smoking histories of the 
recruited subjects it is possible that some of the subjects could actually have 
COPD. COPD is characterised by chronic airflow obstruction, sputum neutrophilia 
and a reduced therapeutic response to treatment with corticosteroids (compared 
to  non smokers  with  asthma).  However  despite  their  substantial  smoking 
histories  the  recruited  smokers  and  ex smokers  with  asthma  did  not  display 
sputum  neutrophilia,  developed  symptoms  at  a  young  age  (majority  teens  to 
twenties) and also displayed significant bronchodilatory responses to inhaled β2 
agonists.  Therefore  I  feel  I  can  safely  argue  that  the  majority  of  recruited 
subjects have asthma and not COPD. An alternative view is that I could have 
recruited a number of subjects who display an overlap in characteristics shared 
by asthma and COPD. This is certainly possible especially in the older subjects 
with substantial smoking histories. To address this issue properly I would have 
had to perform a number of additional screening tests including measurement of 
transfer factor and high resolution CT scans. Unfortunately this was not feasible 
due to time and funding constraints. When confirmatory studies are performed 
to  examine  the  findings  presented  in  this  thesis  then  these  issues  should  be 
addressed to aid interpretation. The issue of overlap between asthma and COPD Chapter 8    209 
is an important one to address as this combination is regularly observed by the 
clinician  and  studies  containing  well  characterised  subjects  who  do  display  a 
mixture of the two conditions would provide useful insights for clinical care. This 
issue coupled to the lack of understanding of the treatment responses of ex 
smokers with asthma should stimulate some interesting and clinically relevant 
future research.   
8.3 Conclusions & future directions 
Smokers with asthma demonstrate detectable responses to treatment with the 
combination  of  low  dose  theophylline  and  inhaled  corticosteroid,  low  dose 
theophylline  alone  and  the  PPARγ  agonist  rosiglitazone.  All  three  treatment 
combinations  should  undergo  detailed  examination  in  adequately  powered 
management  trials  in  smokers  with  asthma.  The  identification  of  a 
bronchodilator response to treatment with a PPARγ agonist is intriguing and may 
herald a new group of anti inflammatory agents.  
Smokers  with  asthma  display  altered  pulmonary  inflammatory  conditions 
compared  to  non smokers  with  asthma  and  therefore  cannot  be  regarded  as 
equivalent  to  this  group.  Further  detailed  research  is  required  to  properly 
understand the mechanisms responsible for this altered response. Comparison 
with smokers and ex smokers with COPD, non smokers with asthma and normal 
smoking  and  non smoking  subjects  is  required  to  detail  the  overlapping  and 
differing patterns  of inflammation. Consideration  should  also  be  given to the 
conduct of a large bronchoscopic biopsy study to characterise the histological, 
immunohistochemical  and  mechanistic  differences  between  these  groups.  As 
smokers  with  asthma  cannot  be  regarded  as  equivalent  to  non smokers  with 
asthma regulatory bodies should require current and future asthma therapies to 
demonstrate  efficacy  in  this  group  as  a  pre requisite  for  licensing.  With 
increased understanding of the pattern of inflammation in this group it is likely 
that  benefits  for  smokers  with  asthma  and  other  groups  with  relative 
corticosteroid resistance will result.  210 
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